[
    {
        "pmid": "40764298",
        "title": "Microhaplotype deep sequencing assays to capture Plasmodium vivax infection lineages.",
        "abstract": "Plasmodium vivax elimination challenged dormant liver stage hypnozoites reactivate month initial infection resulting relapses Relapsing infection confound antimalarial clinical efficacy trial due inability distinguish recurrence arising bloodstage treatment failure recrudescence reinfection relapse Genetic relatedness paired parasite isolates measured identitybydescent IBD provide important information whether individual single multiple mosquito inoculations thus informing recurrence origin developed highthroughput amplicon sequencing assay comprising 93 multiSNP microhaplotype marker determine IBD P vivax clinical isolates assay evaluated 745 global infections including 128 infection pair randomized controlled trial RCT ClinicalTrialsgov NCT01680406 Simulations demonstrate low error pairwise IBD estimation panel RMSE  012 IBDbased network illustrate strong clustering geography IBD analysis RCT demonstrates lower frequency suspected relapse recrudescence patient treated primaquine compared without primaquine impact greater paired chloroquine artemetherlumefantrine result demonstrate potential derive new information P vivax treatment transmission using IBD generated amplicon sequencing data improved timetoevent models",
        "mesh_terms": [
            "Plasmodium vivax",
            "Malaria, Vivax",
            "Humans",
            "High-Throughput Nucleotide Sequencing",
            "Antimalarials",
            "Haplotypes",
            "Polymorphism, Single Nucleotide",
            "Primaquine",
            "Chloroquine",
            "Recurrence"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40764298/"
    },
    {
        "pmid": "40051493",
        "title": "Perception About Factors Affecting Patient Adherence With Cardiac Medicines: A Cross-Sectional Study.",
        "abstract": "Longterm medicine frequently recommended cardiovascular patient control hypertension lower heart burden Patient adherence cardiovascular medicine crucial since stopping increase risk cardiac adverse event pose bigger risk health Perception manufacturers prescribers patient taken account identify important variable positive impact patient satisfaction thereby increase adherence prescribed cardiovascular drug therapy empirical study conducted using quantitative survey method Questionnaire contained variable influencing patient compliance measured 5point Likert scale 1 istrongly disagreei 5 istrongly agreei Questions handed dropoff collect method study conducted 15 tertiary healthcare service center 18 pharmaceutical company across Dhaka district Bangladesh total 156 cardiologists 200 cardiac patient 180 marketing professional manufacturers included survey total 11 variable affect patient compliance utilized create correlation matrix subsequently carry exploratory factor analysis Hypothesis testing done using regression model Fortyeight percent respondent strongly agreed efficacy cardiac medicine influence patient compliance stakeholder 69 agreed company reputation cardiac medicine supplier important criterion Availability affordability highly positively correlated variables variable grouped four category according factor loading scores four factor medicinal issue product strategies economic issue price strategies convenience issue place strategy communication issue promotional strategies finding study contribute comprehension factor influencing patient compliance multiple dimensions Policy maker implement promote policy encourage patient adherence longterm prescription drugs",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40051493/"
    },
    {
        "pmid": "40049185",
        "title": "Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.",
        "abstract": "Despite well documented consequence obesity childhood adolescence future risk excess body mass noncommunicable disease adulthood coordinated global action excess body mass early life still insufficient Inconsistent measurement reporting barrier specific targets resource allocation interventions Article report current estimate overweight obesity across childhood adolescence progress time forecast inform specific actions Using established methodology Global Burden Diseases Injuries Risk Factors Study 2021 modelled overweight obesity across childhood adolescence 1990 2021 forecasted 2050 Primary data model included 1321 unique measured selfreported anthropometric data source 180 country territory survey microdata reports published literature data used estimate agestandardised global regional national overweight prevalence obesity prevalence separately child young adolescent aged 514 years typically school cared child health services older adolescent aged 1524 years increasingly school cared adult services sex 204 country territory 1990 2021 Prevalence estimate 1990 2021 generated using spatiotemporal Gaussian process regression models leveraged temporal spatial correlation epidemiological trend ensure comparability result across time geography Prevalence forecast 2022 2050 generated using generalised ensemble modelling approach assuming continuation current trends every agesexlocation population across time 19902050 estimated obesity vs overweight predominance using log ratio obesity percentage overweight percentage 1990 2021 combined prevalence overweight obesity child adolescent doubled obesity alone tripled 2021 93·1 million 95 uncertainty interval 89·696·6 individual aged 514 year 80·6 million 78·283·3 aged 1524 year obesity superregion level 2021 prevalence overweight obesity highest north Africa Middle East eg United Arab Emirates Kuwait greatest increase 1990 2021 seen southeast Asia east Asia Oceania eg Taiwan province China Maldives China 2021 female age groups many country Australasia eg Australia highincome North America eg Canada already transitioned obesity predominance male female number country north Africa Middle East eg United Arab Emirates Qatar Oceania eg Cook Islands American Samoa 2022 2050 global increase overweight not obesity prevalence forecasted stabilise yet increase absolute proportion global population obesity forecasted greater 1990 2021 substantial increase forecast 2022 2030 continue 2031 2050 2050 superregion obesity prevalence forecasted remain highest north Africa Middle East eg United Arab Emirates Kuwait forecasted increase obesity still expected largest across southeast Asia east Asia Oceania eg TimorLeste North Korea also south Asia eg Nepal Bangladesh Compared aged 1524 years superregions except Latin America Caribbean highincome superregion greater proportion aged 514 year forecasted obesity overweight 2050 Globally 15·6 12·717·2 aged 514 year forecasted obesity 2050 186 million 141221 compared 14·2 11·415·7 aged 1524 year 175 million 136203 forecasted 2050 young male aged 514 years living obesity 16·5 13·318·3 overweight 12·9 12·213·6 female aged 524 years older male aged 1524 years overweight remain prevalent obesity regional level following population forecast transitioned obesity vs overweight predominance 204150 child adolescent males female aged 524 years north Africa Middle East Tropical Latin America male aged 514 year east Asia central southern subSaharan Africa central Latin America female aged 514 year Australasia female aged 1524 year Australasia highincome North America southern subSaharan Africa male aged 1524 year highincome North America overweight obesity increased substantially every world region 1990 2021 suggesting current approach curbing increase overweight obesity failed generation child adolescents Beyond 2021 overweight childhood adolescence forecast stabilise due increase population obesity Increases obesity expected continue population world regions substantial change forecasted occur 2022 2030 immediate action needed address public health crisis Bill  Melinda Gates Foundation Australian National Health Medical Research Council",
        "mesh_terms": [
            "Humans",
            "Adolescent",
            "Child",
            "Prevalence",
            "Female",
            "Male",
            "Forecasting",
            "Global Burden of Disease",
            "Pediatric Obesity",
            "Child, Preschool",
            "Young Adult",
            "Global Health",
            "Overweight",
            "Risk Factors"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40049185/"
    },
    {
        "pmid": "40000077",
        "title": "mHealth intervention (mTB-Tobacco) for smoking cessation in people with drug-sensitive pulmonary tuberculosis in Bangladesh and Pakistan: protocol for an adaptive design, cluster randomised controlled trial (Quit4TB).",
        "abstract": "People tuberculosis TB continue smoke likely poor health outcome quit Established smoking cessation approach mHealth may help patient TB quit smoking paper summarises methodology proposed assess effectiveness costeffectiveness mTBTobacco an mHealth intervention helping patient TB stop smoking improved health outcomes twoarm parallel openlabel multicentre cluster randomised twostage adaptive design trial proposed first evaluate superiority mTBTobacco compared usual care noninferiority mTBtobacco compared facetoface behaviour support Study setting include TB treatment centre Bangladesh Pakistan study population includes adult patients newly diagnosed within 4 weeks pulmonary TB disease daily smokers willing quit access mobile phones primary outcome includes biochemically verified continuous smoking abstinence assessed 6 month per Russell Standard generalised linear mixedeffects model used assess impact mTBTobacco intervention continuous outcomes incorporating fixed effect intervention random effect cluster relevant covariates Costeffectiveness analysis done estimate cost per quitter cost per qualityadjusted life year gained calculate incremental costeffectiveness ratio establish value money mTBTobacco trial conducted compliance International Council Harmonisation  Good Clinical Practice guideline Declaration Helsinki study approved ethic committee University Edinburgh Medical School Research Ethics Committee EMREC UK Bangladesh Medical Research Council BMRC National Bioethics Committee PMRC Pakistan result trial disseminated peerreviewed journal presented academic conferences ISRCTN86971818 httpsdoiorg101186ISRCTN86971818 preenrolment submission date 29 August 2023 registration date 11 September 2023",
        "mesh_terms": [
            "Humans",
            "Bangladesh",
            "Smoking Cessation",
            "Tuberculosis, Pulmonary",
            "Pakistan",
            "Telemedicine",
            "Cost-Benefit Analysis",
            "Randomized Controlled Trials as Topic",
            "Multicenter Studies as Topic",
            "Adult",
            "Female",
            "Male"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40000077/"
    },
    {
        "pmid": "39890793",
        "title": "Investigating new drugs from marine seaweed metabolites for cervical cancer therapy by molecular dynamic modeling approach.",
        "abstract": "etiology cervical cancer woman attributed continuous infection human papillomavirus HPV high cost side effect standard treatment limited efficacy HPV vaccination led quest novel costeffective cervical cancer treatments particularly middle lowincome countries Therefore objective evaluate capacity marine seaweed compound hinder activity cervical cancer E6 Oncoprotein Seaweed Metabolite Database evaluated ability inhibit E6 Oncoprotein function high throughput virtual screening investigation included molecular docking ADMET test MD simulation MMGBSA analysis identify three lead seaweed druglike compounds BC008 89 kcalmol RL379 89 kcalmol BC014 87 kcalmol leading candidate positive characteristic term pharmacokinetics pharmacodynamics toxicity molecular dynamic simulation apoprotein control drug lead compound revealed superior structural stability uniformity main drug candidates MMGBSA study revealed BC008protein complex exhibited significant free binding energy value 5741 kcalmol end finding derived investigation might provide basis developing innovative anticancer treatments",
        "mesh_terms": [
            "Seaweed",
            "Uterine Cervical Neoplasms",
            "Molecular Dynamics Simulation",
            "Female",
            "Humans",
            "Molecular Docking Simulation",
            "Antineoplastic Agents",
            "Oncogene Proteins, Viral"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39890793/"
    },
    {
        "pmid": "39820032",
        "title": "Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae.",
        "abstract": "Streptococcus pneumoniae SPN significant pathogen causing pneumonia meningitis particularly vulnerable population like child elderly Available pneumonia vaccine limitation since cover particular serotypes high production costs emergence antibioticresistant SPN strain underscore need new costeffective broadspectrum vaccine Two potential vaccine candidates CbpA PspA identified Bcell CTL HTL epitope predicted connected suitable linkers adjivant PADRE sequence vaccine construct found antigenic nontoxic nonallergenic soluble threedimensional structure vaccine candidate built validated Docking analysis vaccine candidate ClusPro demonstrated robust stable binding interaction MEV tolllike receptor 4 human animals iMOD server Amber v22 tool verified stability docking complexes GenScript server confirmed high efficiency cloning construct insilico cloning pET28a  vector using SnapGene demonstrating successful translation epitope region Immunological response shown enhanced CIMMSIM server study introduced strong peptide vaccine candidate potential contribute development rapid costeffective solution combating SPN However experimental verification necessary evaluate vaccines effectiveness",
        "mesh_terms": [
            "Streptococcus pneumoniae",
            "Pneumococcal Infections",
            "Epitopes",
            "Bacterial Proteins",
            "Antigens, Bacterial",
            "Pneumococcal Vaccines",
            "Vaccine Development",
            "Molecular Docking Simulation",
            "Toll-Like Receptor 4",
            "Computational Biology",
            "Humans",
            "Animals",
            "Mice"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39820032/"
    },
    {
        "pmid": "39645377",
        "title": "Burden of disease scenarios by state in the USA, 2022-50: a forecasting analysis for the Global Burden of Disease Study 2021.",
        "abstract": "capacity anticipate future health issue important policy maker practitioner USA insight facilitate effective planning investment implementation strategies Forecasting trend disease injury burden crucial policy maker also garner substantial interest general populace lead betterinformed public integration new data sources refinement methodologies inclusion additional causes improved previous forecasting effort within scope Global Burden Diseases Injuries Risk Factors Study GBD produce forecast state national level USA various possible scenarios developed comprehensive framework forecasting life expectancy healthy life expectancy HALE causespecific mortality disabilityadjusted lifeyears DALYs due 359 cause disease injury burden 2022 2050 USA 50 state Washington DC Using GBD 2021 Future Health Scenarios modelling framework forecasted driver disease demographic drivers risk factors temperature particulate matter mortality year life lost YLL population nonfatal burden addition reference scenario representing probable future trajectory explored various future scenario potential impact next several decade human health alternative scenario comprised four risk elimination scenario including safer environment improved behavioural metabolic risks improved childhood nutrition vaccination combined scenario three USAspecific scenario based risk exposure attributable burden bestperforming US state improved high adult BMI high fasting plasma glucose FPG improved smoking improved drug use encompassing opioids cocaine amphetamine others Life expectancy USA projected increase 78·3 year 95 uncertainty interval 78·178·5 2022 79·9 year 79·580·2 2035 80·4 year 79·881·0 2050 sex combined increase forecasted modest compared country around world resulting USA declining global rank 202250 forecasted period among 204 country territory GBD 49th 66th projected decline female life expectancy West Virginia 1990 2050 little change Arkansas Oklahoma Additionally 2023 projected almost change female life expectancy many states notably Oklahoma South Dakota Utah Iowa Maine Wisconsin Female HALE projected decline 1990 2050 20 state remain unchanged three others Drug use disorder low back pain projected leading Level 3 cause agestandardised DALYs 2050 agestandardised DALY rate due drug use disorder projected increase considerably 2022 2050 19·5 6·934·1 combined risk elimination scenario show USA could gain 3·8 additional year 3·64·0 life expectancy 4·1 additional year 3·94·3 HALE 2050 versus reference scenario Using USAspecific scenarios forecasted USA could gain 0·4 additional year 0·30·6 life expectancy 0·6 additional year 0·50·8 HALE 2050 improved drug use scenario relative reference scenario Life expectancy HALE likewise projected 0·40·5 year higher 2050 improved adult BMI FPG improved smoking scenario compared reference scenario However increase scenario would substantially improve USAs global ranking 2050 from 66th 204 life expectancy reference scenario 63rd64th three USAspecific scenarios indicating USAs bestperforming state still lagging behind country rank throughout forecasted period Regardless estimated 12·4 million 11·313·5 death could averted 2022 2050 USA follow combined scenario trajectory rather reference scenario would also 1·4 million 0·72·2 fewer death 28year forecasted period improved adult BMI FPG 2·1 million 1·32·9 fewer death improved exposure smoking 1·2 million 0·91·5 fewer death lower rate drug use deaths finding highlight alarming trajectory health challenge USA which left unaddressed could lead reversal health progress made past three decade US state decline global health standing states evidence alternative scenario along published study suggests collaborative evidencebased strategies opportunity change trajectory health outcome USA investing scientific innovation healthcare access preventive health care risk exposure reduction education forecast clearly show time act now future countrys health wellbeingas well prosperity leadership position science innovationare stake Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Female",
            "Humans",
            "Male",
            "Middle Aged",
            "Cause of Death",
            "Disability-Adjusted Life Years",
            "Forecasting",
            "Life Expectancy",
            "Risk Factors",
            "United States",
            "Cost of Illness",
            "Population Health"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39645377/"
    },
    {
        "pmid": "39547912",
        "title": "Using digital health technologies to optimise antimicrobial use globally.",
        "abstract": "Digital health technology DHT describes tool device generate process health data application DHTs could improve diagnosis treatment surveillance bacterial infection prevention antimicrobial resistance AMR DHTs optimise antimicrobial use rapidly developed support global adoption DHTs opportunity offered optimise antimicrobial use consensus needed data required support antimicrobial decision making Series paper explore bacterial AMR human need optimise antimicrobial use response global threat also describe stateoftheart DHTs optimise antimicrobial prescribing highincome lowincome middleincome countries consider fundamental data ideally required technology support optimised antimicrobial use",
        "mesh_terms": [
            "Humans",
            "Digital Technology",
            "Global Health",
            "Biomedical Technology",
            "Anti-Bacterial Agents",
            "Anti-Infective Agents",
            "Drug Resistance, Bacterial",
            "Antimicrobial Stewardship",
            "Bacterial Infections",
            "Digital Health"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39547912/"
    },
    {
        "pmid": "39454232",
        "title": "Global, regional, and national burden of injuries, and burden attributable to injuries risk factors, 1990 to 2019: results from the Global Burden of Disease study 2019.",
        "abstract": "study trend current situation injury burden well attributable burden injury risk factor global regional national level based Global Burden Diseases Injuries Risk Factors Study GBD 2019 presented assess attributable burden injury risk factors data interest data source retrieved Global Health Data Exchange GHDx analyzed Causespecific death injury estimated using Cause Death Ensemble model GBD 2019 burden attributable injury risk factor incorporated population attributable fraction estimate total attributable death disabilityadjusted life years Sociodemographic Index SDI used evaluate countries developmental status Globally 7139 million 95 uncertainty interval UI 6638 7669 injury incidence 43 million UI 39 46 death caused injury 2019 inverse relationship agestandardized disabilityadjusted life year rate SDI quintiles 2019 Overall low bone mineral density leading risk factor injury death 2019 contribution 105 UI 90 116 total injury agestandardized deaths followed occupational risk 70 UI 6379 alcohol use 68 UI 52 85 Various risk responsible imposed burden injuries study highlighted small persistent share injury global burden disease injury provide beneficial data produce proper policy reach effective global injury prevention plan",
        "mesh_terms": [
            "Humans",
            "Global Burden of Disease",
            "Wounds and Injuries",
            "Risk Factors",
            "Male",
            "Female",
            "Global Health",
            "Adult",
            "Middle Aged",
            "Disability-Adjusted Life Years",
            "Adolescent",
            "Young Adult",
            "Aged",
            "Child, Preschool",
            "Infant",
            "Child",
            "Cause of Death",
            "Incidence",
            "Cost of Illness"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39454232/"
    },
    {
        "pmid": "39366729",
        "title": "Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021.",
        "abstract": "Smoking leading behavioural risk factor mortality globally accounting 175 million death nearly 4·30 billion year life lost YLLs 1990 2021 pace decline smoking prevalence slowed recent year many countries although strategy recently proposed achieve tobaccofree generations none implemented date Assessing could happen current trend smoking prevalence persist could happen additional smoking prevalence reduction occur important communicating effect potential smoking policies analysis use Institute Health Metrics Evaluations Future Health Scenarios platform forecast effect three smoking prevalence scenario allcause causespecific YLLs life expectancy birth 2050 YLLs computed scenario using Global Burden Disease Study 2021 reference life table forecast causespecific mortality scenario reference scenario forecast could occur past smoking prevalence risk factor trend continue Tobacco Smoking Elimination 2023 Elimination2023 scenario quantifies maximum potential future health benefit assuming zero percent smoking prevalence 2023 onwards whereas Tobacco Smoking Elimination 2050 Elimination2050 scenario provides estimate country considering policy steadily reduce smoking prevalence 5 Together scenario underscore magnitude health benefit could reached 2050 country take decisive action eliminate smoking 95 uncertainty interval UI estimate based 2·5th 97·5th percentile draw carried multistage computational framework Global agestandardised smoking prevalence estimated 28·5 95 UI 27·929·1 among male 5·96 5·766·21 among female 2022 reference scenario smoking prevalence declined 25·9 25·226·6 among males 30·0 26·132·1 among female 2022 2050 scenario forecast cumulative 29·3 billion 95 UI 26·832·4 overall YLLs among male 22·2 billion 20·124·6 YLLs among female period Life expectancy birth scenario would increase 73·6 year 95 UI 72·874·4 2022 78·3 year 75·980·3 2050 Elimination2023 scenario forecast 2·04 billion 95 UI 1·902·21 fewer cumulative YLLs 2050 compared reference scenario life expectancy birth would increase 77·6 year 95 UI 75·179·6 among male 81·0 year 78·583·1 among females Elimination2050 scenario forecast 735 million 675808 141 million 131154 cumulative YLLs would avoided among male females respectively Life expectancy 2050 would increase 77·1 year 95 UI 74·679·0 among male 80·8 year 78·382·9 among females Existing tobacco policy must maintained smoking prevalence continue decline forecast reference scenario addition substantial smokingattributable burden avoided accelerating pace smoking elimination Implementation new tobacco control policy crucial avoiding additional smokingattributable burden coming decade ensure gain past three decade lost Bloomberg Philanthropies Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Humans",
            "Life Expectancy",
            "Forecasting",
            "Smoking",
            "Prevalence",
            "Female",
            "Male",
            "Global Burden of Disease",
            "Adult",
            "Middle Aged",
            "Global Health",
            "Aged",
            "Young Adult",
            "Adolescent"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39366729/"
    },
    {
        "pmid": "39304265",
        "title": "Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.",
        "abstract": "Uptodate estimate stroke burden attributable risk trend global regional national level essential evidencebased health care prevention resource allocation planning aimed provide estimate period 19902021 estimated incidence prevalence death disabilityadjusted lifeyear DALY count agestandardised rate per 100 000 people per year overall stroke ischaemic stroke intracerebral haemorrhage subarachnoid haemorrhage 204 country territory 1990 2021 also calculated burden stroke attributable 23 risk factor six risk cluster air pollution tobacco smoking behavioural dietary environmental metabolic risks global regional level 21 GBD region Sociodemographic Index SDI quintiles using standard GBD methodology 95 uncertainty interval UIs individual future estimate derived 2·5th 97·5th percentile distribution generated propagating 500 draw multistage computational pipeline 2021 stroke third common GBD level 3 cause death 7·3 million 95 UI 6·67·8 deaths 10·7 9·811·3 deaths ischaemic heart disease COVID19 fourth common cause DALYs 160·5 million 147·8171·6 DALYs 5·6 5·06·1 DALYs 2021 93·8 million 89·099·3 prevalent 11·9 million 10·713·2 incident strokes found disparity stroke burden risk factor GBD region country territory SDI well stagnation reduction incidence 2015 onwards even increase stroke incidence death prevalence DALY rate southeast Asia east Asia Oceania country lower SDI people younger 70 years Globally ischaemic stroke constituted 65·3 62·467·7 intracerebral haemorrhage constituted 28·8 28·328·8 subarachnoid haemorrhage constituted 5·8 5·76·0 incident strokes substantial increase DALYs attributable high BMI 88·2 53·4117·7 high ambient temperature 72·4 51·1 179·5 high fasting plasma glucose 32·1 26·738·1 diet high sugarsweetened beverage 23·4 12·735·7 low physical activity 11·3 1·834·9 high systolic blood pressure 6·7 2·511·6 lead exposure 6·5 4·511·2 diet low omega6 polyunsaturated fatty acid 5·3 0·510·5 Stroke burden increased 1990 2021 contribution several risk factor also increased Effective accessible affordable measure improve stroke surveillance prevention with emphasis blood pressure lifestyle environmental factors acute care rehabilitation need urgently implemented across country reduce stroke burden Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Humans",
            "Global Burden of Disease",
            "Risk Factors",
            "Stroke",
            "Global Health",
            "Disability-Adjusted Life Years",
            "Incidence",
            "Prevalence",
            "Quality-Adjusted Life Years",
            "Male",
            "Female"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39304265/"
    },
    {
        "pmid": "38484753",
        "title": "Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.",
        "abstract": "Estimates demographic metric crucial assess level trend population health outcomes profound impact COVID19 pandemic population worldwide underscored need timely estimate understand unprecedented event within context longterm population health trends Global Burden Diseases Injuries Risk Factors Study GBD 2021 provides new demographic estimate 204 country territory 811 additional subnational location 1950 2021 particular emphasis change mortality life expectancy occurred 202021 COVID19 pandemic period 22 223 data source vital registration sample registration surveys censuses source used estimate mortality subset source used exclusively estimate excess mortality due COVID19 pandemic 2026 data source used population estimation Additional source used estimate migration effect HIV epidemic demographic discontinuity due conflicts famines natural disasters pandemics used input estimating mortality population Spatiotemporal Gaussian process regression STGPR used generate under5 mortality rates synthesised 30 763 locationyears vital registration sample registration data 1365 survey censuses 80 sources STGPR also used estimate adult mortality between age 15 59 years based information 31 642 locationyears vital registration sample registration data 355 survey censuses 24 sources Estimates child adult mortality rate used generate life table relational model life table system country large HIV epidemics life table adjusted using independent estimate HIVspecific mortality generated via epidemiological analysis HIV prevalence surveys antenatal clinic serosurveillance data sources Excess mortality due COVID19 pandemic 2020 2021 determined subtracting observed allcause mortality adjusted late registration mortality anomalies mortality expected absence pandemic Expected mortality calculated based historical trend using ensemble models locationyears allcause mortality data unavailable estimated excess mortality rate using regression model covariates pertaining pandemic Population size computed using Bayesian hierarchical cohort component model Life expectancy calculated using agespecific mortality rate standard demographic methods Uncertainty interval UIs calculated every metric using 25th 975th ordered value 1000draw posterior distribution Global allcause mortality followed two distinct pattern study period agestandardised mortality rate declined 1950 2019 a 62·8 95 UI 60·565·1 decline increased COVID19 pandemic period 202021 5·1 0·99·6 increase contrast overall reverse mortality trend pandemic period child mortality continued decline 4·66 million 3·985·50 global death child younger 5 year 2021 compared 5·21 million 4·506·01 2019 estimated 131 million 126137 people died globally cause 2020 2021 combined 15·9 million 14·717·2 due COVID19 pandemic measured excess mortality includes death directly due SARSCoV2 infection indirectly due social economic behavioural change associated pandemic Excess mortality rate exceeded 150 death per 100 000 population least one year pandemic 80 country territories whereas 20 nation negative excess mortality rate 2020 2021 indicating allcause mortality country lower pandemic expected based historical trends 1950 2021 global life expectancy birth increased 22·7 year 20·824·8 49·0 year 46·751·3 71·7 year 70·972·5 Global life expectancy birth declined 1·6 year 1·02·2 2019 2021 reversing historical trends increase life expectancy observed 32 15·7 204 country territory 2019 2021 global population reached 7·89 billion 7·678·13 people 2021 time 56 204 country territory peaked subsequently population declined largest proportion population growth 2020 2021 subSaharan Africa 39·5 28·452·7 south Asia 26·3 9·044·7 2000 2021 ratio population aged 65 year older population aged younger 15 year increased 188 92·2 204 nations Global adult mortality rate markedly increased COVID19 pandemic 2020 2021 reversing past decreasing trends child mortality rate continued decline albeit slowly earlier years Although COVID19 substantial impact many demographic indicator first 2 year pandemic overall global health progress 72 year evaluated profound considerable improvement mortality life expectancy Additionally observed deceleration global population growth since 2017 despite steady increasing growth lowerincome countries combined continued global shift population age structure towards older ages demographic change likely present future challenge health systems economies societies comprehensive demographic estimate reported enable researchers policy makers health practitioners key stakeholder better understand address profound change occurred global health landscape following first 2 year COVID19 pandemic longerterm trend beyond pandemic Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Humans",
            "COVID-19",
            "Life Expectancy",
            "Global Burden of Disease",
            "Female",
            "Adult",
            "Male",
            "Adolescent",
            "Child",
            "Middle Aged",
            "Global Health",
            "Child, Preschool",
            "Infant",
            "Young Adult",
            "Aged",
            "SARS-CoV-2",
            "Mortality",
            "Infant, Newborn",
            "Demography",
            "Pandemics",
            "Aged, 80 and over",
            "Age Distribution"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38484753/"
    },
    {
        "pmid": "38379753",
        "title": "A qualitative exploration of purchasing, stockpiling, and use of drugs during the COVID-19 pandemic in an urban city of Bangladesh.",
        "abstract": "research conducted explore pattern behavior panic purchasing stockpiling use drug COVID19 Sylhet city Bangladesh study adopted qualitative exploratory research design 25 indepth interview drug seller client 7 key informant interview conducted pharmacist medical representative pharmaceutical company Sylhet city Bangladesh October 2020 March 2021 Thematic analysis used evaluate primary data finding revealed individual sought out purchased stockpiled prescriptiononly drug selfmedication purpose COVID19 pandemic News rumor spread social media television everyday interaction concerning severity infection number death caused increase selfmedication preventive measure reason panic buying drug identified fear drug shortages price hikes rise infection availability medicine home delivery service pandemic purchasing stockpiling use drug pharmacy varied based person dispensing drugs customer COVID19 pandemic situation Furthermore role social medium spreading rumor dis misinformation drug use greater tendency selfmedicate poor regulation influenced individuals use drugs Therefore drug regulatory authority policymakers need consider real level local drug use order encourage rational use drug help ensure reliable access safe effective highquality medicine vaccine all",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38379753/"
    },
    {
        "pmid": "38146969",
        "title": "Costs of Digital Adherence Technologies for Tuberculosis Treatment Support, 2018-2021.",
        "abstract": "Digital adherence technology increasingly used support tuberculosis TB treatment adherence Using microcosting estimated healthcare system cost in 2022 US dollars 2 digital adherence technologies 99DOTS medication sleeve videoobserved therapy VOT implemented demonstration project 20182021 also obtained cost estimate standard directly observed therapy DOT Estimated perperson cost 99DOTS drugsensitive TB 98 Bangladesh n  719 119 Philippines n  396 174 Tanzania n  976 Estimated perperson cost VOT 1154 Haiti 87 drugsensitive 304 Moldova 173 drugsensitive 452 Moldova 135 drugresistant 661 Philippines 110 drugresistant 99DOTS cost may similar less expensive standard DOT VOT expensive although settings labor cost offset economy scale may yield savings 99DOTS VOT may yield saving local program donor cover infrastructure costs",
        "mesh_terms": [
            "Humans",
            "Bangladesh",
            "Directly Observed Therapy",
            "Haiti",
            "Health Care Costs",
            "Income"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38146969/"
    },
    {
        "pmid": "38123228",
        "title": "Safety and efficacy of primaquine in patients with <i>Plasmodium vivax</i> malaria from South Asia: a systematic review and individual patient data meta-analysis.",
        "abstract": "optimal dosing primaquine prevent relapsing iPlasmodium vivaxi malaria South Asia remains unclear investigated efficacy safety different primaquine regimen prevent iP vivaxi relapse systematic review identified iP vivaxi efficacy study South Asia published 1 January 2000 23 August 2021 onestage metaanalysis available individual patient data cumulative risk iP vivaxi recurrence day 42 180 assessed primaquine total mgkg dose duration risk recurrence day 180 also determined twostage metaanalysis Patients 25 drop haemoglobin 70 gL absolute drop 50 gL day 1 14 categorised daily mgkg primaquine dose 791 patient 7 study onestage metaanalysis day 180 cumulative risk recurrence 611 95 CI 422 804 201 patients 25 recurrences treatment without primaquine 288 95 CI 82 741 398 patients 4 recurrences following low total 2 5 mgkg 0 96 patients 0 recurrences following high total dose primaquine ≥5 mgkg subsequent twostage metaanalysis nine study 3529 patients pooled proportion iP vivaxi recurrence day 180 121 95 CI 77 172 23 95 CI 03 54 07 95 CI 0 61 respectively patient 25 drop haemoglobin 70 gL Primaquine treatment led marked decrease iP vivaxi recurrence following low 35 mgkg high 7 mgkg total doses reported severe haemolytic events CRD42022313730",
        "mesh_terms": [
            "Humans",
            "Primaquine",
            "Malaria, Vivax",
            "Antimalarials",
            "Plasmodium vivax",
            "Recurrence",
            "Asia, Southern",
            "Hemoglobins"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38123228/"
    },
    {
        "pmid": "37979594",
        "title": "Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.",
        "abstract": "area coendemic Plasmodium vivax Plasmodium falciparum increased risk P vivax parasitaemia following P falciparum malaria Radical cure currently recommended patient presenting P vivax malaria Expanding indication radical cure patient presenting P falciparum malaria could reduce risk subsequent P vivax parasitaemia multicentre openlabel superiority randomised controlled trial five health clinic Bangladesh Indonesia Ethiopia Bangladesh Indonesia patient excluded younger 1 year whereas Ethiopia patient excluded younger 18 years Patients uncomplicated P falciparum monoinfection fever history fever 48 h preceding clinic visit eligible enrolment required glucose6dehydrogenase G6PD activity 70 greater Patients received blood schizontocidal treatment artemetherlumefantrine Ethiopia Bangladesh dihydroartemisininpiperaquine Indonesia randomly assigned 11 receive either highdose shortcourse oral primaquine intervention arm total dose 7 mgkg 7 days standard care standard care arm single dose oral primaquine 0·25 mgkg Random assignment done independent statistician block eight use sealed envelopes randomly assigned eligible patient included primary safety analyses perprotocol analysis excluded complete treatment substantial protocol violations primary endpoint incidence risk P vivax parasitaemia day 63 trial registered ClinicalTrialsgov NCT03916003 Aug 18 2019 March 14 2022 total 500 patient enrolled randomly assigned 495 eligible patient included intentiontotreat analysis 246 intervention 249 control incidence risk P vivax parasitaemia day 63 11·0 95 CI 7·515·9 standard care arm compared 2·5 1·05·9 intervention arm hazard ratio 0·20 95 CI 0·080·51 p0·0009 effect size differed blood schizontocidal treatment site Routine symptom reporting day 2 day 7 similar groups first 42 days total four primaquinerelated adverse event reported standard care arm 26 intervention arm 132 92 143 adverse event mild two serious adverse event intervention arm considered unrelated study drug None patient developed severe anaemia defined haemoglobin 5 gdL patient G6PD activity 70 greater highdose shortcourse primaquine safe relatively well tolerated reduced risk subsequent P vivax parasitaemia within 63 day five fold Universal radical cure therefore potentially offer substantial clinical public health operational benefits benefit vary endemic setting Australian Academy Science Regional Collaborations Program Bill  Melinda Gates Foundation National Health Medical Research Council",
        "mesh_terms": [
            "Humans",
            "Primaquine",
            "Antimalarials",
            "Plasmodium vivax",
            "Artemether",
            "Artemether, Lumefantrine Drug Combination",
            "Australia",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Malaria",
            "Plasmodium falciparum",
            "Parasitemia"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37979594/"
    },
    {
        "pmid": "37824592",
        "title": "Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis.",
        "abstract": "Screening G6PD deficiency inform disease management including malaria Treatment antimalarial drug primaquine tafenoquine guided pointofcare testing G6PD deficiency Data similar clinical study evaluating performance STANDARD G6PD Test SD Biosensor South Korea conducted Bangladesh Brazil Ethiopia India Thailand United Kingdom United States pooled Test performance assessed retrospective analysis capillary venous specimens study site used spectrophotometry reference G6PD testing either HemoCue complete blood count reference hemoglobin measurement sensitivity STANDARD G6PD Test using manufacturer threshold G6PD deficient intermediate case capillary specimen 4212 study participant 100 95 Confidence Interval CI 975100 G6PD deficient case 30 activity 77 95 CI 668854 female intermediate activity 3070 Specificity 981 95 CI 976985 928 95 CI 916939 G6PD deficient individual intermediate females respectively 20 G6PD intermediate female false normal results 12 activity level 60 reference assay negative predictive value female G6PD activity 60 996 95 CI 991998 capillary specimens Sensitivity among 396 P vivax malaria case 100 6921000 deficient intermediate cases Across full dataset 37 classified G6PD deficient intermediate resulted true normal cases Despite this 95 case would receive correct treatment primaquine 87 case would receive correct treatment tafenoquine true G6PD deficient case would treated inappropriately based result STANDARD G6PD Test STANDARD G6PD Test enables safe access drug contraindicated individual G6PD deficiency Operational consideration inform test uptake specific settings",
        "mesh_terms": [
            "Female",
            "Humans",
            "Primaquine",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Retrospective Studies",
            "Antimalarials",
            "Malaria, Vivax"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37824592/"
    },
    {
        "pmid": "37646297",
        "title": "Pharmaco-disparities in heart failure: a survey of the affordability of guideline recommended therapy in 10 countries.",
        "abstract": "Heart failure reduced ejection fraction HFrEF treatable guidelinedirected medical therapy GDMT may affordable accessible people living disease crosssectional survey investigated price affordability accessibility four pivotal class HFrEF GDMT angiotensinconverting enzyme inhibitor ACEi angiotensin receptor blocker ARB angiotensinneprilysin inhibitor ARNI betablockers mineralocorticoid receptor antagonist MRA sodium glucose cotransporter 2 inhibitor SGLT2i sampled online community pharmacy 10 country across range World Bank income groups assessing mean 30 day retail prescription prices affordability relative gross national income per caput per month accessibility reported median price ratio relative International Reference Standard performed literature review evaluate accessibility GDMT class publicly funded drug programme country HFrEF GDMT prices absolute relative international reference highest United States lowest Pakistan Bangladesh expensive drug ARNI sacubitrilvalsartan mean standard deviation SD 30 day price ranging 1106 081 Pakistan 61150 354 United States least expensive drug MRA spironolactone mean SD 30 day price ranging 018 000 Pakistan 1232 000 England Affordability SD quadruple therapyARNI betablockers MRA SGLT2iwas best highincome worst lowincome countries ranging 149 000 gross national income per caput per month England 23247 3147 Uganda Publicly funded drug programme offset cost eligible patients ARNI SGLT2i inaccessible programme low middleincome countries Price affordability access substantially improved country substituting ARNI ACEiARB marked variation country retail price HFrEF GDMT Despite higher price highincome countries GDMT accessible affordable low middleincome countries Publicly funded drug programme lower income country increased affordability limited access newer HFrEF GDMT classes Pharmacodisparities must addressed improve HFrEF outcome globally",
        "mesh_terms": [
            "Humans",
            "Heart Failure",
            "Cross-Sectional Studies",
            "Practice Guidelines as Topic",
            "Global Health",
            "Surveys and Questionnaires",
            "Health Services Accessibility",
            "Angiotensin Receptor Antagonists"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37646297/"
    },
    {
        "pmid": "37379283",
        "title": "The reality of embedded drug purchasing practices: Understanding the sociocultural and economic aspects of the use of medicines in Bangladesh.",
        "abstract": "Purchasing drug without prescription retail drug shop common practice Bangladesh However actually take place drug seller customer transaction underresearched study explores drug purchasing practice underlie sociocultural economic aspect Bangladeshi city Adopting ethnographic methods conducted thirty indepth interview IDIs customers patients sale assistants ten key informant interview KIIs drug sellers experienced sale assistant pharmaceutical company representatives Thirty hour spent observing drug sellers buyers conversation interaction medicine total 40 heterogeneous participant purposively selected three drug stores Transcribed data coded analyzed thematically found thematic analysis individual visited drug store fixed idea name brand dose drug wanted Among 30 IDIs participants individual come without preconceived ideas describe symptoms negotiate purchase expectation quick remedies Cultural practice buying medicine full partial course doses without prescription trust sellers positive previous experience medication shape drug purchasing behavior regardless preconceived idea concerning brand name dose customer n  7 sought drug trade name drug seller often offered generic substitute selling nonbrand drug profitable Notably many client n  13 bought drug installment payment loans Community people choose purchase necessary medicine selfmedicated way shortly trained drug seller harm individuals health reduce effectiveness medication addition result buying medicine installment loan suggest research financial burden consumers purchasing behavior Policymakers regulators healthcare professional might implicate study finding deliver practical information rational use medicine seller customers",
        "mesh_terms": [
            "Humans",
            "Bangladesh",
            "Prescriptions",
            "Consumer Behavior",
            "Health Personnel",
            "Commerce"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37379283/"
    },
    {
        "pmid": "37319165",
        "title": "Assessing the critical success factors for implementing industry 4.0 in the pharmaceutical industry: Implications for supply chain sustainability in emerging economies.",
        "abstract": "emerging technology Industry 40 I40 crucial incorporating agility sustainability smartness competitiveness business model enabling longterm sustainability practice pharmaceutical supply chain PSC leveraging latest technology I40 pharmaceutical company gain realtime visibility supply chain SC operations allowing make datadriven decision improve SC performance efficiency resilience sustainability However date research examined critical success factor CSFs enable pharmaceutical industry adopt I40 successfully enhance overall SC sustainability study therefore analyzed potential CSFs adopting I40 increase facet sustainability PSC especially perspective emerging economy like Bangladesh Initially sixteen CSFs identified comprehensive literature review expert validation Later finalized CSFs clustered three relevant group analyzed using Bayesian bestworst method BWMbased multicriteria decisionmaking MCDM framework study finding revealed sufficient investment technological advancement digitalized product monitoring traceability dedicated robust research development RD team top three CSFs adopt I40 PSC studys finding aid industrial practitioners managers policymakers creating effective action plan efficiently adopting I40 PSC avail competitive benefit ensure sustainable future pharmaceutical industry",
        "mesh_terms": [
            "Bayes Theorem",
            "Commerce",
            "Drug Industry",
            "Investments",
            "Pharmaceutical Preparations"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37319165/"
    },
    {
        "pmid": "37243851",
        "title": "Affordability of newer antiseizure medications in Asian resource-limited countries.",
        "abstract": "One objective Intersectoral Global Action Plan epilepsy neurological disorder 2022 2031 ensure least 80 people epilepsy PWE access appropriate affordable safe antiseizure medication ASMs 2031 However ASM affordability significant issue low middleincome countries preventing PWE accessing optimal treatment study aimed determine affordability newer second third generation ASMs resourcelimited country Asia conducted crosssectional survey contacting country representative lowermiddleincome country LMICs Asia including Indonesia Lao Peoples Democratic Republic PDR Myanmar Philippines Vietnam India Bangladesh Pakistan uppermiddleincome country Malaysia March 2022 April 2022 affordability ASM calculated dividing 30day ASM cost daily wage lowest paid unskilled laborers Treatment costing 1 days wage less 30day supply chronic disease considered affordable Eight LMICs one uppermiddleincome country included study Lao PDR newer ASM Vietnam three newer ASMs frequently available ASMs levetiracetam topiramate lamotrigine least frequently available lacosamide majority newer ASMs unaffordable median number days wage 30day supply ranging 56 148 days new generation ASMs whether original generic brands unaffordable Asian LMICs",
        "mesh_terms": [
            "Humans",
            "Cross-Sectional Studies",
            "Asia",
            "India",
            "Anticonvulsants",
            "Epilepsy",
            "Costs and Cost Analysis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37243851/"
    },
    {
        "pmid": "37076740",
        "title": "Optimal Interruption of P. vivax Malaria Transmission Using Mass Drug Administration.",
        "abstract": "Plasmodium vivax geographically widespread malariacausing parasite resulting significant associated global morbidity mortality One factor driving widespread phenomenon ability parasite remain dormant liver Known hypnozoites reside liver following initial exposure activating later cause infections referred relapses around 7996 infection attributed relapse activating hypnozoites expect highly impactful apply treatment target hypnozoite reservoir ie collection dormant parasites eliminate P vivax Treatment radical cure example tafenoquine primaquine target hypnozoite reservoir potential tool control andor eliminate P vivax developed deterministic multiscale mathematical model system integrodifferential equation capture complex dynamic P vivax hypnozoites effect hypnozoite relapse disease transmission Here use multiscale model study anticipated effect radical cure treatment administered via mass drug administration MDA program implement multiple round MDA fixed interval rounds starting different steadystate disease prevalences construct optimisation model three different objective function motivated public health basis obtain optimal MDA interval also incorporate mosquito seasonality model study effect optimal treatment regime find effect MDA intervention temporary depends preintervention disease prevalence and choice model parameters well number MDA round consideration optimal interval MDA round also depends objective combinations expected intervention outcomes find radical cure alone may enough lead P vivax elimination mathematical model and choice model parameters since prevalence infection eventually return preMDA levels",
        "mesh_terms": [
            "Animals",
            "Humans",
            "Malaria, Vivax",
            "Antimalarials",
            "Mass Drug Administration",
            "Models, Biological",
            "Mathematical Concepts",
            "Malaria",
            "Recurrence"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37076740/"
    },
    {
        "pmid": "36931291",
        "title": "International manufacturing and trade in colistin, its implications in colistin resistance and One Health global policies: a microbiological, economic, and anthropological study.",
        "abstract": "emergence colistinresistant Enterobacterales global public health concern yet colistin still widely used animal used food treatment metaphylaxis prophylaxis growth promotion Herein investigate effect colistinresistant Enterobacterales Pakistan global trade colistin colistin use farm level relevant socioeconomic factors conducted microbiological economic anthropological study colistinresistant Escherichia coli humans animals environment international trade knowledge colistin Pakistan Bangladesh Nigeria China India Viet Nam collected backyard poultry cloacal swabs commercial broiler cloacal swabs cattle buffalo rectal swabs human rectal swabs wild bird droppings cattle buffalo meat sewage water poultry flies chicken meat canal water 131 site across Faisalabad Pakistan tested mcr1positive mcr3positive Escherichia coli recruited new patient admitted Allied Hospital Faisalabad Pakistan abdominal pain diarrhoea rectal swabs Patients dysentery already antibiotic treatment excluded Data colistin trade 2017 2020 including importation manufacturing usage accessed online database government source Pakistan Bangladesh Nigeria recruited participant poultry farm veterinary drug store Pakistan Nigeria interviewed using structured questionnaire International manufacturing import export data value analysis trade route colistin pharmaceutical raw material PRM feed additive finished pharmaceutical product FPPs accessed 201721 export data sets collected 1131 sample May 12 2018 July 1 2019 backyard poultry cloacal swab n100 commercial broiler cloacal swab n102 cattle buffalo rectal swab n188 human rectal swab n200 wild bird droppings n100 cattle buffalo meat n100 sewage water n90 poultry fly n100 chicken meat n100 canal water n51 recruited 200 inpatient Allied Hospital Faisalabad Pakistan Nov 15 2018 Dec 14 2018 rectal swabs recruited 21 participant Jan 1 2020 Dec 31 2020 poultry farm drug store Pakistan Nigeria interviewed 75 7 1131 sample contained mcr1positive E coli including wild bird droppings 25 25 100 commercial broiler cloacal swab 17 17 100 backyard poultry cloacal swab one 1 100 chicken meat 13 13 100 cattle buffalo meat two 2 100 poultry fly eight 8 100 sewage water six 7 90 human rectal swab three 2 200 201720 Pakistan imported 275·5 tonne 68·9 tonne per year 95 CI 41·296·6 colistin PRM sourced China 701·9 tonne 175·5 tonne per year 140·9210·1 colistin feed additive China Viet Nam 63·0 tonne 15·8 tonne per year 10·421·1 colistin FPPs various country Asia Europe Bangladesh Nigeria colistin PRM FPPs imported China Europe Colistin knowledge usage practice Pakistan Nigeria unsatisfactory term understanding effect human medicine usage treatment purposes China major manufacturer PRM feed additive colistin exported total 2664·8 tonne 666·2 tonne per year 95 CI 262·1 1070·2 PRM 2570·2 tonne 642·6 tonne per year 89·4 1374·5 feed additive 1330 shipment 201821 21 countries Regardless 193 country signing UN agreement tackle antimicrobial resistance trading colistin PRM FPPs feed additive growth promoter lowincome middleincome country continues unabated Robust national international law urgently required mitigate international trade antimicrobial listed Critically Important Antimicrobials Human Medicine Pakistan Agricultural Research Council INEOS Oxford Institute Antimicrobial Research TRANSLATION Urdu translation abstract see Supplementary Materials section",
        "mesh_terms": [
            "Cattle",
            "Animals",
            "Humans",
            "Colistin",
            "Escherichia coli",
            "Sewage",
            "Buffaloes",
            "Commerce",
            "One Health",
            "Chickens",
            "Internationality",
            "Poultry",
            "Anti-Infective Agents",
            "Policy",
            "Pakistan",
            "Escherichia coli Proteins"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36931291/"
    },
    {
        "pmid": "36864926",
        "title": "Pf7: an open dataset of <i>Plasmodium falciparum</i> genome variation in 20,000 worldwide samples.",
        "abstract": "describe MalariaGEN Pf7 data resource seventh release iPlasmodium falciparumi genome variation data MalariaGEN network comprises 20000 sample 82 partner study 33 countries including several malaria endemic region previously underrepresented first time include dried blood spot sample sequenced selective whole genome amplification necessitating new method genotype copy number variations identify large number newly emerging icrti mutation part Southeast Asia show example heterogeneity pattern drug resistance within Africa within Indian subcontinent describe profile variation Cterminal icspi gene relate sequence used RTSS R21 malaria vaccines Pf7 provides highquality data genotype call 6 million SNPs short indels analysis large deletion cause failure rapid diagnostic tests systematic characterisation six major drug resistance loci freely downloaded MalariaGEN website",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36864926/"
    },
    {
        "pmid": "36813535",
        "title": "Olanzapine cost-effectiveness in vomiting and nausea from highly emetogenic chemotherapy in children and adolescents.",
        "abstract": "assess costeffectiveness addition olanzapine prophylactic antiemetic regimen containing aprepitant dexamethasone ondansetron among child receiving highly emetogenic chemotherapy HEC India Bangladesh Indonesia UK USA Health state estimated using individual patientlevel outcome data randomised trial incremental costutility ratio ICUR incremental costeffectiveness ratio net monetary benefit NMB calculated patient perspective India Bangladesh Indonesia UK USA Oneway sensitivity analysis done varying cost olanzapine cost hospitalisation utility value ±25 olanzapine arm increment 00018 qualityadjusted lifeyears QALY control arm mean total expenditure olanzapine arm greater US051 US043 US673 US1105 US1235 India Bangladesh Indonesia UK USA respectively ICURQALY US28260 India US24142 Bangladesh US375593 Indonesia US616183 UK US688741 USA NMB US986 US1012 US1408 US4474 US9879 India Bangladesh Indonesia UK USA respectively ICUR estimate base case sensitivity analysis willingnesstopay threshold scenarios addition olanzapine fourth agent antiemetic prophylaxis costeffective despite increase overall expenditure Olanzapine uniformly considered child receiving HEC",
        "mesh_terms": [
            "Adolescent",
            "Child",
            "Humans",
            "Antiemetics",
            "Antineoplastic Agents",
            "Cost-Benefit Analysis",
            "Dexamethasone",
            "Nausea",
            "Olanzapine",
            "Vomiting",
            "Randomized Controlled Trials as Topic"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36813535/"
    },
    {
        "pmid": "36782190",
        "title": "Comparison of simplicity, convenience, safety, and cost-effectiveness between use of insulin pen devices and disposable plastic syringes by patients with type 2 diabetes mellitus: a cross-sectional study from Bangladesh.",
        "abstract": "Insulin pen device disposable plastic insulin syrinx two common tool insulin administration study aim compare simplicity convenience safety costeffectiveness insulin pen versus syringe device patient type 2 diabetes mellitus T2DM crosssectional study conducted 14 diabetes clinic throughout Bangladesh November 2021 April 2022 among adult T2DM injecting insulin pen device disposable insulin syrinx least day least one year purposive sampling simplicity convenience safety insulin device assessed using structured questionnaire study subject scored based answers higher score indicated poorer response Total score simplicity convenience safety obtained adding score relevant components average monthly medical expense cost insulin therapy recorded median value total score monthly expense compared pen device disposable syringe users 737 subject evaluated 406 pen users 331 vial syringe users pen user lower median score simplicity 60 5080 vs 70 5090 p  0002 convenience 40 3060 vs 50 4060 p  0001 safety 70 6080 vs 70 6090 p  0008 vial syringe users Pen device expensive vial syrinx term average medical expense per month BDT 5000 35007000 vs 3000 20005000 p  0001 total cost insulin therapy per month BDT 2000 15003000 vs 1200 8001700 p  0001 cost per unit insulin used BDT 208 139278 vs 096 064139 p  0001 Nonsignificant difference favor pen observed HbA1c level 87 7810 vs 89 7910 p  0607 proportion subject HbA1c  7 69 vs 63 p  0991 Insulin pen simpler convenient safe expensive vial syringes Glycemic control comparable pen syringe users Longterm followup study needed determine clinical economic impact benefit insulin pens",
        "mesh_terms": [
            "Adult",
            "Humans",
            "Bangladesh",
            "Cost-Benefit Analysis",
            "Cross-Sectional Studies",
            "Diabetes Mellitus, Type 2",
            "Disposable Equipment",
            "Glycated Hemoglobin",
            "Hypoglycemic Agents",
            "Insulin",
            "Retrospective Studies",
            "Syringes",
            "Drug Delivery Systems"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36782190/"
    },
    {
        "pmid": "36545347",
        "title": "Cost of oral cholera vaccine delivery in a mass immunization program for children in urban Bangladesh.",
        "abstract": "Cholera pose substantial health burden developing world due epidemic endemic diseases World Health Organization recommends oral cholera vaccine mass vaccination campaign addition traditional prevention practice treatment resourcepoor settings many developing country like Bangladesh major challenge behind implementing mass vaccination campaign concern affordability oral cholera vaccine OCV Vaccination child OCV impactful approach controlling cholera population level reducing childhood morbidity also considered costeffective vaccinating ages aim study estimate cost OCV campaign child societal perspective using empirical study total 66311 child aged 1 14 year old fully vaccinated two dos OCV Shanchol 9035 individual received one dose vaccine estimated societal cost per individual full vaccination US 611 includes cost vaccine delivery estimated US 195 cost per single dose estimated US 286 total provider cost full vaccination estimated US 601 recipient cost US 010 estimation OCV delivery cost child relatively higher found similar mass OCV campaign age groups indicating may additional cost factor consider targeted vaccine campaigns analysis provides useful benchmark possible cost related delivery OCV child future OCV costeffectiveness model factor possible cost disparities Attempts reduce cost per dose likely greater impact cost similar vaccination campaign many resourcepoor settings",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36545347/"
    },
    {
        "pmid": "36192508",
        "title": "Cost-effectiveness of universal iron supplementation and iron-containing micronutrient powders for anemia among young children in rural Bangladesh: analysis of a randomized, placebo-controlled trial.",
        "abstract": "Universal provision iron supplement ironcontaining multiple micronutrient powder MNPs widely used prevent anemia young child low middleincome countries BRISC Benefits Risks Iron Interventions Children trial compared iron supplement MNPs placebo child 2 old rural Bangladesh aimed assess costeffectiveness iron supplement ironcontaining MNPs among young child rural Bangladesh costeffectiveness analysis MNPs iron supplement using BRISC trial outcome resource use data programmatic data literature Health care cost assessed health system perspective calculated incremental costeffectiveness ratio ICERs term US per disabilityadjusted lifeyear DALY averted explore uncertainty constructed costeffectiveness acceptability curve using bootstrapped data range costeffectiveness thresholds One 2way sensitivity analysis tested impact varying key parameter value results Provision MNPs estimated avert 00031 95 CI 00022 00041 DALYschild whereas iron supplement averted 00039 95 CI 00030 00048 DALYschild 1 compared intervention Incremental mean cost 075 95 CI 073 077 MNPs compared intervention 064 062 067 iron supplement compared intervention Iron supplementation dominated MNPs cheaper averted DALYs Iron supplementation ICER 1645 1333 2153 per DALY averted compared intervention 0 probability optimal strategy costeffectiveness threshold 200 reflecting health opportunity cost Bangladesh 985 half gross domestic product GDP per capita per DALY averted Scenario sensitivity analysis supported base case findings finding support universal iron supplementation micronutrient powder costeffective intervention young child rural Bangladesh trial registered anzctrorgau ACTRN1261700066038 trialsearchwhoint U111111961125",
        "mesh_terms": [
            "Child",
            "Humans",
            "Child, Preschool",
            "Iron",
            "Micronutrients",
            "Cost-Benefit Analysis",
            "Powders",
            "Bangladesh",
            "Dietary Supplements",
            "Trace Elements",
            "Anemia"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36192508/"
    },
    {
        "pmid": "36182233",
        "title": "Economic loss attributable to cigarette smoking in the USA: an economic modelling study.",
        "abstract": "Despite large geographical disparity prevalence cigarette smoking across USA paucity statelevel estimate economic loss attributable smoking inform tobacco control policy national state levels aimed estimate statelevel economic loss attributable cigarette smoking USA economic modelling study used dynamic macroeconomic model personal income per caput state level Based publicly available data statelevel income determinants smoking status 201120 first estimated elasticity personal income per caput respect prevalence nonsmoking adult aged ≥18 years USA using mixedeffects generalised linear dynamic panel data model used estimated elasticity measure statespecific annual avoidable economic loss attributable cigarette smoking 2020 counterfactual 5 prevalence cigarette smoking estimated statespecific cumulative economic loss attributable cigarette smoking 2020 using coefficient lagged income dynamic model National estimate economic loss attributable cigarette smoking obtained summing statespecific estimates mixedeffects model elasticity personal income per caput respect prevalence nonsmoking adult 0·143 p0·063 estimated annual income loss per caput 2020 ranged US331 Utah 1674 Kentucky state mean populationweighted loss per caput 1100 annual combined loss income unpaid household production national level 436·7 billion equivalent 2·1 US gross domestic product GDP 2020 cumulative loss income unpaid household production 864·5 billion equivalent 4·3 US GDP 2020 Smoking cause substantial economic loss USA Tobacco control effort lower prevalence smoking equitably contribute considerably improved macroeconomic performance short long term reducing health expenditure avoiding productivity losses American Cancer Society",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Cigarette Smoking",
            "Health Expenditures",
            "Humans",
            "Models, Economic",
            "Tobacco Products",
            "United States"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36182233/"
    },
    {
        "pmid": "36145477",
        "title": "Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis.",
        "abstract": "Low glucose6phosphate dehydrogenase enzyme G6PD activity key determinant druginduced haemolysis 230 clinically relevant genetic variant described investigated variation G6PD activity within different genetic variants systematic review individual patient data study reporting G6PD activity measured spectrophotometry corresponding G6PD genotype pooled PROSPERO CRD42020207448 G6PD activity converted percent normal activity applying studyspecific definition 100 total 4320 individual 17 study across 10 country included 1738 402 one 24 confirmed G6PD mutations 61 observation 35 identified outliers median activity hemihomozygotes Ac202GAc376AG 290 range 17 766 102 range 00 325 Mahidol 169 range 33 213 Mediterranean 90 range 29 232 Vanua Lava 75 range 00 183 Viangchan median activity heterozygote 721 range 164 1271 Ac202GAc376AG 545 range 00 1128 Mahidol 379 range 207 805 Mediterranean 538 range 109 825 Vanua Lava 523 range 48 786 Viangchan total 995 hemihomozygotes Mahidol mutation 100 Mediterranean Vanua Lava Viangchan mutation 30 activity Ac202GAc376AG 55 hemihomozygotes 30 activity G6PD activity variant spanned current classification threshold used define clinically relevant category enzymatic deficiency",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36145477/"
    },
    {
        "pmid": "36109733",
        "title": "Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data.",
        "abstract": "2012 World Health Organization WHO recommended single lowdose SLD 025 mgkg primaquine added Plasmodium P falciparum gametocytocide artemisininbased combination therapy ACT without glucose6phosphate dehydrogenase G6PD testing accelerate malaria elimination effort avoid spread artemisinin resistance Uptake recommendation relatively slow primarily due safety concerns systematic review individual patient data IPD metaanalysis singledose SD primaquine study P falciparum malaria performed Absolute fractional change haemoglobin concentration within week adverse effect within 28 day treatment initiation characterised compared primaquine primaquine arm using random intercept models Data comprised 20 study enrolled 6406 participants 5129 801 received single target dose primaquine ranging 00625 075 mgkg effect primaquine G6PDnormal participant haemoglobin concentrations However among 194 G6PDdeficient African participants 025 mgkg primaquine target dose resulted additional 053 gdL 95 CI 017089 reduction haemoglobin concentration day 7 027 95 CI 019034 gdL haemoglobin drop estimated every 01 mgkg increase primaquine dose Baseline haemoglobin young age hyperparasitaemia main determinant becoming anaemic Hb  10 gdL nadir observed ACT day 2 3 regardless G6PD status exposure primaquine Time recovery anaemia took longer young child baseline anaemia hyperparasitaemia Serious adverse haematological event primaquine 93 113 03 transitory One blood transfusion reported primaquine arms primaquinerelated deaths controlled studies proportion either haematological serious adverse event similar primaquine primaquine arms result support recommendation use 025 mgkg primaquine P falciparum gametocytocide including G6PDdeficient individuals Although primaquine associated transient reduction haemoglobin level G6PDdeficient individuals haemoglobin level clinical presentation major determinant anaemia patients PROSPERO CRD42019128185",
        "mesh_terms": [
            "Antimalarials",
            "Artemisinins",
            "Child",
            "Child, Preschool",
            "Glucosephosphate Dehydrogenase",
            "Hemoglobins",
            "Humans",
            "Malaria, Falciparum",
            "Plasmodium falciparum",
            "Primaquine"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36109733/"
    },
    {
        "pmid": "35840634",
        "title": "Antioxidant, cytotoxic and apoptotic activities of the rhizome of Zingiber zerumbet Linn. in Ehrlich ascites carcinoma bearing Swiss albino mice.",
        "abstract": "Due long history traditional us functional food Zingiber zerumbet selected explore inherent antioxidant antineoplastic activity methanolic extract rhizome MEZZR Ehrlich ascites carcinoma EAC cells rich polyphenol containing MEZZR showed marked DPPH ABTS nitric oxide radical lipid peroxidation inhibition activity ICsub50sub 343 ± 125 1138 ± 139 2312 ± 339 1647 ± 147 µgml respectively compared standard catechin vivo MEZZR significantly inhibited EAC cell growth decreased body weight gain increased life span restored altered hematological characteristic EACbearing mice Moreover MEZZR induced nuclear condensation fragmentation notable feature apoptosis observed fluorescence microscopy staining EAC cell MEZZRtreated mouse Hoechst 33342 Additionally vitro cell growth inhibition caused MEZZR MTT assay remarkably decreased presence caspase3 8 9 inhibitors study thus suggests MEZZR may possess promising antiproliferative efficacy EAC cell inducing cell apoptosis",
        "mesh_terms": [
            "Animals",
            "Antineoplastic Agents",
            "Antineoplastic Agents, Phytogenic",
            "Antioxidants",
            "Ascites",
            "Carcinoma, Ehrlich Tumor",
            "Mice",
            "Plant Extracts",
            "Rhizome"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35840634/"
    },
    {
        "pmid": "35710474",
        "title": "The private sector market for malaria rapid diagnostic tests in Nigeria: results of the 2018 market survey.",
        "abstract": "avoid misuse antimalarials correct diagnosis fever prior drug prescription essential Presumptive treatment private healthcare sector concern Nigeria availability affordable artemisininbased combination therapy ACT high following implementation subsidy scheme 2010 2017 Similar subsidy not however implemented malaria rapid diagnostic test RDTs market survey 2018 predominantly designed assess ACT market private sector also collected data related RDTs result presented herein 2018 market survey consisted i outlet survey targeting private pharmacy Proprietary Patent Medicine Vendors PPMVs across different region Nigeria assess supplyside market factor related availability RDTs defined stock available purchase time survey ii household survey determine demandside factor related knowledge RDTs healthcareseeking practice affordability Availability RDTs time survey low outlet type significantly lower PPMVs 221 95 CI among pharmacy versus 136 95 CI among PPMVs p  001 Reasons restocking RDTs included low demand supply majority household diagnose malaria based experience onethird would visit PPMV pharmacy Half household heard RDTs 484 386 thought affordable Low availability RDTs among PPMVs pharmacy may attributed lack demand supplyside issue cost Increasing household knowledge RDTs may aid increasing demand subsidized RDTs may address supply price issues Addressing deficit RDT provision important targeting ACT medicines",
        "mesh_terms": [
            "Antimalarials",
            "Cross-Sectional Studies",
            "Diagnostic Tests, Routine",
            "Humans",
            "Malaria",
            "Nigeria",
            "Private Sector",
            "Surveys and Questionnaires"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35710474/"
    },
    {
        "pmid": "35651694",
        "title": "An open dataset of <i>Plasmodium vivax</i> genome variation in 1,895 worldwide samples.",
        "abstract": "report describes MalariaGEN Pv4 dataset new release curated genome variation data 1895 sample iPlasmodium vivaxi collected 88 worldwide location 2001 2017 includes 1370 new sample contributed MalariaGEN VivaxGEN partner study addition previously published sample sources provide genotype call 45 million variable position including 3 million single nucleotide polymorphism SNPs well short indels tandem duplications enlarged dataset highlight major compartment parasite population structure clear differentiation Africa Latin America Oceania Western Asia different part Southeast Asia sample classified drug resistance sulfadoxine pyrimethamine mefloquine based known marker idhfri idhpsi imdr1i loci prevalence resistance marker much higher Southeast Asia Oceania elsewhere open resource analysisready genome variation data MalariaGEN VivaxGEN network driven collective goal advance research complex biology iP vivaxi accelerate genomic surveillance malaria control elimination",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35651694/"
    },
    {
        "pmid": "35585641",
        "title": "Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA).",
        "abstract": "Plasmodium vivax form dormant liver stage reactivate week month following acute infection Recurrent infection often associated febrile illness cause cumulative risk severe anaemia direct indirect mortality onward transmission parasite increased risk P vivax parasitaemia following falciparum malaria suggesting rationale universal use radically curative treatment patient P falciparum malaria even absence detectable P vivax parasitaemia area coendemic species multicentre health care facilitybased randomized controlled openlabel trial Bangladesh Indonesia Ethiopia Patients uncomplicated falciparum malaria G6PD activity ≥70 adjusted male median AMM haemoglobin level ≥8gdl recruited study randomized either receive standard schizonticidal treatment plus 7day high dose primaquine total dose 7mgkg standard care 11 ratio Patients followed weekly day 63 primary endpoint incidence risk P vivax parasitemia day 63 Secondary endpoint include incidence risk day 63 symptomatic P vivax malaria risk P falciparum parasitaemia Secondary safety outcome include proportion adverse event serious adverse events incidence risk severe anaemia Hb5gdl 7gdl andor risk blood transfusion incidence risk ≥ 25 fall haemoglobin without haemoglobinuria incidence risk ≥ 25 fall haemoglobin 7gdl without haemoglobinuria study evaluates potential benefit universal radical cure P vivax P falciparum different endemic locations found safe effective universal radical cure could represent costeffective approach clear otherwise unrecognised P vivax infection hence accelerate P vivax elimination NCT03916003  Registered 12 April 2019",
        "mesh_terms": [
            "Antimalarials",
            "Hemoglobinuria",
            "Humans",
            "Malaria",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Male",
            "Plasmodium falciparum",
            "Plasmodium vivax",
            "Primaquine"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35585641/"
    },
    {
        "pmid": "35544453",
        "title": "Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria.",
        "abstract": "Primaquine tafenoquine licensed drug activity Plasmodium vivax hypnozoites cause haemolysis patient glucose6phosphate dehydrogenase G6PD deficiency Malaria also cause haemolysis leading replacement older erythrocyte low G6PD activity reticulocyte young erythrocyte higher activity Aim study assess impact acute malaria G6PD activity Selected patient uncomplicated malaria recruited Bangladesh n  87 Indonesia n  75 Ethiopia n  173 G6PD activity measured initial presentation malaria median 176 day later range 140 998 absence malaria Among selected participant deficient participant preferentially enrolled Bangladesh sites G6PD activity fell malaria follow 791 95CI 404 1178 6 participant classified deficient 30 activity 437 95CI 342 531 39 individual intermediate activity 30 70 45 95CI 14 76 290 G6PD normal ≥70 participants Bangladesh Indonesia G6PD activity significantly higher acute malaria individual retested follow 409 95CI 334481 74 95CI 02 146 respectively whereas Ethiopia G6PD activity 36 95CI 10 61 lower acute malaria change G6PD activity apparent patient presenting either P vivax P falciparum infection Overall 667 46 severely deficient participant 872 3439 intermediate deficiency normal activity presenting malaria finding suggest G6PD activity rise significantly clinically relevant level acute malaria Prospective casecontrol study warranted confirm degree predicted population attributable risk drug induced haemolysis lower would predicted cross sectional surveys",
        "mesh_terms": [
            "Antimalarials",
            "Cross-Sectional Studies",
            "Glucosephosphate Dehydrogenase",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Hemolysis",
            "Humans",
            "Malaria",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Primaquine"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35544453/"
    },
    {
        "pmid": "35532103",
        "title": "\"<i>In silico</i> identification of ethoxy phthalimide pyrazole derivatives as IL-17A and IL-18 targeted gouty arthritis agents\".",
        "abstract": "Two proinflammatory cytokines IL17A IL18 observed elevated serum gout patient play crucial role development worsening inflammation severe effects present study combined molecular docking molecular dynamic study MMPBSA analysis study effectiveness ethoxy phthalimide pyrazole derivative series 3a 3e potential inhibitor cytokine IL17A IL18 druggable targets binding energy docked series range 135 100 kcalmol extensively interacts amino acid active pocket IL17A IL18 Compound 3e lowest binding energy IL17A 126 kcalmol compared control allopurinol 332 kcalmol IL18 compound 3a seems lowest binding energy 96 kcalmol compared control allopurinol 318 kcalmol MD simulation studies compound 3a form stable energetically stabilized complex target protein Depending property bound IL17A3a IL183a complex compared mean MMPBSA analysis derivative used scaffold develop promising IL17A IL18 inhibitor assess potential gouty arthritis related diseases Communicated Ramaswamy H Sarma",
        "mesh_terms": [
            "Humans",
            "Interleukin-18",
            "Arthritis, Gouty",
            "Interleukin-17",
            "Allopurinol",
            "Molecular Docking Simulation",
            "Antineoplastic Agents",
            "Cytokines",
            "Phthalimides",
            "Pyrazoles",
            "Molecular Dynamics Simulation"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35532103/"
    },
    {
        "pmid": "35419560",
        "title": "Identification of 1, 2, 4-Triazine and Its Derivatives Against Lanosterol 14-Demethylase (CYP51) Property of <i>Candida albicans:</i> Influence on the Development of New Antifungal Therapeutic Strategies.",
        "abstract": "research aim find whether 1 2 4triazine derivative antifungal effect protect human infection iCandida albicansi Molecular docking molecular dynamic simulation widely used modern drug design target particular protein ligand interested using molecular docking molecular dynamic modeling investigate interaction derivative 1 2 4triazine enzyme Lanosterol 14demethylase CYP51 iCandida albicansi inhibition iCandida albicansi CYP51 main goal research 1 2 4triazine derivative docked CYP51 enzyme involved iCandida albicansi Multidrug Drug Resistance MDR Autodock tool used identify binding affinity molecule target proteins Compared conventional fluconazole molecular docking result indicated drug high binding affinity CYP51 protein form unbound interaction hydrogen bond active residue surrounding allosteric residues docking contact made using 10 n MD simulation nine molecules RMSD RMSF hydrogen bonds Rg confirm conclusions addition compound expected favorable pharmacological profile low toxicity compound offered scaffold development new antifungal drug candidate future iin vitroi testing",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35419560/"
    },
    {
        "pmid": "35402627",
        "title": "Prospective Asian plants with corroborated antiviral potentials: Position standing in recent years.",
        "abstract": "Viral disease extremely widespread infection caused viruses Amongst numerous illnesses viral infection challenged human existence severely history mankind new virus emerged presented u new tests range viral infection varies familiar infectious disease common cold flu wart severe ailment AIDS Ebola COVID19 world racing find effective cure newly evolving viruses Toxic effects nonselectivity drug resistance high price common complication conventional treatment procedures Nature marvelous source phytoconstituents incredible variety biological activities tradition medicinal plant utilized treatment countless infectious disease worldwide contain broad spectrum activities Modern drug discovery development technique offer highly efficient separation techniques inauguration vectorbased scheme original infectious virus cloned noninfectious one antiviral screening targets objective review gather available data 20 cultivated native plant Asia giving antiviral activity provide comprehensive information phytochemical analysis plant potential antiviral compound isolated plants",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35402627/"
    },
    {
        "pmid": "35277538",
        "title": "Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing.",
        "abstract": "pandemic threat COVID19 severely destroyed human life well economy around world Although vaccination reduced outspread people still suffering due unstable RNA sequence pattern SARSCoV2 demand supplementary drugs explore novel drug target proteins study transcriptomics RNASeq data generated SARSCoV2 infection control sample analyzed identified 109 differentially expressed gene DEGs utilized identify 10 hubgenesproteins TLR2 USP53 GUCY1A2 SNRPD2 NEDD9 IGF2 CXCL2 KLF6 PAG1 ZFP36 proteinprotein interaction PPI network analysis GO functional KEGG pathway enrichment analysis hubDEGs revealed important function signaling pathway significantly associated SARSCoV2 infections interaction network analysis identified 5 TFs protein 6 miRNAs key regulator hubDEGs Considering 10 hubproteins 5 key TFsproteins drug target receptors performed docking analysis SARSCoV2 3CL proteaseguided top listed 90 FDA approved drugs found Torin2 Rapamycin Radotinib Ivermectin Thiostrepton Tacrolimus Daclatasvir top ranked seven candidate drugs investigated resistance performance already published COVID19 causing topranked 11 independent 8 protonated receptor protein molecular docking analysis found strong binding affinities indicates proposed drug effective stateofthearts alternative independent receptor protein also Finally investigated stability top three drug Torin2 Rapamycin Radotinib using 100 n MDbased MMPBSA simulation two topranked proposed receptor TLR2 USP53 independent receptor IRF7 STAT1 observed stable performance Therefore proposed drug might play vital role treatment different variant SARSCoV2 infections",
        "mesh_terms": [
            "COVID-19",
            "Case-Control Studies",
            "Drug Repositioning",
            "Gene Regulatory Networks",
            "Genetic Markers",
            "Humans",
            "Molecular Docking Simulation",
            "Protein Interaction Maps",
            "SARS-CoV-2",
            "COVID-19 Drug Treatment"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35277538/"
    },
    {
        "pmid": "34997152",
        "title": "A comprehensive analysis of selected medicines collected from private drug outlets of Dhaka city, Bangladesh in a simple random survey.",
        "abstract": "Comprehensive data needed prevent substandard falsified SF medicine pose major risk human health assess quality selected medicines sample collected random private drug outlet Dhaka North South City Corporation Bangladesh Sample analysis included visual observation packaging authenticity samples legitimacy registration verification manufacturer physicochemical analysis price Chemical analysis sample performed using portable Raman spectroscopy highperformance liquid chromatography according pharmacopoeia Several discrepancy noted visual observation samples Among 189 collected sample esomeprazole ESM cefixime CFIX amoxicillinclavulanic acid CVAAMPC 212 confirmed authentic 913 manufacturer confirmed legitimate 21 sample unregistered Chemical analysis sample revealed 95 95 CI 57146 sample SFs Falsified sample quality variation generic branded sample detected Raman spectroscopic analysis Overall sample price satisfactory relative international reference price study document availability poorquality medicines demonstrating need immediate attention national medicine regulatory authority",
        "mesh_terms": [
            "Bangladesh",
            "Commerce",
            "Drug Contamination",
            "Drug Packaging",
            "Drugs, Generic",
            "Quality Control"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34997152/"
    },
    {
        "pmid": "34967848",
        "title": "Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.",
        "abstract": "Global Burden Diseases Injuries Risk Factors Study 2019 GBD 2019 provided systematic estimate incidence morbidity mortality inform local international effort toward reducing cancer burden estimate cancer burden trend globally 204 country territory Sociodemographic Index SDI quintiles 2010 2019 GBD 2019 estimation method used describe cancer incidence mortality year lived disability year life lost disabilityadjusted life year DALYs 2019 past decade Estimates also provided quintiles SDI composite measure educational attainment income per capita total fertility rate younger 25 years Estimates include 95 uncertainty interval UIs 2019 estimated 236 million 95 UI 222249 million new cancer case 172 million excluding nonmelanoma skin cancer 100 million 95 UI 936106 million cancer death globally estimated 250 million 235264 million DALYs due cancer Since 2010 represented 263 95 UI 203323 increase new cases 209 95 UI 142276 increase deaths 160 95 UI 93228 increase DALYs Among 22 group disease injury GBD 2019 study cancer second cardiovascular disease number deaths year life lost DALYs globally 2019 Cancer burden differed across SDI quintiles proportion year lived disability contributed DALYs increased SDI ranging 14 1118 low SDI quintile 57 4271 high SDI quintile high SDI quintile highest number new case 2019 middle SDI quintile highest number cancer death DALYs 2010 2019 largest percentage increase number case death occurred low lowmiddle SDI quintiles result systematic analysis suggest global burden cancer substantial growing burden differing SDI result provide comprehensive comparable estimate potentially inform effort toward equitable cancer control around world",
        "mesh_terms": [
            "Disability-Adjusted Life Years",
            "Global Burden of Disease",
            "Global Health",
            "Humans",
            "Incidence",
            "Neoplasms",
            "Prevalence",
            "Quality-Adjusted Life Years",
            "Risk Factors"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34967848/"
    },
    {
        "pmid": "34962984",
        "title": "The cost implications of a polypill for primary prevention in the TIPS-3 trial.",
        "abstract": "International Polycap Study 3 TIPS3 trial demonstrated polypill containing cholesterol multiple bloodpressurelowering drug reduces cardiovascular event 20 compared placebo people without cardiovascular disease polypill plus aspirin led 31 relative risk reduction cardiovascular disease event compared double placebo report regional variation cost affordability polypill based TIPS3 trial Countries categorized using World Bank economic groups lowermiddleincome uppermiddleincome highincome countries Countryspecific cost obtained hospitalization events procedures nonstudy medication 2019 US dollars Polypill price based cheapest equivalent substitute CES component polypill vs placebo difference cost 46 year trial 291 95 confidence interval CI 243339 per participant lowermiddleincome countries 1068 95 CI 9921144 uppermiddleincome countries 48 95 CI 271 367 highincome countries Results similar polypill plus aspirin vs double placebo cases polypill affordable group using monthly household capacity pay threshold 4 gross national income per capita use polypill CES TIPS3 increase cost lowermiddleincome country uppermiddleincome country affordable country various economic level cost neutral dominant highincome countries",
        "mesh_terms": [
            "Humans",
            "Aspirin",
            "Cardiovascular Diseases",
            "Drug Combinations",
            "Hydroxymethylglutaryl-CoA Reductase Inhibitors",
            "Platelet Aggregation Inhibitors",
            "Primary Prevention"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34962984/"
    },
    {
        "pmid": "34928380",
        "title": "Genome-wide chromosomal association of Upf1 is linked to Pol II transcription in Schizosaccharomyces pombe.",
        "abstract": "Although RNA helicase Upf1 hitherto examined mostly relation cytoplasmic role nonsense mediated mRNA decay NMD report highthroughput ChIP data indicating genomewide association Upf1 active gene Schizosaccharomyces pombe association RNase sensitive correlate Pol II transcription mRNA expression levels Changes Pol II occupancy detected Upf1 deficient upf1Δ strain prevalently gene showing high Upf1 relative Pol II association wildtype Additionally increased Ser2 Pol II signal detected highly transcribed gene examined ChIPqPCR Furthermore upf1Δ cell hypersensitive transcription elongation inhibitor 6azauracil significant proportion gene associated Upf1 wildtype condition also misregulated upf1Δ data envisage operating nascent transcript Upf1 might influence Pol II phosphorylation transcription",
        "mesh_terms": [
            "Gene Expression Regulation, Fungal",
            "Genome, Fungal",
            "Phosphorylation",
            "RNA Helicases",
            "RNA Polymerase II",
            "Schizosaccharomyces",
            "Schizosaccharomyces pombe Proteins",
            "Transcriptional Activation"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34928380/"
    },
    {
        "pmid": "34790685",
        "title": "Evaluation of the Partial Replacement of Dietary Fish Meal With Fermented or Untreated Soybean Meal in Juvenile Silver Barb, <i>Barbonymus gonionotus</i>.",
        "abstract": "Fish meal FM excellent protein lipid profile However FM losing acceptability substituted plant protein due FM high price high demand sustainability issue global aquaculture production study experimental diet prepared substituting FM fermented soybean meal FSM normal untreated soybean meal SM assess effect growth hematology innate immunity gut physiology digestive enzyme activity juvenile silver barb iBarbonymus gonionotusi Five diets is 40 FM FM 40 20 FM  20 FSM FM 20  FSM 20 20 FM  20 SM FM 20  SM 20 40 FSM FSM 40 40 SM SM 40 fed fish two time daily 90 days 90 day feeding trial FM 40 FM 20  FSM 20 FM 20  SM 20 diet group showed significantly higher weight gain WG specific growth rate SGR compared FSM 40 SM 40 diets Hepatosomatic index HSI viscerosomatic index VSI significantly higher fish fed FSM 40 SM 40 diet fish fed FM 40 diet Hematocrit hemoglobin erythrocyte count significantly lower fish fed SM 40 diet compared fish fed FM 40 FM 20  FSM 20 diets Superoxide dismutase catalase activity liver significantly higher fish fed SM 40 diet compared fish fed FM 40 diet However serum thiobarbituric acid reactive substance fish fed experimental diet unaltered Fish showed significant reduction villus height Vh anterior posterior intestine fish fed FSM 40 SM 40 diets whereas muscular thickness opposite finding Vh Digestive enzyme activity intestine significantly higher fish fed FM 40 diet compared SM 40 diet result present study revealed 50 FM replaced FSM SM source protein without affecting growth juvenile silver barb",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34790685/"
    },
    {
        "pmid": "34758422",
        "title": "Results of the COVID-19 mental health international for the general population (COMET-G) study.",
        "abstract": "published empirical data effect COVID19 mental health now large international study COVID19 pandemic online questionnaire gathered data 55589 participant 40 country 6485 female aged 3580 ± 1361 3405 male aged 3490±1329 110 aged 3164±1315 Distress probable depression identified use previously developed cutoff algorithm respectively Descriptive statistic calculated Chisquare tests multiple forward stepwise linear regression analysis Factorial Analysis Variance ANOVA tested relation among variables Probable depression detected 1780 distress 1671 significant percentage reported deterioration mental state family dynamic everyday lifestyle Persons history mental disorder higher rate current depression 3182 vs 1307 least half participant accepting at least moderate degree nonbizarre conspiracy highest Relative Risk RR develop depression associated history Bipolar disorder selfharmattempts RR  588 Suicidality increased person without history mental disorder Based result model developed final model revealed multiple vulnerability interplay leading simple anxiety probable depression suicidality distress could practical utility since many factor modifiable Future research intervention specifically focus them",
        "mesh_terms": [
            "Adult",
            "Anxiety",
            "COVID-19",
            "Depression",
            "Female",
            "Global Burden of Disease",
            "Humans",
            "Male",
            "Mental Health",
            "Middle Aged",
            "Pandemics",
            "SARS-CoV-2",
            "Stress, Psychological",
            "Suicidal Ideation"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34758422/"
    },
    {
        "pmid": "34503501",
        "title": "Pharmacies in informal settlements: a retrospective, cross-sectional household and health facility survey in four countries.",
        "abstract": "Slums informal settlement characterize large city LMIC Previous evidence suggests pharmacy may frequently used source primary care LMICs pharmacy service variable quality However evidence pharmacy use availability limited slum populations conducted household individual healthcare provider survey qualitative observation pharmacy pharmacy use seven slum site four country Nigeria Kenya Pakistan Bangladesh pharmacy 1200 household site sampled Adults child surveyed use healthcare service pharmacy observed services equipment stock documented completed 7692 household 7451 individual adults 2633 individual child surveys 157 survey pharmacy located within seven sites Visit rate pharmacy drug seller varied 01 Nigeria 30 Bangladesh visit per personyear almost new conditions found highly variable condition constituted pharmacy across site pharmacy employ qualified pharmacist Analgesics antibiotic widely available category medications particularly chronic illness often available anywhere majority pharmacy lacked basic equipment thermometer weighing scales Pharmacies locally widely available resident slums However condition facility availability medicine poor price relatively high Pharmacies may represent large untapped resource improving access primary care urban poor",
        "mesh_terms": [
            "Adult",
            "Child",
            "Cross-Sectional Studies",
            "Health Facilities",
            "Humans",
            "Pharmaceutical Services",
            "Pharmacies",
            "Retrospective Studies"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34503501/"
    },
    {
        "pmid": "34450083",
        "title": "Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.",
        "abstract": "Hypertension detected primary healthcare level lowcost treatment effectively control hypertension aimed measure prevalence hypertension progress detection treatment control 1990 2019 200 country territories used data 1990 2019 people aged 3079 year populationrepresentative study measurement blood pressure data blood pressure treatment defined hypertension systolic blood pressure 140 mm Hg greater diastolic blood pressure 90 mm Hg greater taking medication hypertension applied Bayesian hierarchical model estimate prevalence hypertension proportion people hypertension previous diagnosis detection taking medication hypertension treatment whose hypertension controlled 14090 mm Hg control model allowed trend time nonlinear vary age number people aged 3079 year hypertension doubled 1990 2019 331 95 credible interval 306359 million woman 317 292344 million men 1990 626 584668 million woman 652 604698 million men 2019 despite stable global agestandardised prevalence 2019 agestandardised hypertension prevalence lowest Canada Peru men women Taiwan South Korea Japan country western Europe including Switzerland Spain UK women several lowincome middleincome country Eritrea Bangladesh Ethiopia Solomon Islands men Hypertension prevalence surpassed 50 woman two country men nine countries central eastern Europe central Asia Oceania Latin America Globally 59 5562 woman 49 4652 men hypertension reported previous diagnosis hypertension 2019 47 4351 woman 38 3541 men treated Control rate among people hypertension 2019 23 2027 woman 18 1621 men 2019 treatment control rate highest South Korea Canada Iceland treatment 70 control 50 followed USA Costa Rica Germany Portugal Taiwan Treatment rate less 25 woman less 20 men Nepal Indonesia country subSaharan Africa Oceania Control rate 10 woman men country men country north Africa central south Asia eastern Europe Treatment control rate improved country since 1990 found little change country subSaharan Africa Oceania Improvements largest highincome countries central Europe uppermiddleincome recently highincome country including Costa Rica Taiwan Kazakhstan South Africa Brazil Chile Turkey Iran Improvements detection treatment control hypertension varied substantially across countries middleincome country outperforming highincome nations dual approach reducing hypertension prevalence primary prevention enhancing treatment control achievable highincome country also lowincome middleincome settings WHO",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Antihypertensive Agents",
            "Female",
            "Global Health",
            "Humans",
            "Hypertension",
            "Male",
            "Middle Aged",
            "Prevalence"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34450083/"
    },
    {
        "pmid": "33824913",
        "title": "An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples.",
        "abstract": "MalariaGEN datasharing network enables group around world work together genomic epidemiology malaria describe new release curated genome variation data 7000 iPlasmodium falciparumi sample MalariaGEN partner study 28 malariaendemic countries Highquality genotype call 3 million single nucleotide polymorphism SNPs short indels produced using standardised analysis pipeline Copy number variant associated drug resistance structural variant cause failure rapid diagnostic test also analysed Almost sample showed genetic evidence resistance least one antimalarial drug sample Southeast Asia carried marker resistance six commonlyused drugs Genes expressed mosquito stage parasite lifecycle prominent among locus show strong geographic differentiation continuing enlarge open data resource aim facilitate research evolutionary process affecting malaria control accelerate development surveillance toolkit required malaria elimination",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33824913/"
    },
    {
        "pmid": "34249838",
        "title": "The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.",
        "abstract": "bBackgroundb Diabetes mellitus rate continue rise coupled increasing cost associated complication appreciably increased global expenditure recent years risk complication enhanced poor glycaemic control including hypoglycaemia Longacting insulin analogue developed reduce hypoglycaemia improve adherence considerably higher cost though impacted funding use Biosimilars help reduce medicine costs However introduction affected number factors include originator company dropping price well promoting patented higher strength 300 IUml insulin glargine also concern different device manufacturers bObjectiveb assess current utilisation rate insulins especially longacting insulin analogues rationale pattern seen across multiple country inform strategy enhance future utilisation longacting insulin analogue biosimilars benefit key stakeholders bOur approachb Multiple approach including assessing utilisation expenditure price insulins including biosimilar insulin glargine across multiple continent countries bResultsb considerable variation use longacting insulin analogue percentage insulin prescribed dispensed across country continents ranged limited use longacting insulin analogue among African country compared routine funding use across Europe view perceived benefits Increasing use also seen among Asian country including Bangladesh India similar reasons However concern cost value limited use across Africa Brazil Pakistan though limited use biosimilar insulin glargine 100 IUml compared recent biosimilars especially among European country Korea principally driven small price difference reality originator biosimilars coupled increasing use patented 300 IUml formulation number activity identified enhance future biosimilar use included reimbursing biosimilar longacting insulin analogues introducing prescribing target increasing competition among manufacturer including stimulating local production bConclusionsb concern availability use insulin glargine biosimilars despite lower costs addressed multiple activities",
        "mesh_terms": [
            "Africa",
            "Bangladesh",
            "Biosimilar Pharmaceuticals",
            "Brazil",
            "Europe",
            "Hypoglycemic Agents",
            "India",
            "Insulin, Long-Acting",
            "Pakistan",
            "Republic of Korea"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34249838/"
    },
    {
        "pmid": "34182555",
        "title": "The Burden of Dementia due to Down Syndrome, Parkinson's Disease, Stroke, and Traumatic Brain Injury: A Systematic Analysis for the Global Burden of Disease Study 2019.",
        "abstract": "light increasing trend global number individual affected dementia lack available diseasemodifying therapies necessary fully understand quantify global burden dementia work aimed estimate proportion dementia due syndrome Parkinsons disease clinical stroke traumatic brain injury TBI globally world region order better understand contribution clinical disease dementia prevalence literature review obtained data relative risk dementia condition estimated relative risk age using Bayesian metaregression tool calculated population attributable fraction PAFs proportion dementia attributable condition using estimate relative risk prevalence estimate condition Global Burden Disease Study 2019 Finally multiplied estimate dementia prevalence calculate number dementia case attributable condition clinical condition relative risk dementia decreased age Relative risk highest syndrome followed Parkinsons disease stroke TBI However due high prevalence stroke PAF dementia due stroke highest Together syndrome Parkinsons disease stroke TBI explained 100 95 UI 60165 global prevalence dementia Ten percent dementia prevalence globally could explained syndrome Parkinsons disease stroke TBI quantification proportion dementia attributable 4 condition constitutes small contribution overall understanding cause dementia However epidemiological research modifiable risk factor well basic science research focused elucidating intervention approach prevent delay neuropathological change commonly characterize dementia critically important future effort prevent treat disease",
        "mesh_terms": [
            "Bayes Theorem",
            "Brain Injuries, Traumatic",
            "Dementia",
            "Down Syndrome",
            "Global Burden of Disease",
            "Global Health",
            "Humans",
            "Parkinson Disease",
            "Prevalence",
            "Quality-Adjusted Life Years",
            "Risk Factors",
            "Stroke"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34182555/"
    },
    {
        "pmid": "34166174",
        "title": "Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future.",
        "abstract": "Prevalence rate diabetes mellitus continue rise which coupled increasing cost complications appreciably increased expenditure recent years Poor glycaemic control including hypoglycaemia enhances complication rate associated morbidity mortality costs Consequently need addressed Whilst majority patient diabetes type2 diabetes considerable number patient diabetes require insulin help control diabetes Longacting insulin analogue developed reduce hypoglycaemia associated insulin help improve adherence concern However considerably higher cost impacted funding use especially country affordability issues Biosimilars help reduce cost longacting insulin analogue thereby increasing available choices However availability use longacting insulin analogue affected limited price reduction versus originator limited demandside initiative encourage use Consequently wanted assess current utilisation rate longacting insulin analogues especially biosimilars rationale pattern seen across multiple Asian country ranging Japan highincome Pakistan lowerincome inform future strategies Multiple approach including assessing utilization price insulin including biosimilars among six Asian country comparing finding especially middleincome countries Typically increasing use longacting insulin analogue among selected Asian countries especially case enhanced biosimilars Bangladesh India Malaysia reflecting perceived benefits However limited use Pakistan due issue affordability similar number African countries high use biosimilars Bangladesh India Malaysia helped issue affordability local production limited use biosimilars Japan Korea reflects limited price reduction demandside initiative similar number European countries Increasing use longacting insulin analogue across country welcomed adding range insulin available increasingly includes biosimilars number activity needed enhance use longacting insulin analogue biosimilars Japan Korea Pakistan",
        "mesh_terms": [
            "Asia",
            "Biosimilar Pharmaceuticals",
            "Diabetes Mellitus, Type 2",
            "Humans",
            "Hypoglycemic Agents",
            "Insulin",
            "Insulin, Long-Acting",
            "Japan",
            "Pakistan"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34166174/"
    },
    {
        "pmid": "34051920",
        "title": "Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019.",
        "abstract": "Chewing tobacco type smokeless tobacco use less attention global health community smoked tobacco use However practice popular many part world linked several adverse health outcomes Understanding trend prevalence age time location sex important policy setting relation monitoring assessing commitment Framework Convention Tobacco Control estimated prevalence chewing tobacco use part Global Burden Diseases Injuries Risk Factors Study 2019 using modelling strategy used information multiple type smokeless tobacco products generated time series prevalence chewing tobacco use among individual aged 15 year older 1990 2019 204 country territories including agesex specific estimates also compared trend smoked tobacco time period 2019 273·9 million 95 uncertainty interval 258·5 290·9 people aged 15 year older used chewing tobacco global agestandardised prevalence chewing tobacco use 4·72 4·46 5·01 228·2 million 213·6 244·7 83·29 82·15 84·42 chewing tobacco user lived south Asia region Prevalence among young people aged 1519 year 10 seven location 2019 Although global agestandardised prevalence smoking tobacco use decreased significantly 1990 2019 annualised rate change 1·21 1·26 1·16 similar progress observed chewing tobacco 0·46 0·13 0·79 Among 12 highest prevalence country Bangladesh Bhutan Cambodia India Madagascar Marshall Islands Myanmar Nepal Pakistan Palau Sri Lanka Yemen Yemen significant decrease prevalence chewing tobacco use among male 1990 2019 0·94 1·72 0·14 compared nine 12 country significant decrease prevalence smoking tobacco Among females none 12 country significant decrease prevalence chewing tobacco use whereas seven 12 country significant decrease prevalence tobacco smoking use period Chewing tobacco remains substantial public health problem several region world predominantly south Asia found little change prevalence chewing tobacco use 1990 2019 control effort much larger effect prevalence smoking tobacco use chewing tobacco use countries Mitigating health effect chewing tobacco requires stronger regulation policy specifically target use chewing tobacco especially country high prevalence Bloomberg Philanthropies Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Age Distribution",
            "Female",
            "Global Burden of Disease",
            "Global Health",
            "Health Status",
            "Humans",
            "Male",
            "Middle Aged",
            "Population Surveillance",
            "Prevalence",
            "Quality-Adjusted Life Years",
            "Risk Factors",
            "Sex Distribution",
            "Smoking Cessation",
            "Smoking Prevention",
            "Socioeconomic Factors",
            "Tobacco, Smokeless",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34051920/"
    },
    {
        "pmid": "34030931",
        "title": "\"I held on to the police's leg for mercy\": Experiences of adversity, risk and harm among people who inject drugs during an anti-drug drive in Dhaka, Bangladesh.",
        "abstract": "number country across Asia instituted drug wars aimed eradicating drug supply consumption war often employ strategy like arbitrary arrest detention increased surveillance harassment sometimes extrajudicial killings However measure shown effectively eliminate drug supply consumption rather often predispose people use drug increased risk harm drug war declared form antidrug drive ADD Bangladesh 2018 article examined impact ADD drug injecting activity harm reduction service uptake among people inject drug PWID ethnographic study conducted Dhaka Bangladesh Study participant included PWID harm reduction service provider drug alcohol experts Data collection consisted 2500 hour observations 25 indepth interviews five focus group discussion 15 key informant interviews Data analysed using thematic analysis ADD operation activity subjected PWID multifaceted form violence harassment including extrajudicial killings significantly affected drug procurement drug using practice led increased needle syringe sharing likely increase HIV transmission gradual disappearance established drug markets alongside emergence new one alternate locations resulted dislocation PWID outreach service increased risky injecting practice needle syringe sharing new unfamiliar injecting partners harm compounded unpredictable drug supply price increase stemming ADD turn also increased needle syringe sharing Harm reduction outreach service able adequately adapt volatile dynamic risky nature ADD ADD precipitated risky injecting practice also hindered effective implementation harm reduction outreach service thus undermined public health warrant concerted effort nurture local evidencebased harm reduction approach opposed punitive measures",
        "mesh_terms": [
            "Asia",
            "Bangladesh",
            "HIV Infections",
            "Harm Reduction",
            "Humans",
            "Leg",
            "Needle Sharing",
            "Pharmaceutical Preparations",
            "Police",
            "Substance Abuse, Intravenous"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34030931/"
    },
    {
        "pmid": "33980257",
        "title": "Implementing radical cure diagnostics for malaria: user perspectives on G6PD testing in Bangladesh.",
        "abstract": "radical cure Plasmodium vivax requires treatment 8aminoquinoline drug primaquine tafenoquine eradicate liver hypnozoite stages reactivate cause relapsing infections Safe treatment regimen require prior screening patient glucose6phosphate dehydrogenase G6PD deficiency avoid potential lifethreatening drug induced haemolysis Testing rarely available malaria endemic countries needed support routine use radical cure study investigates enduser perspective Bangladesh introduction quantitative G6PD test SD Biosensor STANDARD™ G6PD analyser support malaria elimination perspective user SD Biosensor test analysed using semistructured interview focus group discussion health care provider malaria programme officer Bangladesh Key emerging theme regarding feasibility introducing test routine practice including perceived barriers analysed total 63 participant interviewed Participants emphasized lifesaving potential biosensor raised concern including impact limited staff time high workload technical aspect device Participants highlighted many P vivax patient implement G6PD testing owing challenge funding workload complex testing infrastructure Implementing biosensor would require flexibility improvisation deal remote sites overcoming low index suspicion mutual interplay declining patient number reluctance test approach would generate new form evidence justify introduction policy carefully consider question deployment given declining patient numbers result study show that elimination context importance malaria need maintained policy maker affected communities case ensuring P vivax PQ treatment G6PD deficiency remain visible Availability new technologies biosensor fuel ongoing debate priority allocating resource must adapted constantly evolving target Technical logistical concern regarding biosensor addressed future product designs adequate training strengthened supply chains careful planning communication advocacy staff interaction health system levels",
        "mesh_terms": [
            "Bangladesh",
            "Diagnostic Tests, Routine",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Health Personnel",
            "Humans",
            "Malaria, Vivax"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33980257/"
    },
    {
        "pmid": "33734004",
        "title": "Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications.",
        "abstract": "Prevalence rate patient diabetes growing across countries Bangladesh exception Associated cost also increasing driven cost associated complication diabetes including hypoglycemia Longacting insulin analogue developed reduce hypoglycemia well improve patient comfort adherence However appreciably expensive reducing affordability use Biosimilars offer way forward Consequently need document current prescribing dispensing rate longacting insulin analogue across Bangladesh including current price differences result affordability issues Mixed method approach including surveying prescribing practice hospital coupled dispensing practice price among community pharmacy drug store across Bangladesh method adopted since public hospital dispense insulin soluble insulin freeofcharge fund run longacting insulin analogue purchased community stores growing prescribing dispensing longacting insulin Bangladesh recent years accounting 80 insulin dispensed minority stores increase helped growing prescribing dispensing biosimilar insulin glargine lower cost originator trend likely continue envisaged growth number patients Consequently Bangladesh serve exemplar low middleincome country struggling fund longacting insulin analogue patients encouraging see continued growth prescribing dispensing longacting insulin analogue Bangladesh via increasing availability biosimilars likely continue benefitting key stakeholder groups",
        "mesh_terms": [
            "Bangladesh",
            "Biosimilar Pharmaceuticals",
            "Diabetes Mellitus",
            "Drug Utilization",
            "Humans",
            "Hypoglycemic Agents",
            "Insulin, Long-Acting",
            "Practice Patterns, Physicians'"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33734004/"
    },
    {
        "pmid": "33353250",
        "title": "Essential Medicines in Universal Health Coverage: A Scoping Review of Public Health Law Interventions and How They Are Measured in Five Middle-Income Countries.",
        "abstract": "study exist legal intervention national laws essential medicine part universal health coverage middleincome countries effect law measured study aim critically assess whether law related universal health coverage use five objective public health law promote medicine affordability financing understand access medicine achieved law measured comparative case study five middleincome country Ecuador Ghana Philippines South Africa Ukraine us public health law framework guide content analysis national law scoping review empirical evidence measuring access medicines Sixty law included country write national law a health equity objectives b remedy userspatients sanction stakeholders c economic policy regulatory objective financing except South Africa pricing benefit selection except South Africa d information dissemination objective ex medicine price except Ghana e public health infrastructure 17 study included scoping review evaluate law economic policy regulatory objective ini  14 articles health equity ini  10 information dissemination ini  3 infrastructure ini  2 sanction ini  1 not mutually exclusive Crosssectional descriptive design ini  8 articles time series analysis ini  5 frequent designs Change patients spending medicine frequent outcome measure ini  5 Although legal intervention pharmaceutical middleincome country commonly use objective public health law intended unintended effect economic policy regulation frequently investigated",
        "mesh_terms": [
            "Adult",
            "Cross-Sectional Studies",
            "Developing Countries",
            "Diabetes Mellitus, Type 2",
            "Ecuador",
            "Ghana",
            "Health Care Reform",
            "Health Services Accessibility",
            "Humans",
            "Longitudinal Studies",
            "Philippines",
            "Public Health",
            "Retrospective Studies",
            "South Africa",
            "Ukraine",
            "Universal Health Insurance"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33353250/"
    },
    {
        "pmid": "33211712",
        "title": "The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network.",
        "abstract": "high risk Plasmodium vivax parasitaemia following treatment falciparum malaria study aimed quantify risk associated determinant using individual patient data metaanalysis order identify population policy universal radical cure combining artemisininbased combination therapy ACT hypnozoitocidal antimalarial drug would beneficial systematic review Medline Embase Web Science Cochrane Database Systematic Reviews identified efficacy study uncomplicated falciparum malaria treated ACT undertaken region coendemic P vivax 1 January 1960 5 January 2018 Data eligible study pooled using standardised methodology risk P vivax parasitaemia day 42 63 associated risk factor investigated multivariable Cox regression analyses Study quality assessed using tool developed Joanna Briggs Institute study registered International Prospective Register Systematic Reviews PROSPERO CRD42018097400 total 42 study enrolling 15341 patient included analysis including 30 randomised controlled trial 12 cohort studies Overall 14146 922 patient P falciparum monoinfection 1195 78 mixed infection P falciparum P vivax median age 170 year interquartile range IQR  90290 years range  080 years 1584 103 patient younger 5 years 2711 177 patient treated artemetherlumefantrine AL 13 studies 651 42 artesunateamodiaquine AA 6 studies 7340 478 artesunatemefloquine AM 25 studies 4639 302 dihydroartemisininpiperaquine DP 16 studies 14537 patient 948 enrolled AsiaPacific region 684 45 Americas 120 08 Africa day 42 cumulative risk vivax parasitaemia following treatment P falciparum 311 95 CI 289334 AL 141 95 CI 108183 AA 74 95 CI 6781 AM 45 95 CI 3953 DP day 63 risk risen 399 95 CI 366433 424 95 CI 347512 228 95 CI 212244 128 95 CI 114145 respectively multivariable analyses highest rate P vivax parasitaemia 42 day followup patient residing area short relapse periodicity adjusted hazard ratio AHR  62 95 CI 20195 p  0002 patient treated AL AHR  62 95 CI 4685 p  0001 AA AHR  23 95 CI 1437 p  0001 AHR  14 95 CI 1019 p  0028 compared DP patient clear initial parasitaemia within 2 day AHR  18 95 CI 1423 p  0001 analysis limited heterogeneity study population lack data low transmission settings Study quality high metaanalysis found high risk P vivax parasitaemia treatment P falciparum malaria varied significantly studies P vivax infection likely attributable relapse could prevented radical cure including hypnozoitocidal agent however benefit novel strategy vary considerably geographical areas",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Aged",
            "Aged, 80 and over",
            "Antimalarials",
            "Artemether, Lumefantrine Drug Combination",
            "Artemisinins",
            "Child",
            "Child, Preschool",
            "Female",
            "Humans",
            "Infant",
            "Malaria",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Male",
            "Middle Aged",
            "Parasitemia",
            "Plasmodium vivax",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33211712/"
    },
    {
        "pmid": "33148540",
        "title": "Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries.",
        "abstract": "aimed examine relationship access medicine cardiovascular disease CVD major adverse cardiovascular event MACEs among people high risk CVD highincome country HICs upper lower middleincome country UMICs LMICs lowincome country LICs participating Prospective Urban Rural Epidemiology PURE study defined high CVD risk presence following hypertension coronary artery disease stroke smoker diabetes age 55 years Availability affordability blood pressure lowering drugs antiplatelets statin obtained pharmacies Participants categorised group 1all three drug type available affordable group 2all three drug available affordable group 3all three drug available used multivariable Cox proportional hazard model nested clustering country community levels adjusting comorbidities sociodemographic economic factors 163 466 participants 93 200 high CVD risk 21 country mean age 547 49 female these 449 group 1 294 group 2 257 group 3 Compared participant group 1 risk MACEs higher among participant group 2 HR 119 95 CI 107 131 among participant group 3 HR 125 95 CI 108 150 Lower availability affordability essential CVD medicine associated higher risk MACEs mortality Improving access CVD medicine key part strategy lower CVD globally",
        "mesh_terms": [
            "Costs and Cost Analysis",
            "Developing Countries",
            "Female",
            "Humans",
            "Income",
            "Male",
            "Middle Aged",
            "Poverty",
            "Prospective Studies"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33148540/"
    },
    {
        "pmid": "33107165",
        "title": "Antibiotic exposure among young infants suffering from diarrhoea in Bangladesh.",
        "abstract": "Appropriate rehydration always significant treating diarrhoeal disease children Irrational antibiotic use among diarrhoeal child remained major public health concern Information regarding antibiotic use young infant suffering diarrhoea limited unique aspect research aimed investigate prevalence antibiotic use community among 26 month infant diarrhoeal illness different nutritional status investigated total 5279 infant aged 26 month Dhaka hospital International Centre Diarrhoeal Disease Research Bangladesh September 2018 June 2019 Among them 257 infant suffering severe acute malnutrition SAM History taking antibiotic ascertained direct observation prescription physician bottle antibiotic asking caregiver name antibiotic price close usual market price antibiotic Overall 52 infant received antibiotic hospital admission NonSAM infant higher odds receiving antibiotic adjusted odds ratio aOR  152 95 confidence interval 118 197 P value  0003 compared infant SAM use antibiotic increased age aOR  111 95 confidence interval 106 117 P value0001 Commonly used antibiotic azithromycin 133 ciprofloxacin 77 erythromycin 77 metronidazole 26 proportion receiving ciprofloxacin significantly lower infant SAM compared nonSAM counterpart 27 vs 797 P value  0004 study underscore excessive use antibiotic among diarrhoeal infants already major public health concern low middleincome countries",
        "mesh_terms": [
            "Anti-Bacterial Agents",
            "Bangladesh",
            "Child",
            "Diarrhea",
            "Diarrhea, Infantile",
            "Female",
            "Humans",
            "Infant",
            "Nutritional Status"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33107165/"
    },
    {
        "pmid": "33082188",
        "title": "Developing core economic parameter sets for asthma studies: a realist review and an analytical framework.",
        "abstract": "develop standardised set economic parameter core economic parameter set economic evaluation asthma studies systematic literature review analytical framework Economic parameter used evaluate cost costeffectiveness healthcare intervention people asthma PubMed Cochrane Database Systematic Reviews National Health Service Economic Evaluation Database Database Abstracts Reviews Effects Health Technology Aaaessment Library starting 1990 Research method based realist review methodology included number nonsequential iterative overlapping components developing analytical framework realist review systematic literature review economic parameters identifying categorising economic parameters producing preliminary list core economic parameters Database search found 2531 publication 224 included systematic review identified 65 economic parameter categorised 11 group enable realist synthesis Parameters related secondary care primary care medication use emergency care work productivity comprised 84 economic parameters analytical framework used investigate rationale behind choice economic parameter studies main framework domain included type intervention research population study design study setting stakeholders perspective Past research thus suggests asthma study parameter depicting use secondary care primary care medication emergency care work productivity considered core economic parameters since apply different type studies Parameters including diagnostics healthcare delivery school activity informal care medical device health utility apply particular type study or research question thus recommended supplemental parameters CRD42017067867",
        "mesh_terms": [
            "Asthma",
            "Cost-Benefit Analysis",
            "Delivery of Health Care",
            "Humans",
            "State Medicine",
            "Systematic Reviews as Topic"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33082188/"
    },
    {
        "pmid": "32981529",
        "title": "Cost-effectiveness of adrenaline for out-of-hospital cardiac arrest.",
        "abstract": "Prehospital Assessment Role Adrenaline Measuring Effectiveness Drug Administration Cardiac Arrest PARAMEDIC2 trial showed adrenaline improves overall survival neurological outcomes sought determine withintrial lifetime health social care cost benefit associated adrenaline including secondary benefit organ donation estimated costs benefit qualityadjusted life year QALYs incremental costeffectiveness ratio ICERs associated adrenaline 6month trial followup Modelbased analysis explored result altered time horizon extended beyond 6 month scope extended include recipient donated organs withintrial 6 months lifetime horizon economic evaluation focussed trial population produced ICERs £1693003 €1946953 £81070 €93231 per QALY gained 2017 prices respectively reflecting significantly higher mean cost marginally higher mean QALYs adrenaline group probability adrenaline costeffective less 1 across range costeffectiveness thresholds Combined direct economic effect lifetime survivor indirect economic effect organ recipient produced ICER £16086 €18499 per QALY gained adrenaline probability adrenaline costeffective increasing 90 £30000 €34500 per QALY costeffectiveness threshold Adrenaline costeffective directly related cost consequence considered However incorporating indirect economic effect associated transplanted organ substantially alters costeffectiveness suggesting decisionmakers consider complexity direct indirect economic impact adrenaline ISRCTN73485024  Registered 13 March 2014",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Cost-Benefit Analysis",
            "Epinephrine",
            "Female",
            "Humans",
            "Male",
            "Middle Aged",
            "Out-of-Hospital Cardiac Arrest",
            "Quality-Adjusted Life Years"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32981529/"
    },
    {
        "pmid": "32925910",
        "title": "Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh.",
        "abstract": "proportion Plasmodium vivax malaria among malaria increasing worldwide Treatment 8aminoquinolines remain radical cure However 8aminoquinolines cause severe hemolysis glucose6phosphate dehydrogenase G6PD deficient patients population multiethnic Chittagong Hill Tracts CHT carry highest malaria burden within Bangladesh many country national treatment guideline recommend 8aminoquinoline based radical cure without routine G6PD deficiency G6PDd testing guide treatment Aim study determine need routine testing within multiethnic population assessing prevalence G6PDd among local population Participants 11 ethnicity randomly selected malaria status assessed microscopy rapid diagnostic test RDT polymerase chain reaction PCR G6PD status determined spectrophotometry G6PD genotyping adjusted male median AMM defined 100 G6PD activity participant categorized G6PD deficient 30 activity G6PD intermediate 30 70 activity G6PD normal 70 activity Median G6PD activity ethnicity compared association G6PD activity malaria status assessed 1002 participant enrolled tested malaria G6PD activity measured spectrophotometry 999 participant host G6PD genotyping undertaken 323 participants Seven participant 07 peripheral parasitaemia detected microscopy RDT 42 PCR 42 Among 106 participant 328 confirmed genotype 99 934 Mahidol variant AMM 703UgHb 90 90 G6PD deficient participant 133 133 intermediate G6PD activity Median G6PD activity differed significantly ethnicity p0001 proportion G6PD deficient individual ranged 2 26 differ participant without malaria high G6PDd prevalence significant variation ethnicity suggest routine G6PDd testing guide 8aminoquinoline based radical CHT comparable settings",
        "mesh_terms": [
            "Adult",
            "Aminoquinolines",
            "Bangladesh",
            "Diagnostic Tests, Routine",
            "Ethnicity",
            "Female",
            "Glucosephosphate Dehydrogenase",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Humans",
            "Malaria, Vivax",
            "Male",
            "Middle Aged",
            "Polymerase Chain Reaction",
            "Prevalence",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32925910/"
    },
    {
        "pmid": "32718342",
        "title": "Implementing parasite genotyping into national surveillance frameworks: feedback from control programmes and researchers in the Asia-Pacific region.",
        "abstract": "AsiaPacific region face formidable challenge achieving malaria elimination proposed target 2030 Molecular surveillance Plasmodium parasite provide important information malaria transmission adaptation inform national malaria control programme NMCPs decisionmaking processes November 2019 parasite genotyping workshop held Jakarta Indonesia review molecular approach parasite surveillance explore way tool integrated public health system inform policy meeting attended 70 participant 8 malariaendemic country partner Asia Pacific Malaria Elimination Network participant acknowledged utility multiple use case parasite genotyping including quantifying prevalence drug resistant parasites predicting risk treatment failure identifying major route reservoir infection monitoring imported malaria contribution local transmission characterizing origin dynamic malaria outbreaks estimating frequency Plasmodium vivax relapses However priority use case varies different endemic settings Although onesizefitsall approach molecular surveillance unlikely applicable across AsiaPacific region consensus spectrum addedvalue activity help support data sharing across national boundaries Knowledge exchange needed establish local expertise different laboratorybased methodology bioinformatics processes Collaborative research involving local international team help maximize impact analytical output operational need NMCPs Research also needed explore costeffectiveness genetic epidemiology different use case help leverage funding widescale implementation Engagement NMCPs local researcher critical throughout process",
        "mesh_terms": [
            "Asia",
            "Congresses as Topic",
            "Epidemiological Monitoring",
            "Feedback",
            "Genotype",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Pacific Islands",
            "Plasmodium falciparum",
            "Plasmodium vivax",
            "Population Surveillance"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32718342/"
    },
    {
        "pmid": "32718336",
        "title": "Cost-effectiveness of inhaled oxytocin for prevention of postpartum haemorrhage: a modelling study applied to two high burden settings.",
        "abstract": "Access oxytocin prevention postpartum haemorrhage PPH resourcepoor setting limited requirement consistent cold chain skilled attendant administer injection overcome barriers heatstable noninjectable formulation oxytocin development including oxytocin inhalation study modelled costeffectiveness inhaled oxytocin product IHO Bangladesh Ethiopia decision analytic model developed assess costeffectiveness IHO prevention PPH compared standard care Bangladesh Ethiopia Bangladesh introduction IHO modelled public facility home delivery without skilled attendant Ethiopia IHO modelled public facility home delivery health extension workers Costs costs introduction PPH prevention PPH treatment effect PPH case averted death averted modelled 12month program Life year gained modelled lifetime horizon discounted 3 Cost maintaining cold chain effect compromised oxytocin quality in absence cold chain modelled Bangladesh IHO estimated avert 18644 case PPH 76 maternal death 1954 maternal life year lost also yielded costsaving majority gain occurring among home delivery IHO would replace misoprostol Ethiopia IHO averted 3111 PPH cases 30 maternal death 767 maternal life year lost full IHO introduction program bear incremental costeffectiveness ratio ICER 2 3 time percapita Gross Domestic Product GDP 1880 USD per maternal life year lost thus unlikely considered costeffective Ethiopia However ICER routine IHO administration considering recurring cost alone fall 25 percapita GDP 175 USD per maternal lifeyear saved IHO potential expand access uterotonics reduce PPHassociated morbidity mortality high burden settings facilitate reduced spending PPH management making product highly costeffective setting coverage institutional delivery lagging",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Bangladesh",
            "Cost-Benefit Analysis",
            "Ethiopia",
            "Female",
            "Humans",
            "Middle Aged",
            "Oxytocin",
            "Postpartum Hemorrhage",
            "Pregnancy",
            "Respiratory Therapy",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32718336/"
    },
    {
        "pmid": "32690512",
        "title": "Estimation of total cardiovascular risk using the 2019 WHO CVD prediction charts and comparison of population-level costs based on alternative drug therapy guidelines: a population-based study of adults in Bangladesh.",
        "abstract": "objective study estimate population distribution 10year cardiovascular disease CVD risk among Bangladeshi adult aged 40 year above using 2019 CVD risk prediction charts Additionally compared cost CVD pharmacological treatment based total CVD risk thresholds ≥30≥20 single risk factor hypertension cutoff level Bangladeshi context Crosssectional populationbased study 2013 2014 collected data nationally representative crosssectional survey adult aged ≥40 year urban rural area Bangladesh n6189 estimated CVD risk using 2019 CVD risk prediction chart categorised low 5 low 5 10 moderate 10 20 high 20 30 high risk ≥30 estimated drug therapy cost using lowest price drug class available aspirin thiazide diuretics statin ACE inhibitors compared total cost drug therapy using total CVD risk versus single risk factor approach primary outcome 10year CVD risk categorised low 5 low 5 10 moderate 10 20 high 20 30 high risk ≥30 majority adult 852 95 CI 843 861 10year CVD risk less 10 proportion adult 10year CVD risk ≥20 051 one adult categorised 10year CVD risk ≥30 Among adult CVD risk group low low moderate 174 279 414 hypertension blood pressure BP ≥14090 01 17 29 severe hypertension BP ≥160100 respectively Using total CVD risk approach would reduce drug cost per million population US144 540 risk ≥20 reduce healthcare expenditure prevention treatment CVD total risk approach using 2019 CVD risk prediction chart may lead cost savings",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Bangladesh",
            "Cardiovascular Diseases",
            "Cross-Sectional Studies",
            "Drug Costs",
            "Female",
            "Heart Disease Risk Factors",
            "Humans",
            "Hypertension",
            "Male",
            "Middle Aged",
            "Risk Assessment"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32690512/"
    },
    {
        "pmid": "32669092",
        "title": "What contributes to inappropriate antibiotic dispensing among qualified and unqualified healthcare providers in Bangladesh? A qualitative study.",
        "abstract": "Overprescribing inappropriate use antibiotic contributes emergence antimicrobial resistance AMR study low middleincome setting employed qualitative approach examine driver antibiotic sale dispensing across full range healthcare provider HCPs aimed explore understanding use function antibiotics awareness AMR perceived patient customer demand adherence among HCPs human animal medicine Bangladesh used ethnographic approach conduct facetoface indepth interview 46 community HCPs one urban one rural area Gazipur Mirzapur district respectively purposefully selected participant four category provider human veterinary medicine qualified semiqualified auxiliary unqualified Using grounded theory approach thematic analysis conducted using framework method Antibiotics considered medicine power give quick result work almost diseases including viruses price antibiotic equated power expensive antibiotic considered powerful medicines Antibiotics also seen preventative medicines provider well informed antibiotic resistance causes others completely unaware Many provider mistook antibiotic resistance side effect antibiotics human animal medicine Despite varied knowledge provider showed concern antibiotic resistance responsibility inappropriate antibiotic use shifted patient client including owner livestock animals Misconceptions misinformation led wide range inappropriate us antibiotic across different category human animal healthcare providers Low awareness antibiotic action antibiotic resistance apparent among healthcare providers particularly little training rural areas Specific targeted intervention address AMR Bangladesh include educational message rational use antibiotic work targeting type healthcare providers tailored training provider may increase understanding antibiotic action improve practices farreaching structural change required influence increase responsibility optimising antibiotic dispensing among HCPs",
        "mesh_terms": [
            "Anti-Bacterial Agents",
            "Antimicrobial Stewardship",
            "Bangladesh",
            "Clinical Competence",
            "Community Health Workers",
            "Drug Resistance, Microbial",
            "Drug Utilization",
            "Health Knowledge, Attitudes, Practice",
            "Health Personnel",
            "Humans",
            "Inappropriate Prescribing",
            "Interviews as Topic",
            "Nonprescription Drugs",
            "Prescription Drugs",
            "Qualitative Research"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32669092/"
    },
    {
        "pmid": "32542043",
        "title": "Healthcare seeking for chronic illness among adult slum dwellers in Bangladesh: A descriptive cross-sectional study in two urban settings.",
        "abstract": "Accompanying rapid urbanization Bangladesh inequity health healthcare visibly manifested slum lowincome settlements study examines socioeconomic demographic geographic pattern selfreported chronic illness healthcare seeking among adult slum dweller Bangladesh Understanding pattern critical designing equitable urban health system enabling countrys goal Universal Health Coverage 2030 descriptive crosssectional study compare survey data slum settlement located two urban site Bangladesh Tongi Sylhet Reported chronic illness symptom associated healthcareseeking strategy compared catastrophic impact household healthcare expenditure assessed Significant difference healthcareseeking chronic illness apparent within slum settlement related sex wealth score PPI location Women likely use private clinic men Compared poorer residents wealthier household sought care greater extent private clinics poorer household relied drug shop public hospitals Chronic symptom also differed greater prevalence musculoskeletal respiratory digestive neurological symptom reported among lower PPIs slum sites reliance private healthcare market widespread greater industrialized Tongi Tongi also experienced higher probability catastrophic expenditure Sylhet Study result point value understanding contextspecific healthseeking pattern chronic illness designing delivery strategy address growing burden NCDs slum environments Slums complex social geographic entity cannot generalized Priority attention focused developing chronic care service meet need working poor term proximity opening hours quality cost",
        "mesh_terms": [
            "Adult",
            "Bangladesh",
            "Chronic Disease",
            "Cross-Sectional Studies",
            "Female",
            "Geography",
            "Health Expenditures",
            "Health Services Needs and Demand",
            "Humans",
            "Male",
            "Patient Acceptance of Health Care",
            "Poverty",
            "Quality of Health Care",
            "Urban Health Services",
            "Urban Population",
            "Urbanization"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32542043/"
    },
    {
        "pmid": "32431267",
        "title": "The WorldWide Antimalarial Resistance Network Clinical Trials Publication Library: A Live, Open-Access Database of <i>Plasmodium</i> Treatment Efficacy Trials.",
        "abstract": "Parasite resistance antimalarial drug pose serious threat malaria control WorldWide Antimalarial Resistance Network WWARN aim provide collaborative platform support global malaria research effort Here describe WWARN clinical trial publication library openaccess uptodate resource streamline synthesis antimalarial safety efficacy data series iteratively refined database search conducted identify prospective clinical trial assessing antimalarial drug efficacy least 28 day followup approximately 45000 article screened 1221 trial published 1946 2018 identified representing 2339 treatment arm 323819 patients trial endemic locations 757 7871040 recruited patient iPlasmodium falciparumi 170 1771040 iPlasmodium vivaxi 69 721040 both 04 41040 iPlasmodiumi species 572 5851022 trial included underfives 53 551036 included pregnant women Africa marked increase iP falciparumi iP vivaxi study last two decades WHOrecommended artemisininbased combination therapy alone gametocidal drug assessed 395 7051783 iP falciparumi treatment arm 105 45429 iP vivaxi arms increasing 780 266341 229 27118 respectively last five years library comprehensive openaccess tool used malaria community explore collective knowledge antimalarial efficacy available httpswwwwwarnorgtoolsresourcesliteraturereviewswwarnclinicaltrialspublicationlibrary first kind field global infectious diseases lesson learnt creation adapted infectious diseases",
        "mesh_terms": [
            "Antimalarials",
            "Clinical Trials as Topic",
            "Databases, Bibliographic",
            "Databases, Factual",
            "Drug Resistance",
            "Drug Therapy, Combination",
            "Humans",
            "Malaria",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Plasmodium",
            "Plasmodium falciparum",
            "Plasmodium knowlesi",
            "Plasmodium malariae",
            "Plasmodium ovale",
            "Plasmodium vivax"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32431267/"
    },
    {
        "pmid": "32407380",
        "title": "Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis.",
        "abstract": "radical cure Plasmodium vivax P ovale requires treatment primaquine tafenoquine clear dormant liver stages Either drug induce haemolysis individual glucose6phosphate dehydrogenase G6PD deficiency necessitating screening reference diagnostic method G6PD activity ultraviolet UV spectrophotometry however universal G6PD activity threshold drug safely administered yet defined study aimed quantify assaybased variation G6PD spectrophotometry explore diagnostic implication applying universal threshold Individuallevel data pooled study used G6PD spectrophotometry Studies identified via PubMed search 25 April 2018 unpublished contribution contacted author PROSPERO CRD42019121414 Studies excluded assessed individual known haematological conditions family studies insufficient details Studies malaria patient included analysed separately Included study assessed risk bias using adapted form Quality Assessment Diagnostic Accuracy Studies2 QUADAS2 tool Repeatability intra interlaboratory variability G6PD activity measurement compared study pooled across dataset universal threshold G6PD deficiency derived diagnostic performance compared sitespecific thresholds Study participant n  15811 aged 0 86 years 444 7083 women Median range activity G6PD normal G6PDn control sample 100 Ug Hb 63140 Trinity assay 83 Ug Hb 68156 Randox assay G6PD activity distribution varied significantly studies 13 study used Trinity assay adjusted male median AMM standardised metric 100 G6PD activity varied 57 126 Ug Hb p  0001 Assay precision varied laboratories assessed variance control measurement from 01 15 Ug Hb p  0001 studywise mean coefficient variation CV replicate measure from 16 149 p  0001 universal threshold 100 G6PD activity defined 94 Ug Hb yielding diagnostic threshold 66 Ug Hb 70 activity 28 Ug Hb 30 activity threshold diagnosed individual less 30 G6PD activity studywise sensitivity 89 95 CI 8194 100 95 CI 96100 specificity 96 95 CI 8999 100 100100 However considering intermediate deficiency 70 G6PD activity sensitivity fell minimum 64 95 CI 5275 specificity 35 95 CI 2446 ability identify underlying factor associated studylevel heterogeneity limited lack availability covariate data diverse study context methodologies finding indicate substantial variation G6PD measurement spectrophotometry sites likely due variability laboratory methods possible contribution unmeasured population factors assayspecific universal quantitative threshold offer robust diagnosis 30 level interstudy variability impedes performance universal threshold 70 level Caution advised comparing finding based absolute G6PD activity measurement across studies Novel handheld quantitative G6PD diagnostics may allow greater standardisation future",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Aged",
            "Aged, 80 and over",
            "Antimalarials",
            "Child",
            "Child, Preschool",
            "Female",
            "Glucosephosphate Dehydrogenase",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Humans",
            "Infant",
            "Infant, Newborn",
            "Malaria",
            "Male",
            "Middle Aged",
            "Spectrophotometry",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32407380/"
    },
    {
        "pmid": "32405422",
        "title": "Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.",
        "abstract": "Many treatment assessed repurposing treat coronavirus disease 2019 COVID19 One drug shown promising result iin vitroi nitazoxanide Unlike postulated drugs nitazoxanide show high ratio maximum plasma concentration Csubmaxsub 1 day 500 mg twice daily BD concentration required inhibit 50 replication ECsub50sub severe acute respiratory syndrome coronavirus 2 SARSCoV2 Csubmax sub ECsub50sub roughly equal 141 such important investigate safety nitazoxanide trials Furthermore treatment COVID19 cheap promote global access price many drug far higher cost production aimed conduct review safety nitazoxanide prior indication calculate minimum cost production review nitazoxanide clinical research conducted using EMBASE MEDLINE databases supplemented ClinicalTrialsgov searched phase 2 3 randomised controlled trial RCTs comparing nitazoxanide placebo active control 514 day participant experiencing acute infection kind Data extracted grade 14 serious adverse event AEs Data also extracted gastrointestinal GI AEs well hepatorenal cardiovascular effectsActive pharmaceutical ingredient cost data 2016 2019 extracted Panjiva database adjusted 5 loss production cost excipients formulation 10 profit margin tax Two dosages 500 mg BD higher dose 1100 mg three time daily TDS considered estimated cost compared publicly available list price selection countries Nine RCTs nitazoxanide identified inclusion RCTs accounted 1514 participant estimated 953 personyearsoffollowup significant difference found AE endpoint assessed across trial subgroup analysis active placebocontrolled trials Mild GI AEs increased dose hepatorenal cardiovascular concern raised appropriate metric reported teratogenic concerns evidence base limitedBased weightedmean cost US 61kg 14day course treatment nitazoxanide 500 mg BD would cost 141 daily cost would therefore 010 14day course could cost 3944 US commercial pharmacies 3 per course Pakistan India Bangladesh higher dose 1100 mg TDS estimated cost 408 per 14day course equivalent 029 per day Nitazoxanide demonstrates good safety profile approved doses However evidence required regarding hepatorenal cardiovascular effects well teratogenicity estimate would possible manufacture nitazoxanide generic 141 14day treatment course 500 mg BD 408 1100 mg TDS trial COVID19 patient initiated efficacy SARSCoV2 demonstrated clinical studies nitazoxanide may represent safe affordable treatment ongoing pandemic",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32405422/"
    },
    {
        "pmid": "32332142",
        "title": "Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017.",
        "abstract": "Past research population health trend shown injury form substantial burden population health loss Regular update injury burden assessment critical report Global Burden Disease GBD 2017 Study estimate morbidity mortality injuries reviewed result injury GBD 2017 study GBD 2017 measured injuryspecific mortality year life lost YLLs using Cause Death Ensemble model measure nonfatal injuries GBD 2017 modelled injuryspecific incidence converted prevalence year lived disability YLDs YLLs YLDs summed calculate disabilityadjusted life year DALYs 1990 4 260 493 4 085 700 4 396 138 injury deaths increased 4 484 722 4 332 010 4 585 554 death 2017 agestandardised mortality decreased 1079 1073 1086 738 730 745 per 100 000 1990 354 064 302 95 uncertainty interval 338 174 876 371 610 802 new case injury globally increased 520 710 288 493 430 247 547 988 635 new case 2017 time agestandardised incidence decreased nonsignificantly 6824 6534 7147 6763 6412 7118 per 100 000 1990 2017 agestandardised DALYs decreased 4947 4655 5233 per 100 000 3267 3058 3505 Injuries important cause health loss globally though mortality declined 1990 2017 Future research injury burden focus prevention highburden populations improving data collection ensuring access medical care",
        "mesh_terms": [
            "Global Burden of Disease",
            "Global Health",
            "Humans",
            "Incidence",
            "Life Expectancy",
            "Morbidity",
            "Quality-Adjusted Life Years",
            "Wounds and Injuries"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32332142/"
    },
    {
        "pmid": "32094104",
        "title": "The effect of doxofylline in asthma and COPD.",
        "abstract": "Theophylline still one widely prescribed drug treatment asthma COPD developing country majority asthma COPD medicine largely unavailable also cheap option case antiinflammatory effect capacity reverse corticosteroid resistance deserve consideration induce numerous side effect drugdrug interaction frequently requires measurement drug level plasma order overcome problem posed theophylline xanthine developed Doxofylline newer generation xanthine bronchodilating antiinflammatory activity reason called novofylline differs substantially theophylline pharmacological level Clinical study shown substantial difference doxofylline theophylline particular efficacysafety profile doxofylline better theophylline",
        "mesh_terms": [
            "Anti-Inflammatory Agents",
            "Asthma",
            "Bronchodilator Agents",
            "Drug Costs",
            "Economics, Pharmaceutical",
            "Female",
            "Humans",
            "Male",
            "Pulmonary Disease, Chronic Obstructive",
            "Theophylline",
            "Treatment Outcome"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32094104/"
    },
    {
        "pmid": "32074419",
        "title": "A Community-Based Intervention for Managing Hypertension in Rural South Asia.",
        "abstract": "burden hypertension escalating control rate poor low middleincome countries Cardiovascular mortality high rural areas conducted clusterrandomized controlled trial rural district Bangladesh Pakistan Sri Lanka total 30 community randomly assigned either multicomponent intervention intervention group usual care control group intervention involved home visit trained government community health worker bloodpressure monitoring counseling training physicians care coordination public sector total 2645 adult hypertension enrolled primary outcome reduction systolic blood pressure 24 months Followup 24 month completed 90 participants baseline mean systolic blood pressure 1467 mm Hg intervention group 1447 mm Hg control group 24 months mean systolic blood pressure fell 90 mm Hg intervention group 39 mm Hg control group mean reduction 52 mm Hg greater intervention 95 confidence interval CI 32 71 P0001 mean reduction diastolic blood pressure 28 mm Hg greater intervention group control group 95 CI 17 39 Bloodpressure control 14090 mm Hg achieved 532 participant intervention group compared 437 control group relative risk 122 95 CI 110 135 Allcause mortality 29 intervention group 43 control group rural community Bangladesh Pakistan Sri Lanka multicomponent intervention centered proactive home visit trained government community health worker linked existing public health care infrastructure led greater reduction blood pressure usual care among adult hypertension Funded Joint Global Health Trials scheme COBRABPS ClinicalTrialsgov number NCT02657746",
        "mesh_terms": [
            "Aged",
            "Antihypertensive Agents",
            "Asia, Western",
            "Blood Pressure",
            "Blood Pressure Determination",
            "Checklist",
            "Community Health Workers",
            "Developing Countries",
            "Education, Medical, Continuing",
            "Female",
            "Health Care Costs",
            "House Calls",
            "Humans",
            "Hypertension",
            "Male",
            "Middle Aged",
            "Patient Education as Topic",
            "Public Health Practice",
            "Rural Population"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32074419/"
    },
    {
        "pmid": "31915349",
        "title": "Nitrous Oxide versus Medical Air Using in General Anaesthesia During Laparoscopic Cholecystectomy: A Comparative Study.",
        "abstract": "study designed observe haemodynamic changes recovery status cost effectiveness anaesthesia laparoscopic cholecystectomy medical air comparison anaesthesia nitrous oxide associated maintain adequate analgesia conducted department Analgesia Intensive Care Medicine Bangabandhu Sheikh Mujib Medical University BSMMU Dhaka Bangladesh January 2017 June 2017 Nitrous oxide popularly using analgesic current balanced general anesthesia addition carrier agent anesthetic Intraoperative pain intensity depends many variable including type surgery surgical stimulation surgical incision difficult measure intraoperative pain properly general anesthesia therefore anesthetist depends surrogate marker inadequate analgesia like raised heart rate blood pressure sweating lacrimation However unfortunately parameter may change direction light plane anesthesia hypercarbia ongoing procedural status patient",
        "mesh_terms": [
            "Analgesics",
            "Anesthesia",
            "Anesthesia Recovery Period",
            "Anesthesia, General",
            "Bangladesh",
            "Cholecystectomy, Laparoscopic",
            "Cholelithiasis",
            "Cost-Benefit Analysis",
            "Hemodynamics",
            "Humans",
            "Monitoring, Intraoperative",
            "Nitrous Oxide",
            "Postoperative Period"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31915349/"
    },
    {
        "pmid": "31915273",
        "title": "Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017.",
        "abstract": "epidemiological transition noncommunicable disease replacing infectious disease main contributor disease burden well documented global health literature Less focus however given relationship sociodemographic change injury aim study examine association disabilityadjusted life year DALYs injury 195 country territory different level along development spectrum 1990 2017 based Global Burden Disease GBD 2017 estimates Injury mortality estimated using GBD mortality database correction garbage coding CODEmthe cause death ensemble modelling tool Morbidity estimation based survey inpatient outpatient data set 30 causeofinjury 47 natureofinjury category each Sociodemographic Index SDI composite indicator includes lagged income per capita average educational attainment age 15 year total fertility rate many cause injury agestandardised DALY rate declined increasing SDI although road injury interpersonal violence selfharm follow pattern Particularly selfharm opposing pattern observed region similar SDI levels road injuries effect less pronounced overall global pattern declining injury burden increasing SDI However injury follow pattern suggests multiple underlying mechanism influencing injury DALYs need detailed understanding pattern help inform national global effort address injuryrelated health outcome across development spectrum",
        "mesh_terms": [
            "Adolescent",
            "Persons with Disabilities",
            "Global Burden of Disease",
            "Global Health",
            "Humans",
            "Life Expectancy",
            "Quality-Adjusted Life Years",
            "Wounds and Injuries"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31915273/"
    },
    {
        "pmid": "31752841",
        "title": "Antenatal care in rural Bangladesh: current state of costs, content and recommendations for effective service delivery.",
        "abstract": "Measurement antenatal care ANC service coverage often limited number contact type providers reflecting gap assessment quality well cost estimation health impact study aim determine service subcomponents provider patient cost ANC service compare community ie satellite clinics facility care ie primary secondary health centers setting rural Bangladesh Service content cost data collected one researcher four interviewer various community facility health care setting Gaibandha district September December 2016 conducted structured interview organization managers observational study ANC service provision n  70 service content provider cost service drug costs exit interview pregnant woman n  70 patient cost direct indirect costs health clinic community facility levels Fishers exact test used determine different patient characteristic community facility settings ANC service content assessed 63 subitems categorized 11 group compared within across community facility settings Provider patient cost collected Bangladesh taka analyzed 2016 US Dollars 0013 exchange rate found generally similar provider patient characteristic community facility setting except clients gestational age High compliance  50 service subcomponents observed blood pressure monitoring weight measurement iron folate supplementation given tetanus vaccine lower compliance service subcomponents  50 observed physical examination edema ultrasonogram routine test blood test urine test Average unit cost ANC service provision double facility level 275 compared communitybased care 162 ANC patient cost facility 266 three time higher community 078 study reveals delay pregnant womens initial ANC care seeking gap compliance ANC subcomponents difference provider patient cost facility community settings",
        "mesh_terms": [
            "Bangladesh",
            "Female",
            "Health Care Costs",
            "Health Services Research",
            "Humans",
            "Pregnancy",
            "Prenatal Care",
            "Rural Health Services"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31752841/"
    },
    {
        "pmid": "31706178",
        "title": "Comparative Analysis of Prescription Drug Prices in South Asian Association for Regional Cooperation Countries.",
        "abstract": "SAARC South Asian Association Regional Cooperation geopolitical organization composed 8 neighboring countries Afghanistan Bangladesh Bhutan India Maldives Nepal Pakistan Sri Lanka objective study compare price selected drug SAARC countries list 24 drug prepared based certain inclusion exclusion criteria retail price drug determined different source verified manually open market price obtained local currency converted US dollar comparison purposes another analysis gross domestic product GDP country factored comparative analysis 23 drugs 17 comparison across country statistically different P  05 analysis revealed large difference drug price among SAARC countries GDPadjusted median drug price revealed polarized picture Nepal generally highest price 19 24 drugs Sri Lanka lowest 19 24 drugs example widely used antipsychotic drug risperidone 7 time expensive Pakistan 0316 compared Sri Lanka 0045 Adjusting GDP made risperidone 18 time expensive 2190 120 across 2 countries Prices selected drug varied markedly SAARC countries adjusting GDP drug price became polarized across countries Nepal featuring highest prices determining drug prices countrys GDP populations purchasing power need taken account",
        "mesh_terms": [
            "Afghanistan",
            "Analysis of Variance",
            "Asia, Southeastern",
            "Bangladesh",
            "Bhutan",
            "Cooperative Behavior",
            "Costs and Cost Analysis",
            "Humans",
            "India",
            "Indian Ocean Islands",
            "Nepal",
            "Pakistan",
            "Prescription Drugs",
            "Sri Lanka"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31706178/"
    },
    {
        "pmid": "31699941",
        "title": "The Threat of Emerging and Re-emerging Infections in Indonesia.",
        "abstract": "Human immunodeficiency virus HIV one example emerging infection total 386 district province Indonesia reported infection cumulative number HIV infected patient year 1987 2014 150296 AIDS 55799 patients access care available 153887 patient among HIVAIDS patient 70 eligible antiretroviral ARV treatment half adhered ARV treatment addition that increased risk emerging disease Zika virus Monkey pox Hanta pulmonary syndrome since sporadic case reported around regionBeside new diseases tuberculosis dengue virus malaria diphteria continuously reported Indonesia classified reemerging illnesses edition data diphteria epidemiology Indonesia shown Karyanti et al6 recent outbreak diphteria Indonesia involved almost province country led response named ORI outbreak response Immunization Regardless immunization proper treatment including distribution antitoxin antibiotic needed stop spread particular bacteria decreasing mortality rate conclusion author paper mentioned immunization gap need handle systematically Immunization data released 2017 showed complete immunization given 20 targeted group almost 75 either unvaccinated unknown outbreak diphteria Indonesia also reported several country similar problem Bangladesh Haiti Yamen shown coordination doctor clinichospital public health officer conduct epidemiological investigation conjunction giving prophylaxis assuring logistics antidiphteria toxin antibiotic accessible key success eliminating diphteria like BangladeshAdherence treatment multifactorial illnesses First duration treatment potential adverse event due medication Ministry Health Republic Indonesia support early diagnosis HIV delivering treatment soon possible order avoid transmission disease Second looking another side story HIV infected patients receiving ARV treatment long life treatment could possibly cause adverse event somewhere along line Budiman etal reported factor might contribute liver injury study show measuring baseline liver function test AST routinely might minimize toxicity ARV patient particularly low body mass index Last despite adherence treatment procedure minimizing risk adverse event medication facing primary resistance virus transmitted community mentioned Megasari et al8 report regarding transmission drug resistance HIV virus naïve patient BaliThe Indonesian government Indonesian Ministry Health established collaboration one health approach tackle threat disease country particularly infectious diseases",
        "mesh_terms": [
            "Communicable Diseases, Emerging",
            "Cost of Illness",
            "Diphtheria",
            "HIV Infections",
            "Humans",
            "Indonesia",
            "Tuberculosis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31699941/"
    },
    {
        "pmid": "31648271",
        "title": "Economic evaluation of community acquired pneumonia management strategies: A systematic review of literature.",
        "abstract": "Communityacquired pneumonia CAP major cause mortality morbidity worldwide Efficient use resource fundamental best use money among available novel treatment option management pneumonia objective study systematically review economic analysis management strategy pneumonia systematic search performed using Academic Search Complete MEDLINE EconLit Global health MEDLINE complete Embase database using specific subject heading key word May 2018 without restricting publication year search result recorded type economic evaluation management CAP included detailed review Consolidated Health Economic Evaluation Reporting Standards CHEERS checklist used quality appraisal Nineteen study met inclusion criteria ten study trial based five conducted analysis using model based technique rest study either based observational record review prepost intervention studies study conducted costeffectiveness analysis n  15 compared different combination antimicrobials based developed country n  17 considered adult age group n  16 used provider perspective n  14 Nine study reported dominant alternative lower cost higher benefit Sensitivity analysis performed majority study n  15 Fourteen study assessed either excellent good good quality relationship found publication year study quality Methodological variation type microbial used perspective cost outcome measure limit compatibility among result included studies Economic evaluation intervention management CAP date support costeffectiveness studied interventions However evidence relates largely antimicrobial choice older population developed countries Parallel economic evaluation different management strategy CAP recommended developed developing country support rigorous robust comparative economic analysis within health care systems PROSPERO registration no CRD42018097174",
        "mesh_terms": [
            "Anti-Bacterial Agents",
            "Community-Acquired Infections",
            "Cost-Benefit Analysis",
            "Delivery of Health Care",
            "Disease Management",
            "Humans",
            "Pneumonia",
            "Quality-Adjusted Life Years"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31648271/"
    },
    {
        "pmid": "31645575",
        "title": "Acetic acid: a cost-effective agent for mitigation of seawater-induced salt toxicity in mung bean.",
        "abstract": "current study sought effective mitigation measure seawaterinduced damage mung bean plant exploring potential role acetic acid AA Principal component analysis PCA revealed foliar application AA control condition improved mung bean growth interlinked enhanced level photosynthetic rate pigments improved water status increased uptake Ksupsup comparison watersprayed control Mung bean plant exposed salinity exhibited reduced growth biomass production emphatically correlated increased accumulation Nasupsup reactive oxygen specie malondialdehyde impaired photosynthesis evidenced PCA heatmap clustering AA supplementation ameliorated toxic effect seawater improved growth performance salinityexposed mung bean AA potentiated several physiobiochemical mechanism connected increased uptake Casup2sup Mgsup2sup reduced accumulation toxic Nasupsup improved water use efficiency enhanced accumulation proline total free amino acid soluble sugars increased catalase activity heightened level phenolic flavonoids Collectively result provided new insight AAmediated protective mechanism salinity mung bean thereby proposing AA potential costeffective chemical management saltinduced toxicity mung bean perhaps cash crops",
        "mesh_terms": [
            "Acetic Acid",
            "Biomass",
            "Cost-Benefit Analysis",
            "Gases",
            "Minerals",
            "Osmosis",
            "Oxidative Stress",
            "Phenotype",
            "Photosynthesis",
            "Pigments, Biological",
            "Plant Leaves",
            "Plant Stomata",
            "Plant Transpiration",
            "Potassium",
            "Principal Component Analysis",
            "Reactive Oxygen Species",
            "Salinity",
            "Seawater",
            "Sodium",
            "Vigna",
            "Water"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31645575/"
    },
    {
        "pmid": "31560378",
        "title": "Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.",
        "abstract": "Cancer noncommunicable disease NCDs widely recognized threat global development latest United Nations highlevel meeting NCDs reaffirmed observation also highlighted slow progress meeting 2011 Political Declaration Prevention Control Noncommunicable Diseases third Sustainable Development Goal Lack situational analyses priority setting budgeting identified major obstacle achieving goals common require information local cancer epidemiology Global Burden Disease GBD study uniquely poised provide crucial data describe cancer burden 29 cancer group 195 country 1990 2017 provide data needed cancer control planning used GBD study estimation method describe cancer incidence mortality year lived disability year life lost disabilityadjusted lifeyears DALYs Results presented national level well Sociodemographic Index SDI composite indicator income educational attainment total fertility rate also analyzed influence epidemiological v demographic transition cancer incidence 2017 245 million incident cancer case worldwide 168 million without nonmelanoma skin cancer NMSC 96 million cancer deaths majority cancer DALYs came year life lost 97 3 came year lived disability odds developing cancer lowest low SDI quintile 1 7 highest high SDI quintile 1 2 sexes 2017 common incident cancer men NMSC 43 million incident cases tracheal bronchus lung TBL cancer 15 million incident cases prostate cancer 13 million incident cases common cause cancer death DALYs men TBL cancer 13 million death 284 million DALYs liver cancer 572 000 death 152 million DALYs stomach cancer 542 000 death 122 million DALYs woman 2017 common incident cancer NMSC 33 million incident cases breast cancer 19 million incident cases colorectal cancer 819 000 incident cases leading cause cancer death DALYs woman breast cancer 601 000 death 174 million DALYs TBL cancer 596 000 death 126 million DALYs colorectal cancer 414 000 death 83 million DALYs national epidemiological profile cancer burden GBD study show large heterogeneities reflection different exposure risk factors economic settings lifestyles access care screening GBD study used policy maker stakeholder develop improve national local cancer control order achieve global target improve equity cancer care",
        "mesh_terms": [
            "Persons with Disabilities",
            "Global Burden of Disease",
            "Global Health",
            "Humans",
            "Incidence",
            "Neoplasms",
            "Quality-Adjusted Life Years"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31560378/"
    },
    {
        "pmid": "31516106",
        "title": "A Cross-Sectional Investigation of the Quality of Selected Medicines for Noncommunicable Diseases in Private Community Drug Outlets in Cambodia during 2011-2013.",
        "abstract": "Although issue substandard falsified medicine quite well known research focused medicine used treat communicable diseases relatively little research carried quality medicine noncommunicable disease NCDs study designed assess quality seven widely used medicine NCDs Cambodia 20112013 Medicines collected private community drug outlet Phnom Penh urban area stratified random sampling Battambang Kandal Kampong Speu Takeo rural areas convenience sampling Samples subsequently analyzed visual inspection authenticity investigation pharmacopoeial analysis highperformance liquid chromatography Various discrepancy observed visual inspection package medicines 372 tabletcapsule sample 64 manufacturer 16 countries manufacturer confirmed 107 288 authentic authenticity sample could verified Three hundred sixtyfour 978 sample registered Cambodia Among samples 234 95 CI 192280 noncompliant one quality tests 129 95 CI 97167 contained amount active pharmaceutical ingredient outside permitted range including showing extreme deviations 14 95 CI 106179 failed content variation 108 95 CI 78144 failed meet pharmacopoeial reference range dissolution tests Pharmaceutical quality appeared unrelated storage conditions Although sample obviously falsified high prevalence substandard medicine NCDs Cambodia indicating need focused regulatory action including collaborative initiative manufacturers",
        "mesh_terms": [
            "Cambodia",
            "Commerce",
            "Counterfeit Drugs",
            "Cross-Sectional Studies",
            "Drug Contamination",
            "Drug Packaging",
            "Humans",
            "Noncommunicable Diseases",
            "Pharmaceutical Preparations",
            "Pharmacies",
            "Quality Control"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31516106/"
    },
    {
        "pmid": "31455307",
        "title": "Type 2 diabetes mellitus in Bangladesh: a prevalence based cost-of-illness study.",
        "abstract": "economic burden type 2 diabetes adequately investigated many low lower middleincome countries including Bangladesh aim study estimate costofillness type 2 diabetes find determinant Bangladesh crosssectional study conducted 2017 recruit 1253 participant type 2 diabetes six diabetes hospitals providing primary tertiary health care services located northern central region Bangladesh structured questionnaire used facetoface interviewing collect nonclinical data Patients medical record reviewed clinical data hospital record reviewed hospitalisation data Cost calculated patients perspective using bottomup methodology direct cost patient indirect cost patient attendant calculated microcosting approach used calculate direct cost human capital approach used calculate indirect cost Median regression analysis performed identify determinant average annual cost Among participants 54 male mean ±SD age 551 ± 125 year duration diabetes 107 ± 77 years average annual cost US8647 per patient Medicine cost accounted 607 direct cost followed hospitalisation cost 277 average annual cost patient hospitalisation 42 time higher compared without hospitalisation females use insulin longer duration diabetes presence diabetes complication significantly related average annual cost per patient cost diabetes care considerably high Bangladesh primarily driven medicine hospitalisation costs Optimisation diabetes management positive lifestyle change urgently required prevention comorbidities complications turn reduce cost",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Bangladesh",
            "Comorbidity",
            "Cost of Illness",
            "Cross-Sectional Studies",
            "Diabetes Complications",
            "Diabetes Mellitus, Type 2",
            "Drug Costs",
            "Female",
            "Humans",
            "Interviews as Topic",
            "Male",
            "Middle Aged",
            "Prevalence",
            "Qualitative Research",
            "Surveys and Questionnaires"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31455307/"
    },
    {
        "pmid": "31366382",
        "title": "The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.",
        "abstract": "Malaria cause reduction haemoglobin compounded primaquine particularly patient glucose6phosphate dehydrogenase G6PD deficiency aim study determine relative contribution red cell loss malaria primaquine patient uncomplicated Plasmodium vivax systematic review identified P vivax efficacy study chloroquine without primaquine published January 2000 March 2017 Individual patient data pooled using standardised methodology haematological response versus time quantified using multivariable linear mixed effect model nonlinear term time Mean difference haemoglobin treatment group day nadir day 42 estimated model total 3421 patient 29 study included 1692 495 normal G6PD status 1701 497 unknown status 28 08 deficient borderline individuals 1975 patient treated chloroquine alone mean haemoglobin fell 1222 gdL 95 CI 1193 1250 day 0 nadir 1164 gdL 1136 1193 day 2 rising 1288 gdL 1260 1317 day 42 comparison chloroquine alone mean haemoglobin 1446 patient treated chloroquine plus primaquine  013 gdL  027 001 lower day nadir p  0072 049 gdL 028 069 higher day 42 p  0001 day 42 patient recurrent parasitaemia mean haemoglobin concentration  072 gdL  090  054 lower patient without recurrence p  0001 Seven day starting primaquine G6PD normal patient 03 1389 risk clinically significant haemolysis fall haemoglobin  25  7 gdL 1 4389 risk fall haemoglobin  5 gdL Primaquine potential reduce malariarelated anaemia day 42 beyond preventing recurrent parasitaemia widespread implementation require accurate diagnosis G6PD deficiency reduce risk druginduced haemolysis vulnerable individuals trial registered PROSPERO CRD42016053312 date first registration 23 December 2016",
        "mesh_terms": [
            "Adult",
            "Anemia, Hemolytic",
            "Antimalarials",
            "Chloroquine",
            "Female",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Hemolysis",
            "Humans",
            "Malaria, Vivax",
            "Male",
            "Middle Aged",
            "Plasmodium vivax",
            "Primaquine"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31366382/"
    },
    {
        "pmid": "31190922",
        "title": "Self-medication of antibiotics: investigating practice among university students at the Malaysian National Defence University.",
        "abstract": "bBackgroundb Selfmedication drug alleviate symptom common global behavior helping relieve burden health services many drug eg antibiotic prescriptiononly Selfmedication antibiotic SMA irrational use drugs contributing microbial resistance increasing health care cost higher mortality morbidity study aimed assess SMA among university students bMethodsb crosssectional study conducted among medical nonmedical student National Defence University Malaysia validated instrument used gather data Ethics approval obtained Random universal sampling adopted SPSS 21 used data analysis bResultsb total 649 student participated study 485 male 515 female 393 reported selfmedicating antibiotics Penicillin doxycycline clarithromycin antibiotic used majority reporting adverse drug reactions Cost saving convenience principal reason SMA mainly obtained local retail pharmacies Despite medical student particularly senior better knowledge antibiotic use nonmedical students 89 research participant responded practicing SMA goodacceptable practice bConclusionb SMA common amongst Malaysian student and despite understanding SMA unwise even medical student selfmedicate",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31190922/"
    },
    {
        "pmid": "31031031",
        "title": "The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations.",
        "abstract": "development group B Streptococcus GBS vaccine maternal immunization constitutes global public health priority prevent GBSassociated early life invasive disease stillbirth premature birth maternal sepsis adverse neurodevelopmental consequences reduce perinatal antibiotic use Sample size requirement conduct randomized placebocontrolled trial assess vaccine efficacy relevant clinical endpoints condition appropriate ethical standard care constitute significant obstacle pathway vaccine availability Alternatively indirect evidence protection based immunologic data vaccine seroepidemiological studies complemented data opsonophagocytic vitro assay animal models could considered pivotal data licensure subsequent confirmation effectiveness disease outcome postlicensure evaluations Based discussion initiated World Health Organization present key consideration potential role correlate protection towards accelerated pathway GBS vaccine licensure wide scale use Priority activity support progress regulatory policy decision outlined",
        "mesh_terms": [
            "Cost-Benefit Analysis",
            "Drug Approval",
            "Female",
            "Humans",
            "Infant, Newborn",
            "Infant, Newborn, Diseases",
            "Maternal Health",
            "Pregnancy",
            "Pregnancy Complications, Infectious",
            "Premature Birth",
            "Stillbirth",
            "Streptococcal Infections",
            "Streptococcal Vaccines",
            "Streptococcus agalactiae",
            "Vaccination",
            "World Health Organization"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31031031/"
    },
    {
        "pmid": "30681305",
        "title": "Business of Health. International Healthcare.",
        "abstract": "",
        "mesh_terms": [
            "Africa",
            "Asia",
            "Bangladesh",
            "Biosimilar Pharmaceuticals",
            "Canada",
            "China",
            "Commerce",
            "Delivery of Health Care",
            "Drug Approval",
            "Drug Costs",
            "Drug Industry",
            "Drugs, Generic",
            "Economics, Pharmaceutical",
            "Europe",
            "Finland",
            "France",
            "Fraud",
            "Germany",
            "Health Care Reform",
            "Health Care Sector",
            "Humans",
            "India",
            "Insurance, Health",
            "Kenya",
            "North America",
            "Norway",
            "Pharmaceutical Preparations",
            "Philippines",
            "Prostheses and Implants",
            "Taxes",
            "United Kingdom"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30681305/"
    },
    {
        "pmid": "30587297",
        "title": "Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.",
        "abstract": "14day course primaquine used radical cure Plasmodium vivax Plasmodium ovale malaria only quantified risk P vivax parasitaemia treatment Plasmodium falciparum commonly used antimalarial drug assess potential benefit radical cure patient uncomplicated malaria coendemic regions systematic review metaanalysis searched MEDLINE Embase Web Science Cochrane Database Systematic Reviews prospective clinical study language published Jan 1 1960 Jan 5 2018 assessing drug efficacy patient uncomplicated P falciparum malaria country coendemic P vivax Studies included presence absence P vivax parasitaemia recorded treatment primary outcome risk P vivax parasitaemia day 7 day 42 initiation antimalarial treatment P falciparum pooled risk calculated randomeffects metaanalysis compared risk P vivax parasitaemia treatment different artemisininbased combination therapy ACTs study registered PROSPERO number CRD42017064838 153 891 screened study included analysis including 31 262 patient 323 sitespecific treatment groups 130 85 study AsiaPacific region 16 10 Americas seven 5 Africa risk P vivax parasitaemia day 42 5·6 95 CI 4·07·4 Isup2sup92·0 117 estimates risk P vivax parasitaemia 6·5 95 CI 4·68·6 region short relapse periodicity compared 1·9 0·44·0 region long periodicity greater treatment rapidly eliminated ACT 15·3 5·129·3 artemetherlumefantrine compared 4·5 1·29·3 dihydroartemisininpiperaquine 5·2 2·97·9 artesunatemefloquine Recurrent parasitaemia delayed patient treated ACTs containing mefloquine piperaquine compared artemetherlumefantrine day 63 risk vivax parasitaemia 15 ACTs assessed finding show high risk vivax parasitaemia treatment falciparum malaria particularly area short relapse periodicity rapidly eliminated treatment coendemic regions universal radical cure patient uncomplicated malaria potential substantially reduce recurrent malaria Australian National Health Medical Research Council Royal Australasian College Physicians Wellcome Trust Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Antimalarials",
            "Artemisinins",
            "Child",
            "Child, Preschool",
            "Coinfection",
            "Female",
            "Humans",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Male",
            "Parasitemia",
            "Plasmodium falciparum",
            "Plasmodium vivax",
            "Quinolines",
            "Risk",
            "Treatment Outcome",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30587297/"
    },
    {
        "pmid": "30289078",
        "title": "Burden of Congenital Rubella Syndrome (CRS) in Bangladesh: Systematic Review of Existing Literature and Transmission Modelling of Seroprevalence Studies.",
        "abstract": "Congenital Rubella Syndrome CRS leading cause vaccinepreventable congenital anomalies Comprehensive countrylevel data burden CRS low middleincome countries Bangladesh scarce information essential assessing impact rubella vaccination programs aim systematically review literature epidemiology CRS estimate burden CRS Bangladesh conducted systematic review existing literature transmission modelling seroprevalence study estimate prevaccine period burden CRS Bangladesh OVID Medline 1948  23 November 2016 OVID EMBASE 1974  23 November 2016 searched using combination databasespecific controlled vocabulary free text terms used agestratified deterministic model estimate prevaccination burden CRS Bangladesh Ten article identified published 2000 2014 including seven crosssectional studies two case series one analytical casecontrol study Rubella seropositivity ranged 470 860 among age population Rubella seropositivity increased age Rubella seropositivity among woman childbearing age 810 overall estimated incidence CRS 0·99 per 1000 live births corresponds approximately 3292 CRS case annually Bangladesh estimated burden CRS Bangladesh prevaccination period high provide important baseline information assess impact costeffectiveness routine rubella immunisation introduced 2012 Bangladesh",
        "mesh_terms": [
            "Bangladesh",
            "Case-Control Studies",
            "Cost of Illness",
            "Cross-Sectional Studies",
            "Female",
            "Humans",
            "Incidence",
            "Pregnancy",
            "Pregnancy Complications, Infectious",
            "Rubella Syndrome, Congenital",
            "Seroepidemiologic Studies"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30289078/"
    },
    {
        "pmid": "30266330",
        "title": "Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016.",
        "abstract": "Shigella enterotoxigenic Escherichia coli ETEC bacterial pathogen frequently associated diarrhoeal disease significant cause mortality morbidity worldwide Global Burden Diseases Injuries Risk Factors study 2016 GBD 2016 systematic scientific effort quantify morbidity mortality due 300 cause death disability aimed analyse global burden shigella ETEC diarrhoea according age sex geography year 1990 2016 modelled shigella ETECrelated mortality using Bayesian hierarchical modelling platform evaluates wide range covariates model type basis vital registration verbal autopsy data used compartmental metaregression tool model incidence shigella ETEC enforces association incidence prevalence remission basis scientific literature population representative surveys healthcare data calculated 95 uncertainty interval UIs point estimates Shigella second leading cause diarrhoeal mortality 2016 among ages accounting 212 438 death 95 UI 136 979326 913 13·2 9·217·4 diarrhoea deaths Shigella responsible 63 713 death 41 19193 611 among child younger 5 year frequently associated diarrhoea across adult age groups increasing elderly people broad geographical distribution ETEC eighth leading cause diarrhoea mortality 2016 among age groups accounting 51 186 death 26 75783 064 3·2 1·84·7 diarrhoea deaths ETEC responsible 4·2 2·26·8 diarrhoea death child younger 5 years health burden bacterial diarrhoeal pathogen difficult estimate Despite existing prevention treatment options remain major cause morbidity mortality globally Additional emphasis public health official needed reduction disease due shigella ETEC reduce disease burden Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Aged",
            "Aged, 80 and over",
            "Biostatistics",
            "Child",
            "Child, Preschool",
            "Cost of Illness",
            "Diarrhea",
            "Dysentery, Bacillary",
            "Enterotoxigenic Escherichia coli",
            "Epidemiologic Methods",
            "Escherichia coli Infections",
            "Female",
            "Global Health",
            "Humans",
            "Infant",
            "Infant, Newborn",
            "Male",
            "Middle Aged",
            "Prevalence",
            "Risk Factors",
            "Shigella",
            "Survival Analysis",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30266330/"
    },
    {
        "pmid": "30170987",
        "title": "Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance.",
        "abstract": "Typhoid fever acute systemic infectious disease responsible estimated 1220 million illness 150 000 death annually March 2018 new recommendation issued programmatic use typhoid conjugate vaccine endemic countries Health economic analysis typhoid vaccine informed funding decision national policy regarding vaccine rollout However focusing averted typhoid case associated costs traditional costeffectiveness analysis might underestimate crucial benefit typhoid vaccination programmes potential effect typhoid vaccine treatment patient nonspecific acute febrile illness considered every true case typhoid fever three 25 patient without typhoid disease treated antimicrobial unnecessarily conservatively amounting 50 million prescription per year Antimicrobials suspected typhoid might therefore important selective pressure emergence spread antimicrobial resistance globally propose largescale aggressive typhoid vaccination programmesincluding catchup campaign child 15 year age vaccination lower incidence settingshave potential reduce overuse antimicrobial thereby reduce antimicrobial resistance many bacterial pathogens Funding body national government must therefore consider potential broad reduction antimicrobial use resistance decision related rollout typhoid conjugate vaccines",
        "mesh_terms": [
            "Adolescent",
            "Anti-Bacterial Agents",
            "Child",
            "Child, Preschool",
            "Cost-Benefit Analysis",
            "Drug Resistance, Bacterial",
            "Female",
            "Humans",
            "Incidence",
            "Infant",
            "Male",
            "Salmonella typhi",
            "Typhoid Fever",
            "Typhoid-Paratyphoid Vaccines",
            "Vaccination",
            "Vaccines, Conjugate"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30170987/"
    },
    {
        "pmid": "30170949",
        "title": "Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.",
        "abstract": "Data scarce availability affordability essential medicine diabetes aim examine availability affordability metformin sulfonylureas insulin across multiple region world explore effect medicine use Prospective Urban Rural Epidemiology PURE study participant aged 3570 year n156 625 recruited 110 803 households 604 community 22 countries availability presence dose medication pharmacy day audit medicine cost data collected pharmacy Environmental Profile Communitys Health audit tool primary analysis describe availability affordability metformin insulin also commonly used prescribed combination two medicine diabetes management two oral drugs metformin plus sulphonylurea either glibenclamide also known glyburide gliclazide one oral drug plus insulin metformin plus insulin Medicines defined affordable cost medicine less 20 capacitytopay the household income minus food expenditure analysis included data collected pharmacy data representative sample households Data availability ascertained pharmacy audit data cost medications cost data used estimate cost months supply essential medicine diabetes estimated affordability medicine using income data household surveys Metformin available 113 100 113 pharmacy highincome countries 112 88·2 127 pharmacy uppermiddleincome countries 179 86·1 208 pharmacy lowermiddleincome countries 44 64·7 68 pharmacy lowincome country excluding India 88 100 88 pharmacy India Insulin available 106 93·8 pharmacy highincome countries 51 40·2 pharmacy uppermiddleincome countries 61 29·3 pharmacy lowermiddleincome countries seven 10·3 pharmacy lowerincome countries 67 76·1 88 pharmacy India estimated 0·7 household highincome country 26·9 household lowincome country could afford metformin 2·8 household highincome country 63·0 household lowincome country could afford insulin Among 13 569 8·6 PURE participants reported diagnosis diabetes 1222 74·0 participant reported diabetes medicine use highincome country compared 143 29·6 participant lowincome countries multilevel models availability affordability significantly associated use diabetes medicines Availability affordability essential diabetes medicine poor lowincome middleincome countries Awareness global difference might importantly drive change access patient diabetes Full funding source listed end paper see Acknowledgments",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Costs and Cost Analysis",
            "Diabetes Mellitus",
            "Drugs, Essential",
            "Economic Status",
            "Health Services Accessibility",
            "Humans",
            "Hypoglycemic Agents",
            "Insulin",
            "Metformin",
            "Middle Aged",
            "Prospective Studies",
            "Rural Population",
            "Sulfonylurea Compounds",
            "Urban Population"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30170949/"
    },
    {
        "pmid": "30076604",
        "title": "The Global Wicked Problem of Corruption and Its Risks for Access to HIV/AIDS Medicines.",
        "abstract": "discus corruption affect access antiretroviral therapy ARVs globally Recent case theft ARVs collusion manipulation procurement found country Central African Republic Bangladesh Malawi Guinea show still much work done reduce risk corruption includes addressing structural weakness procurement mechanism supply chain management system health commodity medicines",
        "mesh_terms": [
            "Anti-HIV Agents",
            "Commerce",
            "Counterfeit Drugs",
            "Developing Countries",
            "Drug Costs",
            "Global Health",
            "HIV Infections",
            "Health Services Accessibility",
            "Humans",
            "Rate Setting and Review",
            "Theft"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30076604/"
    },
    {
        "pmid": "30033231",
        "title": "The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.",
        "abstract": "Chloroquine remains mainstay treatment Plasmodium vivax malaria despite increasing report treatment failure systematic review metaanalysis investigate effect chloroquine dose addition primaquine risk recurrent vivax malaria across different settings systematic review done MEDLINE Web Science Embase Cochrane Database Systematic Reviews identified P vivax clinical trial published Jan 1 2000 March 22 2017 Principal investigator invited share individual patient data pooled using standardised methods Cox regression analysis random effect study site used investigate role chloroquine dose primaquine use rate recurrence day 7 day 42 primary outcome review protocol registered PROSPERO number CRD42016053310 134 identified chloroquine studies 37 study from 17 countries 5240 patient included 2990 patient treated chloroquine alone 1041 34·8 received dose target 25 mgkg risk recurrence 32·4 95 CI 29·835·1 day 42 controlling confounders 5 mgkg higher chloroquine dose reduced rate recurrence overall adjusted hazard ratio AHR 0·82 95 CI 0·690·97 p0·021 child younger 5 year 0·59 0·410·86 p0·0058 Adding primaquine reduced risk recurrence 4·9 95 CI 3·17·7 day 42 lower chloroquine alone AHR 0·10 0·050·17 p0·0001 Chloroquine commonly underdosed treatment vivax malaria Increasing recommended dose 30 mgkg child younger 5 year could reduce substantially risk early recurrence primaquine given Radical cure primaquine highly effective preventing early recurrence may also improve blood schizontocidal efficacy chloroquineresistant P vivax Wellcome Trust Australian National Health Medical Research Council Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Aged",
            "Aged, 80 and over",
            "Antimalarials",
            "Child",
            "Child, Preschool",
            "Chloroquine",
            "Drug Resistance",
            "Drug Therapy, Combination",
            "Female",
            "Humans",
            "Infant",
            "Infant, Newborn",
            "Malaria, Vivax",
            "Male",
            "Middle Aged",
            "Plasmodium vivax",
            "Primaquine",
            "Recurrence",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30033231/"
    },
    {
        "pmid": "30021742",
        "title": "Two for the price of one: emerging carbapenemases in a returning traveller to New York City.",
        "abstract": "report case complex orthopaedic infection patient returning New York City Bangladesh involved serious motor vehicle accident developed extensive osteomyelitis carbapenemresistant iKlebsiella pneumoniaei isolate unique due coexistence New Delhi metalloβlactamase1 Oxacillinase type181 carbapenemases relatively uncommon North America presumably acquired Bangladesh Herein explore challenge associated management carbapenemresistant Enterobacteriaceae infections including limited available data effective antimicrobial therapy also highlight added value rapid diagnostic technology guiding clinical management Ultimately patient required aggressive surgical management combination therapy aztreonam ceftazidimeavibactam true source control favourable clinical outcome",
        "mesh_terms": [
            "Adult",
            "Anti-Bacterial Agents",
            "Azabicyclo Compounds",
            "Aztreonam",
            "Ceftazidime",
            "Drug Combinations",
            "Drug Resistance, Multiple, Bacterial",
            "Humans",
            "Klebsiella Infections",
            "Klebsiella pneumoniae",
            "Male",
            "Mucormycosis",
            "Osteomyelitis",
            "Pseudomonas Infections",
            "Pseudomonas aeruginosa",
            "Rhizopus",
            "Travel-Related Illness",
            "beta-Lactamase Inhibitors"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30021742/"
    },
    {
        "pmid": "29925430",
        "title": "Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group.",
        "abstract": "goal eliminate malaria AsiaPacific 2030 require safe widespread delivery effective radical cure malaria October 2017 Asia Pacific Malaria Elimination Network Vivax Working Group met discus impediment primaquine PQ radical cure overcome methodological difficulty assessing clinical effectiveness radical cure salient discussion meeting involved 110 representative 18 partner country 21 institutional partner organization reported Context specific strategy improve adherence needed increase understanding awareness PQ within affected communities must include education health promotion programs Lessons learned disease program highlight package approach greatest potential change patient prescriber habits however optimizing component approach quantifying effectiveness challenging trial setting reactivity participant result patient altering behaviour creates inherent bias Although bias reduced integrating data collection routine health care surveillance systems come cost decreasing detection clinical outcomes Measuring adherence factor relate it also requires indepth understanding context underlying sociocultural logic support it Reaching elimination goal require innovative approach improve radical cure vivax malaria well method evaluate effectiveness",
        "mesh_terms": [
            "Antimalarials",
            "Asia",
            "Humans",
            "Malaria, Vivax",
            "Pacific Islands",
            "Plasmodium vivax",
            "Primaquine",
            "Treatment Adherence and Compliance",
            "Treatment Outcome"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/29925430/"
    },
    {
        "pmid": "29459592",
        "title": "Current Trends of Using Systemic Antifungal Drugs and their Comparative Efficacy in Tinea Corporis and Tinea Cruris in Outpatient Department of Dermatology in a Tertiary Level Hospital.",
        "abstract": "Tinea corporis  cruris one earliest known fungal infection common throughout world Although tinea corporis tinea cruris cause mortality cause morbidity pose major health problem study conducted evaluate Comparative Efficacy Terbinafine Fluconazole Treatment Tinea corporis Tinea cruris cross sectional comparative type analytical study carried department Pharmacology  Therapeutics collaboration Dermatology Venereology Mymensingh Medical College Hospital Mymensingh Bangladesh January 2016 December 2016 study 168 newly diagnosed Tinea corporis Tinea cruris patient purposively selected pattern comparative efficacy terbinafine fluconazole analyzed Among 168 patient patient presented tinea corporis 5833 patient belong 2130 year age group Male female ratio study 1151 study 143 patient treated fluconazole 50mg daily 4 week 25 patient treated terbinafine 250 mg daily 4 weeks 4 weeks improvement rate fluconazole 8602 terbinafine 9600 clinical score group 4th week treatment slight reduction clinical score terbinafine using group fluconazole using group difference two clinical score statistically significant p005 Although significant difference observed two group patient clinical aspect due lower price availability hospital suggested fluconazole suitable treatment tinea corporis tinea cruris",
        "mesh_terms": [
            "Adult",
            "Antifungal Agents",
            "Bangladesh",
            "Cross-Sectional Studies",
            "Female",
            "Humans",
            "Male",
            "Outpatients",
            "Tinea",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/29459592/"
    },
    {
        "pmid": "29447176",
        "title": "Cost-effectiveness of prenatal food and micronutrient interventions on under-five mortality and stunting: Analysis of data from the MINIMat randomized trial, Bangladesh.",
        "abstract": "Nutrition intervention may favourable well unfavourable effects Maternal Infant Nutrition Interventions Matlab MINIMat early prenatal food micronutrient supplementation reduced infant mortality reported costeffective However multiple micronutrient MMS supplement associated increased risk stunted growth infancy early childhood unfavourable outcome included previous costeffectiveness analysis aim study evaluate whether MINIMat intervention remain costeffective view favourable decreased underfiveyears mortality unfavourable increased stunting outcomes Pregnant woman rural Bangladesh food insecurity still prevalent randomized early E usual U invitation given food supplementation daily dos 30 mg 60 mg iron 400 μg folic acid MMS 15 micronutrient including 30 mg iron 400 μg folic acid E reduced stunting 45 year compared U MMS increased stunting 45 year compared Fe60 combination EMMS reduced infant mortality compared UFe60 outcome measure used disability adjusted life year DALYs measure overall disease burden combine year life lost due premature mortality under fiveyear mortality year lived disability stunting Incremental cost effectiveness ratio calculated using cost data already published studies incrementing UFe60 standard practice EMMS one DALY could averted cost US24 favourable unfavourable outcome included analysis early prenatal food multiple micronutrient intervention remained highly cost effective seem meaningful public health perspective",
        "mesh_terms": [
            "Adult",
            "Bangladesh",
            "Child, Preschool",
            "Cost-Benefit Analysis",
            "Dietary Supplements",
            "Female",
            "Folic Acid",
            "Food Supply",
            "Growth Disorders",
            "Humans",
            "Infant",
            "Infant Mortality",
            "Infant Nutritional Physiological Phenomena",
            "Infant, Newborn",
            "Iron",
            "Male",
            "Micronutrients",
            "Nutrition Policy",
            "Pregnancy",
            "Prenatal Care",
            "Prenatal Nutritional Physiological Phenomena",
            "Trace Elements",
            "Vitamins"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/29447176/"
    },
    {
        "pmid": "29253412",
        "title": "Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data.",
        "abstract": "Hypertension considered important risk factor cardiovascular diseases control poor worldwide aimed assess availability affordability blood pressurelowering medicines association use medicine blood pressure control country varying level economic development analysed availability costs affordability blood pressurelowering medicine data recorded 626 community 20 country participating Prospective Urban Rural Epidemiological PURE study Medicines considered available present local pharmacy surveyed affordable combined cost less 20 households capacity pay related information availability affordability use medicine blood pressure control multilevel mixedeffects logistic regression models compared result highincome uppermiddleincome lowermiddleincome lowincome countries Data India presented separately large generic pharmaceutical industry higher availability medicine country economic level availability two class blood pressurelowering drug lower lowincome middleincome country except India highincome countries proportion community four drug class available 94 highincome country 108 115 communities 76 India 68 90 71 uppermiddleincome country 90 126 47 lowermiddleincome country 107 227 13 lowincome country nine 68 proportion household unable afford two blood pressurelowering medicine 31 lowincome country 1069 3479 households 9 middleincome country 5602 65 471 less 1 highincome country 44 10 880 Participants known hypertension community four drug class available likely use least one blood pressurelowering medicine adjusted odds ratio OR 2·23 95 CI 1·593·12 p0·0001 combination therapy 1·53 1·132·07 p0·054 blood pressure controlled 2·06 1·692·50 p0·0001 community blood pressurelowering medicine available Participants known hypertension household able afford four blood pressurelowering drug class likely use least one blood pressurelowering medicine adjusted 1·42 95 CI 1·251·62 p0·0001 combination therapy 1·26 1·081·47 p0·0038 blood pressure controlled 1·13 1·001·28 p0·0562 unable afford medicines large proportion community lowincome middleincome country access one blood pressurelowering medicine and available often affordable factor associated poor blood pressure control Ensuring access affordable blood pressurelowering medicine essential control hypertension lowincome middleincome countries Population Health Research Institute Canadian Institutes Health Research Heart Stroke Foundation Ontario Canadian Institutes Health Research Strategy Patient Oriented Research Ontario SPOR Support Unit Ontario Ministry Health LongTerm Care pharmaceutical company with major contribution AstraZeneca Canada Sanofi Aventis France Canada Boehringer Ingelheim Germany amd Canada Servier GlaxoSmithKline Novartis King Pharma national local organisation participating countries",
        "mesh_terms": [
            "Aged",
            "Antihypertensive Agents",
            "Developed Countries",
            "Developing Countries",
            "Female",
            "Humans",
            "Hypertension",
            "Income",
            "Male",
            "Middle Aged",
            "Treatment Outcome"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/29253412/"
    },
    {
        "pmid": "40824635",
        "title": "Conflicts of Interest in Federal Vaccine Advisory Committees.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40824635/"
    },
    {
        "pmid": "40816710",
        "title": "Commercialization of cell and gene therapy in Canada: Current landscape, challenges and opportunities.",
        "abstract": "Cell gene therapy CGTs offer transformative treatment certain genetic disease cancers growing number global approvals Yet Canadian commercialization lag behind USA Europe review identifies key barrier proposes policy solution informed international examples policyoriented environmental scan conducted using regulatory documents peerreviewed literature government reports industry publications Barriers solution organized four domains regulation manufacturing pricing reimbursement access equity Despite recent investment downturn therapeutic area Canadas approval first clustered regularly interspaced short palindromic repeat CRISPRbased therapy chimeric antigen receptor CAR Tcell expansion suggest future growth Strategic reform could improve domestic CGT innovation affordability equitable access",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40816710/"
    },
    {
        "pmid": "40815523",
        "title": "Prices and Affordability of Essential Medicines in 72 Low-, Middle-, and High-Income Markets.",
        "abstract": "Little known price affordability medicine included World Health Organizations Model List Essential Medicines vary across globe compare list price affordability essential medicine across high middle lowincome markets crosssectional study examined data 2022 list price volume 549 essential medicine 72 high middle lowincome market covering 87 countries data obtained IQVIA statistical analysis performed August 2024 March 2025 Laspeyres price index used compare average drug price across countries nominal purchasing power parityadjusted terms affordability 8 essential medicines used treat major cause death disability globally assessed calculating many day minimum wage would required pay 1 month treatment availability essential medicine ranged 225 41 Kuwait 438 80 Germany base country accounting purchasing power parities price essential medicine Lebanon were average 181 Germany Lebanon price index 181 v Germany price index 100 average price US 30 time higher Germany US price index 2982 positive association observed countries gross domestic product per caput expressed logarithmic terms nominal drug price R  030 P  01 indicating richer country generally higher drug prices However adjusting purchasing power different currencies inverse association observed R  035 P  003 suggesting richer country lower real prices Drug affordability measured number days minimum wage needed purchase months treatment varied widely median affordability highest Europe Western Pacific lowest Africa Southeast Asia result crosssectional analysis showed significant variation price affordability 549 essential medicine across 72 market 2022 Strategies promote equitable drug price improve drug affordability urgently needed",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815523/"
    },
    {
        "pmid": "40813984",
        "title": "The impact of deep brain stimulation payment adjustments on healthcare utilization in Shanghai, China: a regression discontinuity analysis of health insurance claims.",
        "abstract": "Recently financial burden medical insurance fund increased rapidly policy effect paying innovation await scientific measurement study us DBS highvalue medical product example quantify causal effect insurance coverage change healthcare utilization informing global valuebased payment strategies identified 2665 DBSrelated records excluding case missing data implantation diagnosis comorbidity management device adjustment presurgery admissions abnormal length stay 2471 case included analysis nonparametric sharp regression discontinuity design adopted assess causal effect reimbursement strategy adjustment eight measure healthcare utilization addition performed robustness analyses reimbursement strategy adjustment significantly reduced individual outofpocket expenditure β10905130 P  0001 increased medical insurance reimbursement cost β  12834714 P  0001 shortened average length recovery β2823 P  001and average length stay β3741 P  0001 accounting covariates result remained significant though effect estimate attenuated suggesting strong association demographic medical characteristic healthcare utilization Additionally effect total surgical cost surgical consumable cost proportion drug cost statistically significant 005 level medical insurance reimbursement strategy adjustment effectively reduces patients economic burden improves healthcare utilization However crucial consider strengthening cost monitoring highvalue medical technologies optimizing clinical pathways balancing interest patients hospitals insurance funds",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813984/"
    },
    {
        "pmid": "40811746",
        "title": "Pharmaceutical expenditure changes under the volume-based procurement policy: Effects and influencing factors.",
        "abstract": "estimate impact Chinas volumebased procurement VBP policy expenditure policycovered uncovered drugs identify element contribute drug expenditure change VBP policy Using national drug procurement data public medical institutions study included 25 policycovered VBP drug 99 policyuncovered alternative drug samples seven 47 pilot city eight 47 expansion province observation regions Timevarying differenceindifference DID model applied quantify policy impact drug expenditures drug expenditure index decomposition method employed analyze determinant drug expenditure change following VBP policy expenditure VBP drug significantly decreased 4219 VBP policy β  055 p  0001 alternative drug increased 1152 β  011 p  0001 significant reduction overall expenditure observed drug β  005 p  0001 decrease VBP drug expenditure showed trend tertiary hospital β  064 p  0001  secondary hospital β  057 p  0001  primary healthcare center β  039 p  0001 index decomposition showed manufacturer structure index IM decline primary driver expenditure reduction policycovered drugs IM decrease 5417 pilot city 4086 expansion regions secondary driver price index IP decline 3168 pilot city 3608 expansion regions restraining factor quantity index IQ increasing 9254 pilot city 5204 expansion regions IQ also drove increase alternative drug expenditures increasing 9556 pilot city 3276 expansion regions VBP policy effectively promoted decline total drug expenditures primarily manufacturerlevel market displacement absolute price reduction However spillover effect alternative drug weakened overall effect cost control Strengthening holistic governance improving quality intensiveness drug use important direction future policy perfection",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40811746/"
    },
    {
        "pmid": "40791629",
        "title": "Global burden on drug use disorders from 1990 to 2021 and projections to 2046.",
        "abstract": "Drug use disorder DUDs continue pose heavy burden individuals families societies Despite extensive research remains paucity comprehensive report spatiotemporal distribution driving factors future trend DUDs global regional national levels study aim address gap investigating critical aspect DUDs epidemic Annual data DUDsrelated burden collected Global Burden Diseases injuries risk factor Study GBD 2021 Ageperiodcohort APC analysis estimated annual percentage change used evaluate spatiotemporal trend burden Decomposition analysis used identify temporal populationspecific variation burden slope index inequality concentration index utilized summarize health inequality burden Frontier analysis performed evaluate relationship burden DUDs sociodemographic development Nordpred model Bayesian ageperiodcohort BAPC model introduced forecast burden 2021 global prevalence DUDs reached 53115936 95 UI 4699980560949054 marking 3550 increase since 1990 projected continue rising next 25 years increment incidence deaths disabilityadjusted life year DALYs 3550 12222 7465 respectively Despite declining trend global rate incidence prevalence DALYs mortality still show upward trend increasing 126 165 per 100000 Opioid cocaine use disorder primary contributor overall increase DUDs DALYs 8207 5957 respectively Population growth primary driver increase DUDs DALYs 3531 higher burden observed male population aged 1539 years Health inequality insufficient healthcare performance regarding DUDs remain prominent issue high low sociodemographic index SDI regions study underscore persistent evolving nature DUDs Future research focus understanding complex interplay age gender disparities socioeconomic development drug policies DUDs burden inform effective global strategies",
        "mesh_terms": [
            "Humans",
            "Male",
            "Female",
            "Substance-Related Disorders",
            "Adult",
            "Global Health",
            "Middle Aged",
            "Global Burden of Disease",
            "Adolescent",
            "Prevalence",
            "Young Adult",
            "Cost of Illness",
            "Risk Factors",
            "Forecasting",
            "Quality-Adjusted Life Years"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40791629/"
    },
    {
        "pmid": "40789697",
        "title": "Trends in 25 years of antihypertensive agent utilization in Croatia - an alert for scientific community and healthcare providers.",
        "abstract": "Hypertension leading modifiable risk factor cardiovascular mortality worldwide study aimed evaluate 25year trend antihypertensive agent AHA utilization Croatia 2000 2024 conducted national populationbased analysis using IMS IQVIA pharmaceutical databases Drug utilization measured defined daily dos per 1000 inhabitant per day DDD1000day alongside trend financial expenditure prescribing patterns 2000 2024 total AHA utilization tripled increasing 14457 43913 DDD1000day Agents acting reninangiotensin system RAS prescribed class throughout period prescribing volume rising 335 largely driven increased utilization fixeddose combinations Class shift included growing uptake βblockers RAS inhibitors alongside relative decline calcium channel blocker diuretics Total national expenditure AHAs increased €5362 million 2000 €9661 million 2024 reflecting evolving market dynamic sustained decrease average drug price per DDD change related broader access AHAs expanding role combination therapy regimen completely parallel introduction updated international guidelines Nevertheless demographic pressures clinical inertia policyrelated barrier continue constrain optimal blood pressure control finding highlight importance aligning national prescribing practice clinical evidence health system reform improve longterm cardiokidneymetabolic outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789697/"
    },
    {
        "pmid": "40789184",
        "title": "Bolstering the Medication Supply Chain and Ameliorating Medication Shortages: A Position Paper From the American College of Physicians.",
        "abstract": "US health care system experiencing numerous supply chain disruptions including important medications Prescription drug shortage record level affected drug recent years especially generic sterile injectables lowmargin medications shortage arise confluence factors including complexity entire production delivery supply chain quality issues outdated manufacturing facility practices drug purchasing policy prioritize lowest price reliable production change prescribing usage patterns geopolitical constraints market concentration among factors prescription drug shortage patient face negative health outcome due unable obtain necessary treatments stress associated securing medications adverse effect alternative treatments Physicians also face substantial burden navigating drug shortage must expend time resource identifying alternative treatment option obtaining prior authorization coverage alternative drugs negatively affecting patientphysician relationship Policymakers regulators manufacturers health systems health professionals relevant entity must collaborate effort ameliorate drug shortage promote equitable access treatments addition shortterm measure address immediate effect drug shortages policymakers manufacturers drug purchaser also undertake effort prevent future drug shortage investing in strengthening diversifying prescription drug supply chain incentivizing procurement practice emphasize reliable sustainable production practices effort must undergirded policy improve monitoring transparency prescription drug supply chain",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789184/"
    },
    {
        "pmid": "40779264",
        "title": "Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide.",
        "abstract": "Semaglutide glucagonlike peptide1 receptor agonist demonstrated substantial weight reduction cardiovascular benefit clinical trials However association clinical outcome health care expenditure remains underexplored evaluate change cardiovascular risk factor health care expenditure among patient prescribed semaglutide across multicenter cohorts retrospective cohort study included 23 522 adult ≥18 years received initial semaglutide prescription January 1 2018 January 1 2025 Sentara Healthcare January 1 2018 May 1 2025 Yale New Health System first prescription semaglutide identified ingredient level stratified type 2 diabetes status Primary outcome included change weight  baseline blood pressure BP total cholesterol hemoglobin A1c Secondary outcome assessed health care expenditure using Medicarebased cost estimates staggered differenceindifferences design compared outcome patient first semaglutide prescription patient yet received prescription period study cohort included 23 522 patient mean SD age initiation semaglutide 562 129 years 667 female 686 diabetes overall cohort initiation semaglutide significantly associated 38 95 CI 39 37 reduction weight 13 24 months 51 95 CI 55 47 reduction weight among patient without diabetes Significant reduction diastolic BP 15 mm Hg 95 CI 17 14 mm Hg systolic BP 11 mm Hg 95 CI 14 08 mm Hg total cholesterol 128 mgdL 95 CI 143 114 mgdL also observed Hemoglobin A1c reduction greater among patient diabetes 03 95 CI 03 02 compared patient without diabetes 01 95 CI 02 001 Imputed health care expenditures excluding cost semaglutide increased 80 per month 95 CI 6892 per month 13 24month period associated inpatient stay shifting expensive circulatory metabolic diagnoses cohort study adult prescribed semaglutide initiation associated reduction weight cardiovascular risk factor increase health care expenditures excluding semaglutide costs finding suggest potential clinical benefit routine practice highlighting need evaluate longterm impact semaglutide economic outcomes",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Female",
            "Humans",
            "Male",
            "Middle Aged",
            "Blood Pressure",
            "Cardiovascular Diseases",
            "Diabetes Mellitus, Type 2",
            "Glycated Hemoglobin",
            "Health Expenditures",
            "Heart Disease Risk Factors",
            "Retrospective Studies",
            "United States",
            "Glucagon-Like Peptide-1 Receptor Agonists",
            "Glucagon-Like Peptide 1"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40779264/"
    },
    {
        "pmid": "40779257",
        "title": "Prescription Drug Utilization and Spending by Race, Ethnicity, Payer, Health Condition, and US State.",
        "abstract": "Achieving equitable access medicine requires understanding pharmaceutical use spending vary race ethnicity across US quantify variation prescription drug utilization spending per caput per prevalent case race ethnicity health condition payer US state crosssectional study US Disease Expenditure project extended incorporate disaggregation race ethnicity statelevel retail prescription drug utilization spendingin addition 143 health conditions 38 age sex groups 4 payer Medicare Medicaid private insurance pocketacross 2019 population 50 state Washington DC Data analyzed October 2023 April 2025 Four mutually exclusive racial ethnic group Asian Pacific Islander Black Hispanic White Outcomes include prescription dispensed spending retail pharmaceuticals Estimates standardized population size population age andwhere data permittedby disease burden 52 conditions Das Gupta decomposition used estimate relative contribution 3 factor disease prevalence prescription per prevalent case spending per prescription observed disparity agestandardized per caput pharmaceutical spending 2019 agestandardized pharmaceutical utilization spending per person given disease substantially lower allpopulation mean Black populations close mean Hispanic populations often higher mean Asian Pacific Islander White populations trendsparticularly Black populationwere generally consistent across 52 health condition varied widely across payer US states decomposition analysis 52 condition showed difference per caput pharmaceutical spending across race ethnicity group primarily explained disease prevalence Black population associated increased per caput spending utilization rate per prevalent case Hispanic population also associated increased spending contrast difference drug price product type spending per prescription contributed less observed spending disparities crosssectional study racial ethnic disparity medication use persisted notably underutilization medicine relative disease burden among Black populations pattern varied state highlighting need local conditionspecific approach advancing pharmacoequity US",
        "mesh_terms": [
            "Humans",
            "United States",
            "Cross-Sectional Studies",
            "Ethnicity",
            "Health Expenditures",
            "Prescription Drugs",
            "Racial Groups",
            "Male",
            "Female",
            "Drug Utilization",
            "Middle Aged",
            "Adult",
            "Aged"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40779257/"
    },
    {
        "pmid": "40779237",
        "title": "A Framework for Considering the Role of the Public Sector in R&D of Health Technology.",
        "abstract": "development health technology involves complex costly risky investments significant contribution public private sectors Recent EU pharmaceutical directive propose transparency public funding aid pricing negotiation affordability However question remain regarding public investment measured influence pricing reimbursement PR decisions paper characterise public sector institution payers RD investors regulators myriad agency decisions institution directly indirectly sometime unexpectedly influence risk return private research development RD PR direct investments regulatory policy PR decision payer innovative therapy influence risk expected return future RD Valuebased pricing offer reliable signal payers priority costplus international reference pricing greatest impact public RD investment directed area market deficient basic science translational research realworld studies towards emerging field like AI gene editing play increasing role healthcare drug development Applied RD conducted financially sustainable basis Licensing arrangement used recover investments promoting spillover benefit wider society Market access regulator aware need scrupulous transparency neutrality public sector actor payers RD investors also must recognise policy affect level playing field",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40779237/"
    },
    {
        "pmid": "40775352",
        "title": "Multiple first-line therapeutic strategies to mitigate artemisinin resistance: cost analysis of a pilot study from a health system perspective in Kaya health district, Burkina Faso.",
        "abstract": "emergence artemisinin resistance Africa increasingly evident threat malaria control elimination anticipatory measure needed Mathematical modelling study demonstrated simultaneous deployment multiple firstline therapy MFT strategy delay spread resistance evidence concerning implementation strategies important factor decisionmaking Incremental financial cost implementing MFT strategy district scale estimated analysed compared routine practice scalingup perspective government Then implication finding improving malaria control Burkina Faso part subSaharan Africa highlighted Microcosting activitybased costing approach used assess cost providers MFT pilot study implemented Kaya Heath District December 2019 November 2020 Quantitative et qualitative data collected seven semistructured thirtyeight structured interviews interview conducted research team including member National Malaria Control Programme health district official chief doctor chief pharmacist manager public health facility MFT strategy implemented six activity involved routine malaria care delivery four incur additional cost MFT strategy implemented support material production health worker training supervision chosen artemisininbased combination therapy ACT costs different standard cost basis uncomplicated malaria case reported national level 2022 MFT implementation cost country level estimated 20840880 USD 92 related drug cost recurrent character weight drug cost MFT strategy depends artemisininbased combination chosen subsidy free care policies pilot strategy cost MFT drug double routine practice 19175568 USD versus 8554365 USD result MFT strategy cost analysis presented may assist policy maker choice malaria ACT combination mitigating emergence drug resistance Although MFT strategy cost almost twice much current single firstline treatment strategy cost saving due avoiding treatment failure likely substantial result also highlight necessity better organizing stabilizing malaria control financing source particularly view recent funding challenge facing global health system",
        "mesh_terms": [
            "Burkina Faso",
            "Pilot Projects",
            "Artemisinins",
            "Antimalarials",
            "Drug Resistance",
            "Humans",
            "Malaria",
            "Costs and Cost Analysis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40775352/"
    },
    {
        "pmid": "40770604",
        "title": "Optimization of pharmaceutical research and development by early-phase assessment of investigational medicinal products.",
        "abstract": "Small midsized pharmaceutical innovator often limited inhouse health economics market access expertise may struggle align development strategy investigational medicinal product health system need payer expectations Limited attention building health economic story early development phase may ultimately result suboptimal return investment Earlyphase health technology assessment eHTA provides structured approach value maximization Selection payment model help understand value proposition taken account general target payer new medicine Fair judgement degree innovation expected launch date essential choose relevant proposition general list value drivers Development conceptual value framework translates target product profile policyrelevant value propositions health gain expected cost saving avoided medical event delayed disease progression value use health system benefits Implementation health economics outcome research strategy help justify premium price based added value facilitate appropriate order target indication return investment Effective integration eHTA research development process enables innovator shorten time reimbursement increase probability clinical commercial success investigational medicinal products",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40770604/"
    },
    {
        "pmid": "40768370",
        "title": "Investing in Infrastructure: A Mixed-Methods Cost Analysis of Implementation Strategies to Address Emerging Youth Drug Trends.",
        "abstract": "Schools engaged prevention effort struggle respond quickly effectively changing drug use trend due insufficient investment infrastructure local state national levels result preventable morbidity mortality among adolescents study estimated cost associated implementing Rapid Adaptation Prevent Drug use RAPD infrastructurebuilding implementation strategies using mixed method optimize data collection feasibility quality support comprehensive understanding outcomes conducted semistructured interview Step 1 prepilot trial inform initial cost data collection approach Step 2 used activitybased costing conducted sensitivity analysis estimated budget impact replication Step 3 included interview pilot participant contextualize result verify time reporting Thirtyfour school personnel participated Step 1 interview four health coordinator six teacher participated pilot study identified cost driver pragmatic constraint related effective timecost data collection developed activitybased costing data collection plan estimated cost deploying RAPD Step 2 6215school estimated budget impact replication 5551school 52 cost preimplementation phase Step 3 interview participant identified financial staffing resource central challenge infrastructure development study us mixed method approach including exploratory sequential design proactively guide microcosting identifying potential barrier advance enhanced rigor feasibility data collection process study offer preliminary cost estimate deploy RAPD infrastructurebuilding strategy address emerging drug trend sustain prevention efforts Building prevention infrastructure essential preventing onset escalation substance use among youth Implementation strategy key building robust implementation infrastructure prevention Estimating cost associated infrastructure building strategy vital realizing public health impact prevention interventions",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40768370/"
    },
    {
        "pmid": "40767240",
        "title": "Assessment of Financial Impact of Expanding the Scope of Drug Usage in South Korea.",
        "abstract": "increasing utilization highcost drug multiple indication pose significant financial challenge healthcare system worldwide study evaluates financial impact expanding drug indication Korea focusing pharmaceutical expenditure trend study analyzed claim data National Health Insurance Service NHIS examine drug characteristic annual expenditure Interrupted timeseries analysis assessed monthly expenditure change following indication expansions analyzed 57 drug expanded indication 2012 2023 2012 2022 drug expenditure increased 15fold compound annual growth rate CAGR 308 significantly larger rise compared 19fold rise CAGR 65 total pharmaceutical expenditure covered NHIS Notably expenditure increased 35fold 35 drug classified anatomical therapeutic chemical ATC code L antineoplastic immunomodulating agents 375fold 26 drug risksharing agreement RSAs Interrupted timeseries analysis n  27 demonstrated significant monthly expenditure increase expansion US 033 million per month iPi000 significant increase expenditure pre postexpansion period US 499564 million iPi000 Moreover postexpansion trend showed significant additional increase expenditure US 013 million per month iPi003 24 month US 007 million per month iPi037 36 months Despite price reduction strategy multiindication drugs expenditure accelerated increase expenditure postexpansion indication highlight need robust postpricing management listed drugs long term total budget system could ensure predictable sustainable financing providing clear financial boundary within health insurance budget",
        "mesh_terms": [
            "Republic of Korea",
            "Humans",
            "Health Expenditures",
            "Drug Costs",
            "National Health Programs",
            "Interrupted Time Series Analysis",
            "Drug Utilization"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40767240/"
    },
    {
        "pmid": "40767199",
        "title": "Impact of China's National Volume-Based Drug Procurement: A Multilevel Interrupted Time Series Analysis on Medical Expenditures in Hypertensive Patients.",
        "abstract": "National VolumeBased Procurement NVBP implemented China 2019 aim reduce patients economic burden lowering drug price promoting use NVBP drug public hospitals evaluated impact NVBP medical expenditure among hypertensive patients analyzing overall impact variation policy effect across individual hospitals Using medical record 117 million hypertensive patient across 82 hospital Tianjin 20172021 conducted interrupted time series analysis assess expenditure change among hypertensive patient treatment hypertension dyslipidaemia type 2 diabetes chronic ischemic heart disease IHD Multilevel model employed estimate overall impact hospitalspecific variation policy effects NVBP implementation significantly reduced pervisit outpatient expenditure among hypertensive patient treatment hypertension 1561 dyslipidaemia 2577 diabetes 1759 lowering drug expenditures Although drug expenditure chronic IHD decreased nondrug expenditure increased leading significant change total expenditure chronic IHD 897 inpatient expenditures significant change total peradmission expenditure observed chronic IHD diabetes hospitalizations Drug expenditure diabetes decreased significantly diagnostic expenditure increased significant change found chronic IHD drug expenditures individual hospital level significant variation policy effect observed Despite overall decrease outpatient expenditure treatment hypertension dyslipidaemia diabetes 456 672 463 hospitals respectively showed significant decreases remainder exhibited either nonsignificant change increases NVBP effectively reduced outpatient expenditure among hypertensive patient treatment hypertension dyslipidaemia diabetes suggesting potential alleviate patients economic burdens However increase nondrug expenditure substantial variation policy effect across hospital highlight room improvement policy implementation overall effectiveness",
        "mesh_terms": [
            "Humans",
            "Hypertension",
            "China",
            "Health Expenditures",
            "Interrupted Time Series Analysis",
            "Female",
            "Male",
            "Middle Aged",
            "Antihypertensive Agents",
            "Dyslipidemias",
            "Drug Costs",
            "Aged",
            "Diabetes Mellitus, Type 2",
            "Myocardial Ischemia",
            "Hospitals, Public"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40767199/"
    },
    {
        "pmid": "40765838",
        "title": "Legal challenges to the 340B drug pricing program: administration, regulation, and reform.",
        "abstract": "340B Drug Pricing Program 340B Program created help safety net hospital clinic stretch scarce federal resources discounting price outpatient drug purchases spread discounted price sale price drug retained hospital clinics subsidizing operational cost funding service would otherwise possible provide 340B Program grown dramatically since inception eliciting significant criticism call reform Many legal challenge 340B Program agency tasked administering programthe Health Resources Services Administration HRSAhave brought highlighting limitation HRSAs powers Specifically HRSAs lack broad regulatory authority hampered ability oversee reform 340B Program article analyzes litigation challenging 340B Programincluding case regarding orphan drug exclusion definition 340B patient use contract pharmaciesand explores scope HRSAs authority regulate 340B Program so article emphasizes need reform ensure 340B Program operates consistent congressional purpose patient maintain access safety net care across country",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40765838/"
    },
    {
        "pmid": "40761422",
        "title": "Revision of medicine prices and sales price evolution in Moroccan pharmacies.",
        "abstract": "Morocco adopted new medicine pricing policy 2013 introduced price revision following implementation Decree No 213852 study aim describe evolution medicine price decrease Moroccan pharmacy following price revision published Ministry Health part retrospective descriptive study price revision list five year 20142019 crossed database sale medicine sold pharmacies price decrease affected 1704 medicines 54 originator drugs therapeutic class involved 227 antiinfective 185 cardiovascular system Medicines public selling price 5 10 US dollar 254 affected drop even concerned price ranges 228 medicine decreased less equal 01 US dollar 287 recorded decrease less equal 1 public selling price Five medicine 03 reduced 70 732 maximum drop percentage following implementation Decree no 213852 series medicine price revision adopted price range therapeutic class affected price decrease several variations However complementary policy still needed improve access medicines",
        "mesh_terms": [
            "Morocco",
            "Humans",
            "Retrospective Studies",
            "Commerce",
            "Pharmacies",
            "Drug Costs",
            "Pharmaceutical Preparations"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40761422/"
    },
    {
        "pmid": "40760754",
        "title": "Navigating Regulatory Complexities in Biosimilar Approvals and Imports for Autoimmune Disorder Management: A Comparative Analysis of FDA (US), EMA (EU), and CDSCO (India) Guidelines.",
        "abstract": "Biosimilars offer costeffective alternative autoimmune disorder treatment However Indias stringent regulatory barriers including mandatory local trials unclear interchangeability guidelines strict pricing controls hinder market access study conduct comparative analysis FDA US EMA EU CDSCO India regulatory frameworks highlighting key difference approval pathways postmarketing surveillance import regulations Unlike previous studies paper employ structured SWOT analysis assess impact Indias regulatory landscape biosimilar accessibility finding reveal Indias local clinical trial mandate complex approval process hinder biosimilar adoption despite prior FDA EMA approvals Additionally absence interchangeability guideline discourages physician confidence stringent pricing policy Drug Price Control Order DPCO reduce manufacturer incentives improve biosimilar market penetration India must streamline regulatory approvals harmonize clinical trial requirement international standards establish clear interchangeability guidelines reform essential enhance affordability accessibility biosimilars management autoimmune disorders",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40760754/"
    },
    {
        "pmid": "40760733",
        "title": "Self-Reported Cannabis Prices and Expenditures From Legal and Illegal Sources Five Years After Legalisation of Non-Medical Cannabis in Canada.",
        "abstract": "price cannabis important implication many outcome discussed legalisation debates paper report legal illegal price different cannabis products National survey conducted 2022 2023 among Canadians aged 1665 year part International Cannabis Policy Study Selfreported price purchase quantity legal versus illegal source thelast cannabis purchased examined 2686 respondent used cannabis past 12 month nine cannabis product types average consumer report 78 cannabis came legal source past year Differences selfreported price paid legal illegal purchase varied product type Price per unit higher legal source dried flower 238 p  0001 vapes 187 p  0006 hash 384 p  0001 lower capsule 284 p  0008 statistically significant difference found drop 33 p  076 edible 39 p  049 cannabis drink 88 p  021 concentrate 138 p  015 tincture 170 p  028 Substantial quantity discount dried flower observed legal illegal sources Differences legal illegal cannabis price narrowed considerably likely due decline price cannabis legal store since opening legal market Canada difference expected across two market considering difference standard quantity purchased presence quantity discount markets Analyses omitting purchase quantity may overestimate price differential legal illegal sources",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40760733/"
    },
    {
        "pmid": "40754325",
        "title": "Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings.",
        "abstract": "SARSCoV2 endemic expected remain health threat new variant continuing emerge potential vaccine become less effective effective vaccine natural immunity significantly reduced hospitalisation need critical care outpatient treatment option remain limited realworld evidence clinical costeffectiveness lacking paper present design Canadian Adaptive Platform Trial Treatments COVID Community Settings CanTreatCOVID evaluating multiple treatment option pragmatic adaptive platform trial study generate highquality generalisable evidence inform clinical guideline healthcare decisionmaking CanTreatCOVID openlabel individually randomised multicentre national adaptive platform trial designed evaluate clinical costeffectiveness therapeutic nonhospitalised SARSCoV2 patient across Canada Eligible participant must present symptomatic SARSCoV2 infection confirmed PCR rapid antigen testing RAT within 5 day symptom onset trial target two group expected higher risk severe disease 1 individual aged 50 year older 2 aged 1849 year one comorbidities CanTreatCOVID us numerous approach recruit participant study including multifaceted public communication strategy outreach primary care outpatient clinic emergency departments Participants randomised receive either usual care including supportive symptombased management investigational therapeutic selected Canadian COVID19 Outpatient Therapeutics Committee first therapeutic arm evaluates nirmatrelvirritonavir Paxlovid administered two time per day 5 days second therapeutic arm investigates combination antioxidant therapy selenium 300 µg zinc 40 mg lycopene 45 mg vitamin C 15 g administered 10 days primary outcome allcause hospitalisation death within 28 day randomisation CanTreatCOVID master protocol subprotocols approved Health Canada local research ethic board participating province across Canada result study disseminated policymakers presented conference published peerreviewed journal ensure finding accessible broader scientific medical communities study approved Unity Health Toronto Research Ethics Board 22179 Clinical Trials Ontario Project ID 4133 NCT05614349",
        "mesh_terms": [
            "Humans",
            "COVID-19",
            "Canada",
            "SARS-CoV-2",
            "Cost-Benefit Analysis",
            "COVID-19 Drug Treatment",
            "Randomized Controlled Trials as Topic",
            "Adult",
            "Multicenter Studies as Topic",
            "Middle Aged",
            "Male",
            "Antiviral Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40754325/"
    },
    {
        "pmid": "40753662",
        "title": "Impact of the 2012 pharmaceutical co-payment reform on drug consumption among children in Catalonia: Evidence from a regression discontinuity design.",
        "abstract": "Poor childhood health negatively affect health socioeconomic status later life One crucial policy tool modification copayment conditions cause parent experience rigid budget constraint cause reduction number prescription drug given children study estimate price sensitivity prescription drug demand using data prescription drug purchase nonadult population Catalonia 2010 2015 use sharp regression discontinuity design RDD bandwidth exploiting 2012 reform Catalonia Spain result indicate overall reduction defined daily dose DDD consumption three year postreform child parent experienced increase copayment level 81  10  increase contrast whose parent experience reduction copayment rate 70 percentage point increase number prescription used corroborated finding considering drug stockpiling Interestingly prescription related female showed higher reduction males Disentangling drug consumption type condition show drug purchase related respiratory health condition experienced smaller reduction and specifically one associated asthma compared mental health disease AttentionDeficitHyperactivity Disorder evidence significant change overall drug consumption young people Spain following reform copayments",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40753662/"
    },
    {
        "pmid": "40753376",
        "title": "Cost trends of potentially inappropriate medications among older adults between 2012 and 2021 in Quebec, Canada: a population-based repeated cross-sectional study.",
        "abstract": "Potentially inappropriate medication PIMs frequent older adults contributing hospitalizations adverse events healthcare burden aimed estimate direct PIM cost trend 2012 2021 among older woman men Quebec Canada Using medicoadministrative data assessed direct cost paid public insurer medication cost professional fee excluding outofpocket payment individuals PIMs claimed adult ≥65 year covered public drug plan Costs 16 PIM classes identified using 2015 2019 Beers criteria calculated stratified sex age group 6574 7584 ≥85 fiscal year assessed proportion PIMs among medication expenditures computed average costsenrollee usage prevalence costliest PIM classes Trends estimated using univariate linear regression 95 confidence intervals found nonstatistically significant decrease total PIM claim costs 206 million 2012 186 million 2021 trend 29174 116 representing 54 medication expenditure adult ≥65 2021 reduction total cost accentuated women whose annual cost higher men age groups Average costenrollee decreased 179 119 trend 719 5 drop 216 142 woman 132 92 men Costsenrollee higher 7584 ≥85 age groups Costliest PIM class included protonpump inhibitors benzodiazepines antipsychotics antidepressants estrogen women hypoglycemic agent men Cost trend always follow prevalence trend PIM classes PIM cost among older adult slightly decreased 2012 2021 Appropriate prescribing deprescribing appear crucial reducing costs research focus estimating societal impact costeffectiveness analysis deprescribing initiative regulatory measures",
        "mesh_terms": [
            "Humans",
            "Aged",
            "Female",
            "Male",
            "Cross-Sectional Studies",
            "Quebec",
            "Aged, 80 and over",
            "Potentially Inappropriate Medication List",
            "Inappropriate Prescribing",
            "Drug Costs",
            "Health Expenditures",
            "Population Surveillance"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40753376/"
    },
    {
        "pmid": "40749000",
        "title": "Medical costs for patients with rheumatoid arthritis who have comorbid diabetes mellitus.",
        "abstract": "evaluate medical cost resource use patient rheumatoid arthritis RA without diabetes mellitus DM Data obtained Japan Medical Data Center JMDC claim database baseline period comprised 6 month index date first prescription date postRA diagnosis 12month duration postindex date followup period Patients RA DM prescribed antidiabetic drug baseline period constituted DM group patient RA without DM antidiabetic prescription baseline followup period belonged nonDM group Patients matched sex age Charlson Comorbidity Index CCI month first RA codes medications primary endpoint total medical cost per patient followup period secondary endpoint cost drugs treatments materials subcategories proportion patient using subcategories One hundred sixtyone DM group patient 2974 nonDM group patient eligible inclusion 109 patient matched group median value age CCI 59 year 20 groups excluding DMspecific costs total medical cost drug cost significantly higher DM group compared nonDM group total medical costs DM nonDM 5163 USD 3782 USD P  005 drug costs DM nonDM 2242 USD 1066 USD P  005 higher proportion biological diseasemodifying antirheumatic drug DMARD user DM group DM nonDM 147 55 Treatment cost material cost differ two groups Medical cost RA higher DM group nonDM group higher proportion biological DMARD users",
        "mesh_terms": [
            "Humans",
            "Arthritis, Rheumatoid",
            "Female",
            "Male",
            "Middle Aged",
            "Aged",
            "Health Care Costs",
            "Comorbidity",
            "Diabetes Mellitus",
            "Japan",
            "Hypoglycemic Agents",
            "Adult",
            "Antirheumatic Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40749000/"
    },
    {
        "pmid": "40744435",
        "title": "Estimates of first-year OTC naloxone sales in four U.S. states with high rates of opioid overdose deaths: KY, MA, NY, OH.",
        "abstract": "March 2023 US Food Drug Administration approved naloxone nasal spray overthecounter OTC sale creating directtoconsumer path increase access utilized weekly NielsenIQ NIQ retail sale data OTC naloxone local area within Kentucky KY Massachusetts MA New York NY Ohio OH week ending 992023 week ending 4272024 sale occurring physical store eg grocery pharmacy analyzed percentage store selling average price per kit sales assessed pattern local sale Social Deprivation Index accounting poverty housing transit education employment brand Narcan made approximately 99  recorded OTC naloxone sale September 2023 April 2024 Weekly sale OTC naloxone KY MA NY OH spiked initially September October 2023 stabilized April 2024 average price per OTC naloxone kit 45 across state brand 50  86  NIQ participating store state sold OTC naloxone large proportion local area three state demonstrated high social deprivation low OTC naloxone sales OTC naloxone increase access though price may deter people low income evidenced finding lower sale among area high social deprivation emphasizing importance naloxone access laws opioid education naloxone distribution programs Medicaid coverage OTC naloxone creates new channel market penetration satisfying previously untapped demand support naloxone saturation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40744435/"
    },
    {
        "pmid": "40741379",
        "title": "Copay Accumulators: A Legislative Issue in Dermatology.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40741379/"
    },
    {
        "pmid": "40740994",
        "title": "Pakistan's first medicine price deregulation policy: assessing its impact on prices, affordability, and availability of oral anti-diabetic medicines in private pharmacies.",
        "abstract": "Pakistans highest diabetes prevalence necessitates equitable access antidiabetic medicines study evaluated access Oral antidiabetic OADs effect Pakistans recently launched price deregulation policyapplicable medicine included National Essential Medicines List nonNEMLon price affordability comparing NEML nonNEML OADs WHOHAI methodologybased survey 30 private pharmacy across six region gathered price availability data 30 OADs including Lowest Price Generic LPG Highest Price Generic HPG originator brand OB selected OADs consisted 11 product NEML 19 nonNEML products comprising 17 singleactive ingredient 13 multiactive ingredient formulations Published surveyed retail price OADs in Pakistani Rupees PKR deregulation compared policys effect determined differenceindifferences DiD analysis Affordability lowestpaid employee medicine availability percentage calculated analysis revealed unit price OADs significantly increased PKR 1508 OB PKR 589 HPG PKR 281 LPG ipi  005 within 6 month policys introduction Medicines listed NEML remained consistently cheaper nonNEML difference 3020 OBs 983 HPGs 751 LPGs PKR ipi  0001 per interaction term NEML enlistment status × deregulation greater increase price nonNEML OBs observed compared NEML counterpart PKR 1085 ipi ≈ 005 difference observed LPGs PKR 077 ipi  073 HPGs PKR 020 ipi  095 insignificant Prices single multiactive ingredient formulation also increased significantly ipi  005 Although OADs fair availability 47 97 deregulation seven 30 OADs remained unaffordable time points overall affordability declined significantly postderegulation ipi  005 study revealed significant price escalation OADs particularly enlisted NEML highlighting access challenge diabetic patient necessitating targeted policy reform address key marketrelated factor ensure equitable access OADs",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40740994/"
    },
    {
        "pmid": "40740949",
        "title": "Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023.",
        "abstract": "Obesity pose significant public health economic challenge United States US rising prevalence particularly among individual enrolled Medicaidthe nations public health insurance program lowincome populations Antiobesity medication AOMs become integral managing obesity trend utilization spending within Medicaid remain underexplored examine Medicaids utilization reimbursement price trend AOMs 1999 2023 retrospective analysis assessing utilization reimbursement pricing older newer AOMs Yearly prescription number reimbursement calculated seven AOMs billed Medicaid 1999 2023 average expenditure per prescription used indicator drug pricing AOM prescription rose 13855 1999 938663 2023 6674 increase Spending surged 77805466 due introduction newer effective medications including Wegovy tirzepatide largest share market growth 2023 driven medications significant increase AOM utilization spending highlight growing burden obesity Medicaid emphasizing need policy measure manage rising cost ensure equitable access treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40740949/"
    },
    {
        "pmid": "40739691",
        "title": "The Economics of Drug Development: A Comparison Between Orphan and Non-Orphan Drugs.",
        "abstract": "Drug development cost orphan nonorphan drug range greatly variation market size legal constraints financial incentives order overcome tiny patient population high perpatient costs orphan drug target rare disease frequently need customized techniques Since nonorphan drug intended larger populations require thorough clinical trial fierce rivalry market Clinical trial data orphan nonorphan drug authorized 2010 2020 compared term cost study Trial duration overall development expenditures perpatient cost important criteria estimate cost components secondary data source industry report regulatory filing consulted Significant cost driver variation found using statistical analysis study show orphan pharmaceutical generally lower overall clinical development costs cost per patient much higher nonorphan drugs Financial incentive including tax credit accelerated regulatory process helped orphan drug trial save money overall However nonorphan drug required extensive safety efficacy evaluation larger Phase III trials cost higher study emphasizes orphan nonorphan drug different clinical cost structure economic tradeoffs necessity sustainable financing option highlighted high cost per patient even regulatory incentive successfully lower barrier orphan drug research economic impact drug research cost various stakeholders including drug companies physicians lawmakers enables make sound choice regarding resource allocation investment drug development Policymakers industry stakeholder use data help create fair effective framework drug development",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40739691/"
    },
    {
        "pmid": "40739256",
        "title": "Economic evaluation of a robotic chemotherapy compounding system and its service expansion to network hospital in Thailand.",
        "abstract": "Robotic system chemotherapy preparation offer improved accuracy staff safety require substantial capital investment study assessed economic performance domestically developed robotic chemotherapy compounding system Udon Thani Cancer Hospital service expansion network hospital Thailand descriptive study economic evaluation conducted including costbenefit analysis unit cost analysis breakeven analysis provider health system perspectives Data fiscal year 2023 used Direct indirect cost assessed clinical outcome documented scenariobased sensitivity analysis performed examine cost variation different capacity utilisation levels Robotic preparation higher perdose cost THB 538 4173 doses manual preparation THB 250 20310 doses associated total estimated economic benefit THB 188 million including labour training saving improved pharmaceutical care breakeven point estimated 41802 dos robotic compounding 5122 dos service expansion incremental benefitcost ratio IBCR 1566 increased 3018 including delivery network hospital robotic system demonstrated potential economic operational advantages particularly scaled serve additional facilities finding offer preliminary evidence inform future policy consideration Thailands Cancer Service Plan evaluation needed assess longterm sustainability broader systemlevel outcomes",
        "mesh_terms": [
            "Thailand",
            "Humans",
            "Cost-Benefit Analysis",
            "Robotics",
            "Drug Compounding",
            "Antineoplastic Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40739256/"
    },
    {
        "pmid": "40735811",
        "title": "'Industry still has too loud a voice': expert views on government policy consultations about gambling marketing.",
        "abstract": "Marketing part suite tactic used gambling industry ally promote normalize gambling increased public call restriction gambling marketing government developed comprehensive policy response counter public health threat Consultation process widely seen important part public decisionmaking policy formation However limited focus process gambling policy development Using online qualitative survey study gathered opinion 33 expert Australia UK USA including local governments academia profits lived experience organizations consultation process related gambling marketing policy current process could improved reflexive approach thematic analysis used construct three theme data First participant perceived current consultation process inconsistent public health value approach limited meaningful opportunity community actor shape strengthen policy response gambling marketing Second participant stated consultation practice prioritized industry view concerns industry actor and allies disproportionate access policymakers decisionmakers Finally participant commented mechanism ensure policy development related gambling marketing protected vested interests paper provides new information factor influence policy decision gambling marketing Mechanisms protect policy vested interest essential developing comprehensive public health response gambling marketing",
        "mesh_terms": [
            "Gambling",
            "Humans",
            "Marketing",
            "Australia",
            "Policy Making",
            "Public Policy",
            "United States",
            "United Kingdom",
            "Qualitative Research",
            "Public Health",
            "Health Policy",
            "Surveys and Questionnaires",
            "Decision Making"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40735811/"
    },
    {
        "pmid": "40732312",
        "title": "Bridging the Regulatory Divide: A Dual-Pathway Framework Using SRA Approvals and AI Evaluation to Ensure Drug Quality in Developing Countries.",
        "abstract": "bBackgroundb Developing country face significant challenge accessing highquality pharmaceutical product due resource constraints limited regulatory capacity market dynamic often prioritize cost quality review address critical gap regulatory framework fail ensure pharmaceutical quality equity developed developing nations bObjectiveb comprehensive review examines novel dualpathway regulatory framework leverage stringent regulatory authority SRA approvals artificial intelligencebased evaluation systems harmonized pricing mechanism ensure pharmaceutical quality equity across global markets bMethodsb comprehensive systematic analysis current regulatory challenges proposed solutions implementation strategy conducted extensive literature review 202 sources 20192025 expert consultation regulatory science AI implementation healthcare pharmaceutical policy development methodology included analysis regulatory precedents economic impact assessment feasibility evaluation based existing technological implementations bResultsb proposed framework address key regulatory capacity gap two complementary pathways Pathway 1 enables samebatch distribution SRAapproved product pricing parity mechanisms time Pathway 2 provides independent evaluation using AIenhanced system differentiated products Key component include indigenous AI development requires systematic implementation 46 year across three distinct stages outsourced auditing framework reduce cost 4050 qualityfirst principle categorically reject costbased quality compromises Implementation analysis demonstrates potential achieving 9095 quality standardization accompanied 200300 increase regulatory evaluation capability bConclusionsb framework potential significantly improve pharmaceutical quality access developing country maintaining rigorous safety efficacy standard innovative regulatory approaches evidence demonstrates substantial public health benefit projected improvement population access 8595 coverage treatment success rate 9095 efficacy economic benefit USD 1530 billion system efficiencies providing compelling case implementation aligns global scientific consensus Sustainable Development Goal 38",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40732312/"
    },
    {
        "pmid": "40730420",
        "title": "Financial protection and universal health coverage in Georgia: an analysis of impoverishing healthcare costs using household income and expenditure surveys .",
        "abstract": "Financial protection important objective universal health coverage ensures individual access necessary healthcare without financial hardship typically assessed two indicators catastrophic outofpocket OOP health spending impoverishing health spending Despite introduction Georgias Universal Health Coverage Programme UHCP 2013 cover nearly 90 population incidence impoverishing catastrophic health spending remains high compared European country changed much past decade study aim identify factor associated impoverishing health expenditure among Georgian household inform financing policy decision prevent individual driven deeper poverty due healthcare costs used data Georgian Household Income Expenditure Surveys spanning 20092023 n198 292 households surveyweighted logistic regression accounted complex design element stratification clustering unequal selection probabilities outcome variable impoverishing health spending defined using relative poverty line Andersens behavioural model healthcare utilisation guided explanatory variable selection OOP spending drug strongest determinant impoverishment OR 433 95 CI 393 477 p0001 poorest quintile especially burdened OR 445 95 CI 221 897 p0001 second quintile also elevated risk odds impoverishment declined 2009 2013when benefit targeted poorbut rose slightly afterwards 2014 2023 average probability impoverishment around 034 compared 028 2013 finding suggest targeted benefit UHCP may offered stronger protection broader less targeted approach post2013 Enhanced coverage outpatient drug costsespecially poorestthrough increased public investment progressive benefit expansion could improve financial protection",
        "mesh_terms": [
            "Humans",
            "Health Expenditures",
            "Universal Health Insurance",
            "Georgia (Republic)",
            "Poverty",
            "Female",
            "Male",
            "Adult",
            "Income",
            "Middle Aged",
            "Financing, Personal",
            "Family Characteristics",
            "Surveys and Questionnaires"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40730420/"
    },
    {
        "pmid": "40729790",
        "title": "Pregabalin and gabapentin use in France from 2012 to 2023, impact of prescription restrictions, a time series analysis.",
        "abstract": "Gabapentinoids use accompanied increased misuse particularly pregabalin May 2021 France introduced secure prescription requirement pregabalin paper aim analyse variation gabapentinoid dispensing focus change prescription rules performed ecological study using French national health insurance database January 2012 December 2023 analysed pregabalin gabapentin dos sold city pharmacy expressed monthly defined daily dose per thousand inhabitant day DDDTID January 2012 December 2023 Dose sale trend May 2021 compared using segmented analysis Autoregressive Integrated Moving Average models Descriptive analysis performed analyse associated expense expressed euros 2012 2020 pregabalin dos sold rose 3228 DDDTID 4908 DDDTID reform declined 3923 DDDTID 2023 Gabapentin dos sold increased 1042 DDDTID 1257 DDDTID 2012 2020 rose postreform reaching 1705 DDDTID Costs related pregabalin dos sold decreased €13247 €5136 million 2012 2023 Costs related gabapentin decrease €3231 €2684 million 2012 2021 increase €3770 million 2023 data suggest May 2021 reform reduced pregabalin consumption induced increase gabapentin use Cost implication remain difficult interpretation due multiple confounding factors research could clarify trend used optimize prescription practices",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40729790/"
    },
    {
        "pmid": "40721270",
        "title": "Effect of universal no-cost coverage on use of long-acting reversible contraception and all prescription contraception: population based, controlled, interrupted time series analysis.",
        "abstract": "estimate effect policy introducing universal nocost public coverage prescription contraception use British Columbia Canada Population based controlled interrupted time series analysis 10 Canadian provinces Prescription medication dispensed reproductive aged 1549 years female resident British Columbia Canada compared synthetic control derived nine Canadian province population based cohort 859 845 female individual British Columbia age 1549 years 1 April 2021 30 June 2024 Introduction universal contraception coverage policy April 2023 public insurer pay 100 prescription costs Number monthly dispensation longacting reversible contraception LARC number monthly dispensation form prescription contraception including LARC percentage reproductive aged female resident using LARC using form prescription contraception proportion people using prescription contraception use LARC LARC market share Segmented regression model used estimate policy effect comparing expected outcome value 15 month policy ie counterfactual derived trend policy change control observed values 95 confidence interval CIs estimated using bootstrapping April 2021 3249 95 CI 3066 3391 LARC prescription dispensed British Columbia declining slope trend 17 30 7 fewer dispensed per month policy Monthly LARC dispensation increased 1050 942 1487 immediately British Columbias policy change saw steady increasing trend policy introduction additional 1273 963 1698 monthly LARC prescription dispensed 15 month policy implementation compared expected volume representing estimated 149fold 134 177 increase Dispensations prescription contraception including LARC increased 1981 356 3324 per month representing 104fold 101 107 increase Among 859 845 female resident aged 1549 year population 91 using LARC April 2021 15 month policy 11 375 10 273 13 013 individual using LARC expected without policy representing additional 13 12 15 population policy led additional 17 15 23 population using prescription contraception 15 month policy LARC market share 19 12 23 higher expected Universal nocost public coverage British Columbia increased prescription contraception use overall driven increased LARC use such cost seems important contributor contraception use method selection population level",
        "mesh_terms": [
            "Humans",
            "Female",
            "Adult",
            "Interrupted Time Series Analysis",
            "Adolescent",
            "Long-Acting Reversible Contraception",
            "British Columbia",
            "Young Adult",
            "Middle Aged",
            "Contraception",
            "Universal Health Insurance"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40721270/"
    },
    {
        "pmid": "40716340",
        "title": "Moralisation, stigmatisation, and downstream interventions: How symbolic violence sustains geographic inequalities in deaths of despair in England.",
        "abstract": "paper examines symbolic violence contributes persistence geographic inequality death despair DoD drug suicide alcoholspecific mortality two deindustrialised town North East England Although evidence DoD driven structural determinants economic policies inadequate social safety nets poverty less known determinant ideologically obscured Drawing qualitative data collected 30 resident Middlesbrough South Tyneside two town average rate DoD analysis explores symbolic violence form moralisation stigma downstream interventions frame behaviour individual failings downplays structural determinants sustains inaction maintaining appearance intervention diverting attention away root cause DoD symbolic violence function mechanism inequality reproduced highlighting cultural ideological process allow structural determinant go unaddressed study deepens understanding inequality death sustained legitimised marginalised places finding point need future intervention improve material condition also critically engage symbolic force reinforce geographic disparity DoD",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40716340/"
    },
    {
        "pmid": "40716165",
        "title": "The associations between prices and taxes and the use of tobacco products in Latin America and the Caribbean: a systematic review and meta-analysis.",
        "abstract": "Although tax raise retail tobacco price industryinitiated price increase shown decrease tobacco consumption scarcity study Latin America Caribbean using household individuallevel data existing review limit policy relevance conduct systematic review metaanalysis assess association price tax use tobacco product Latin America Caribbean searched six electronic bibliographic databases two online search engines two working paper repositories handsearched seven journals included quantitative study used measure individual household tobacco use outcome written English Portuguese Spanish used randomeffects metaanalyses pool result across studies found consistent evidence Latin American countries higher cigarette price associated lower cigarette smoking participation consumption initiation effect size large enough policy meaningful Pooled ownprice elasticity indicate higher price associated less proportional decrease tobacco use pooled ownprice elasticities participation 014 95 CI 022 006 consumption 054 95 CI 075 034 total 075 95 CI 114 036 found consistent evidence socioeconomic status age sex rurality geographic region affected price responsiveness review confirms tax raise tobacco price effectively lower tobacco use Moreover raising tobacco price increased tax anticipated boost tax revenue due inelastic nature demand tobacco",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40716165/"
    },
    {
        "pmid": "40720104",
        "title": "Reducing Drug Prices-The Most Favored Nation Policy vs Price Negotiation.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40720104/"
    },
    {
        "pmid": "40720101",
        "title": "The Role of Combination Drugs in the Medicare Drug Price Negotiation Program.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40720101/"
    },
    {
        "pmid": "40717766",
        "title": "What drug characteristics explain the wide range of manufacturer rebates?",
        "abstract": "Prescription drug list prices often cited policy discussions account rebate negotiated manufacturer payers study examines factor influencing rebate United States focusing specialty drugsie high priced therapy often biologics payer issue specific coverage policies Rebate data came SSR Health drug attribute Tufts Medical Center Specialty Drug Evidence Coverage Database stratified rebate data drug type characteristics identified 161 drug found SSR Health SPEC December 2023 found rebate vary substantially across drug median 27 IQR 1653 Biosimilar originator drug highest variable rebate median 71 IQR 5379 rebate cancer treatment orphan drug lower medians 19 23 respectively vary less IQR 1228 1429 respectively Drugs face competition alternative option within therapeutic class selfadministered received Food Drug Administration approval past higher rebates finding indicate rebate sizeable vary along several dimensions many relating market competition complicating policy discussion around drug pricing",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40717766/"
    },
    {
        "pmid": "40717765",
        "title": "Research and development investments for biologics independently developed by US biotechnology startups, 2017-2023.",
        "abstract": "Despite policy interest pharmaceutical innovation little known investment needed venture capitalbacked startup develop innovative biologics growing segment pharmaceutical marketplace crosssectional analysis Food Drug Administration FDA drug approval data investment deal records clinical trial data estimated investment needed biotechnology startup company independently develop biologic approved US FDA priority review indicator innovation isolate homogenous set cases sample focused independent drug development 13 drug 9 biotechnology startup company retained ownership drug start development FDA approval without acquired licensing product found median investment per FDAapproved biologic 3041 million IQR 28997903 million uncapitalized costs accounting cost failures estimate represents direct drug RD investment needed independent development innovative biologic product biotechnology startup companies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40717765/"
    },
    {
        "pmid": "40713845",
        "title": "Efficiency in health care: connecting economic evaluations with implementation objectives.",
        "abstract": "Economic evaluation helpful efficient resource use paper aim clarify relationship economic evaluation method two type health care efficiency aiding implementation scientist selecting appropriate approach research clarify connection costeffectiveness analysis CEA allocative efficiency explain budget impact analysis BIA closely connects productive efficiency also discus method researcher use analyze organizations productive efficiency given increasing pressure health care organization efficient Allocative efficiency seek maximize social welfare optimal resource distribution Productive efficiency focus organizations ability maximize output given resource constraints CEA particularly incorporating societal perspective assesses allocative efficiency BIA often short time horizon focused perspective assesses productive efficiency organizational leader ask implementation scientist economic evaluation important determine whether want CEA BIA given answer different questions often employing different methods also present method measuring efficiency cause inefficiency stemming fixed costs scale scope regulations labor decisionmaking Implementation scientist must recognize CEA BIA serve distinct purpose interchangeable Choosing right economic evaluation tool crucial answering specific research question building research teams Future implementation work also need measure efficiency sustainable",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40713845/"
    },
    {
        "pmid": "40712615",
        "title": "Clinical impact and cost-effectiveness of the WHO-recommended advanced HIV disease package of care.",
        "abstract": "subSaharan Africa 2040 people living HIV present advanced HIV disease AHD diagnosed treated prevented using package care recommended WHO aimed project costeffectiveness budget impact WHOrecommended AHD package Malawi Using CostEffectiveness Preventing AIDS ComplicationsInternational model simulated cohort nonhospitalised people living HIV aged 19 years initiating antiretroviral therapy ART 25 AHD CD4 count 200 cell per μL andor stage 3 4 disease assessed 13 increasingly comprehensive strategies ranging ART WHOrecommended AHD package including tuberculosis diagnostics ie sputum Xpert urine lipoarabinomannan tuberculosis preventive therapy serum cryptococcal antigen CrAg screening preemptive fluconazole treatment CrAgpositive cotrimoxazole prevent bacterial infections Model outcome included 1 year survival life expectancy costs incremental costeffectiveness ratio ICERs US per qualityadjusted lifeyear QALY considered strategy costeffective ICER less 600 per QALY based 2023 Malawi per caput gross domestic product ART resulted life expectancy 17·45 undiscounted QALYs discounted lifetime cost 1450 strategy would increase QALYs costs WHOrecommended AHD package would result greatest life expectancy 19·30 undiscounted QALYs costeffective ICER 580 per QALY AHD prevalence intervention efficacy greatest influence ICERs however WHOrecommended AHD package would remain costeffective wide range estimates WHOrecommended AHD package care ART initiation would provide substantial clinical benefit costeffective Malawi package AHD made widely available Malawi similar settings WHO HIV Modelling Consortium within Institute Global Health University College London Bill  Melinda Gates Foundation National Institute Allergy Infectious Diseases Massachusetts General Hospital Jerome Celia Reich Endowed Scholar HIVAIDS Research Award Steve Deborah Gorlin Massachusetts General Hospital Research Scholars Award Chichewa translation abstract see Supplementary Materials section",
        "mesh_terms": [
            "Humans",
            "Cost-Benefit Analysis",
            "HIV Infections",
            "Malawi",
            "World Health Organization",
            "Male",
            "Adult",
            "Female",
            "Quality-Adjusted Life Years",
            "Tuberculosis",
            "Anti-HIV Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40712615/"
    },
    {
        "pmid": "40709376",
        "title": "Economic evaluation of oral Nirmatrelvir/ritonavir versus best supportive care in patients at high risk for progression to severe COVID-19 in Germany: a cost-effectiveness analysis.",
        "abstract": "estimate costeffectiveness Nirmatrelvirritonavir NMVr versus best supportive care BSC patient highrisk progression severe COVID19 German health payer perspective closed cohort static model 1000 COVID19 patient capturing shortterm 1 year iviai decisiontree longterm lifetime outcome iviai Markov model used assess costeffectiveness NMVr versus BSC Model input derived EPICHR clinical trial published contemporary realworld data Probabilistic deterministic sensitivity analysis PSA DSA conducted test robustness model results base case treatment NMVr versus BSC reduced COVID19 related hospitalisation 0042 intensive care unit admission 0006 inpatient death 0003 increasing lifeyears LY 0047 per patient result incremental costeffectiveness ratio 10845 € per hospitalisation avoided 9773 € per LY gained Sensitivity analysis suggests magnitude benefit increased increasing hospitalisation risk NMVr emerged dominant strategy population hospitalisation risk equivalent 60 year older Outcomes similar real world effectiveness data DSA showed model sensitive hospitalisation inpatient mortality risk NMVr medication cost efficacyeffectiveness NMVr reducing hospitalisation PSA confirmed robustness model results COVID19 dynamic disease caution taken generalizing results Contemporary data essential ensure model input outcome remain relevant may change natural disease course effectiveness NMVr costeffectiveness analysis NMVr treatment German healthcare payer perspective demonstrates preventing progression severe COVID19 NMVr reduces healthcare resource use associated cost preserve LY patients analysis provides crucial economic rationale decision making policy makers",
        "mesh_terms": [
            "Germany",
            "Humans",
            "Male",
            "Female",
            "Middle Aged",
            "Aged",
            "Cost-Effectiveness Analysis",
            "Antiviral Agents",
            "COVID-19",
            "COVID-19 Drug Treatment",
            "Decision Trees",
            "Markov Chains",
            "Hospitalization",
            "Disease Progression",
            "Risk Factors",
            "Clinical Trials as Topic",
            "Sensitivity and Specificity",
            "Intensive Care Units",
            "SARS-CoV-2",
            "Quality-Adjusted Life Years",
            "Cost-Benefit Analysis",
            "Palliative Care",
            "Lactams",
            "Ritonavir",
            "Drug Combinations",
            "Nitriles",
            "Proline",
            "Leucine"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40709376/"
    },
    {
        "pmid": "40709284",
        "title": "The cost of misaligned incentives in the pharmaceutical supply chain.",
        "abstract": "Recent concern rising drug price focused role pharmacy benefit manager PBMs multiple player make pharmaceutical supply chain PBMs conductor effectively decide drug covered cost PBM contract tie compensation percentage drugs list price creating financial incentive favor highcost highrebate drug plan formulary expense lowercost generic biosimilars Furthermore PBM industry highly concentrated vertically integrated countrys largest health insurers making even harder assess PBM performance profitability simple analysis annual drug spending different reporting level provides important insight money go saving could achieved find simply delinking compensation list price drug throughout supply chain could reduce annual drug spending 95b nearly 15 net spending without adversely affecting manufacturers incentive innovate",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40709284/"
    },
    {
        "pmid": "40708038",
        "title": "Are there differences in efficacy and safety between local and imported direct-acting antiviral agents for hepatitis C in China?",
        "abstract": "Despite price advantages local directacting antiviral agent DAAs hepatitis C hep C widely used China compared imported ones evidence relative efficacy safety whether small market share local DAAs attributable potential differences study systematically evaluated efficacy safety evidence 5 local 6 imported DAAs valid Chinese registration number January 25 2024 Metaanalyses subgroup analysis metaregressions performed synthesize evidence compared outcome using randomeffects empirical Bayes model Nineteen randomized controlled trial 82 singlearm trial SATs included result demonstrated statistically significant difference 12week sustained virological response 097 95 confidence interval CI 095 099 v 096 95 CI 094 098 P  021 relapse 002 95 CI 001 004 v 002 95 CI 001 003 P  065 virological breakthrough 0003 95 CI  0001 002 v 00000002 95 CI  0001 00006 P  051 serious adverse event SAEs 004 95 CI 003 006 v 003 95 CI 002 003 P  012 local imported DAAs controlling ethnicity patient multiple metaregression local DAAs 337 higher rate adverse event AEs 0337 95 CI 0188 0486 P  0001 statistically significant difference found interaction test local imported pangenotypic DAAs regarding rate AEs 072 95 CI 064 079 v 073 95 CI 065 050 P  081 Current evidence demonstrates statistically significant difference efficacy SAEs local imported DAAs Given simplified pangenotypic DAA regimen standard care local pangenotypic DAAs hold potential increase hepatitis C virus treatment rate China critical local DAA developer generate evidence expanded patient population term age treatment experience genotype hepatitis C virus conducting headtohead study directly comparing efficacy safety Clinical policy decisionmaking adaptive evolve new evidence generated",
        "mesh_terms": [
            "Humans",
            "China",
            "Antiviral Agents",
            "Hepatitis C",
            "Hepacivirus",
            "Treatment Outcome",
            "Randomized Controlled Trials as Topic"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40708038/"
    },
    {
        "pmid": "40707087",
        "title": "Enhancing tuberculosis care in Madhya Pradesh through public-private partnerships: An evaluation of the patient provider support agency (PPSA) model.",
        "abstract": "quality care patient receive private sector reported poor Madhya Pradesh began adopting PPSA model September 2020 initially covering 44 districts April 2022 state achieved 100 coverage becoming first state country implement PPSA across 52 districts Although PPSA operational every district health indicator private sector shown little improvement notification private sector remain significantly annual target patient provider support agency PPSA pilot program demonstrated newer strategy private sector engagement able deliver significant outcomes study explores strength limitation private sector engagement model healthcare providers perspective mixedmethods study quantitative qualitative data simultaneously collected Quantitative data collection using routinely collected programmatic data supported qualitative data collection indepth interviews study conducted study impact PPSA service implementation model notification status patient care activity outcome record review among 52 district Madhya Pradesh October 2020December 2022 well explore strength limitation PPSA model healthcare providers perspective using mixedmethods approach increase number TB patient notified private sector 62 number patient receiving benefit Nikshay Poshan Yojna Direct Bank Transfer 91 number patient tested Human Immunodeficiency Virus 100 Diabetes universal drug susceptibility testing 25 well successful treatment outcome postPPSA period compared prePPSA period Seventeen indepth interview health care provider public n  8 private sector n  9 highlighted operational challenge solution implementation PPSA Inadequate Human resource poor coordination NTEP Staff poor mapping PPs mobile based counselling  limited home visit TB patient perceived challenge regular support private health facility MIS data training handholding supportive supervision State strict need based tendering policy suggestion improve PPSA model solutions implementation Patient Provider Support Agency PPSA model Madhya Pradesh improved notification rate successful treatment outcome also strengthened overall engagement private healthcare provider TB management Enhanced collaboration regular facility mapping sustained educational effort led robust approach TB care extends across public private sectors challenge funding inconsistency service delivery fluctuation highlight area improvement overall success PPSA model Madhya Pradesh provides promising framework region aiming enhance TB care publicprivate partnerships Future effort focus addressing identified gap scaling successful practice ensure highquality care TB patients irrespective seek treatment",
        "mesh_terms": [
            "Humans",
            "India",
            "Public-Private Sector Partnerships",
            "Tuberculosis",
            "Health Personnel",
            "Private Sector",
            "Quality of Health Care"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40707087/"
    },
    {
        "pmid": "40705731",
        "title": "Understanding insurance coverage policies for incretin mimetics for weight management.",
        "abstract": "Given wide variation insurance coverage incretin mimetics weight management IMWM US aimed understand 1 coverage policy IMWM influencing factors 2 coverage policy weight management treatments 3 opportunity support weight management constraining health care costs Qualitative study Participants leader highlevel employee large health insurance organization US aim survey 20 participants 10 organization covered IMWM 10 excluded coverage IMWM Participants completed 30minute interview Interviews audio recorded transcribed verbatim analyzed using directed content analysis Twenty individual completed interview 9 interviewee organization covered IMWM time study 11 organization excluded coverage IMWM identified 5 key themes 1 high cost primary barrier coverage IMWM 2 perception obesity lifestyle choice 3 current planned use varied utilization management strategy limit initial ongoing prescribing IMWM 4 coverage lifestylechange program support weight management 5 perceived responsibility pharmaceutical company lower list price IMWM enable broad coverage advance health equity High cost IMWM primary limiting factor coverage policies variability plan design utilization management strategy aim reduce nearterm spending Health plan leader call pharmaceutical company reduce list price increase equitable access IMWM",
        "mesh_terms": [
            "Humans",
            "Insurance Coverage",
            "United States",
            "Incretins",
            "Male",
            "Female",
            "Qualitative Research",
            "Obesity",
            "Middle Aged",
            "Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40705731/"
    },
    {
        "pmid": "40705178",
        "title": "Cost-effectiveness of benmelstobart-anlotinib-chemotherapy in extensive-stage small-cell lung cancer: A comparative analysis across United States and Chinese healthcare systems.",
        "abstract": "Benmelstobart anlotinib plus etoposidecarboplatin EC group demonstrated substantial clinical efficacy improving survival outcome patient extensivestage smallcell lung cancer ESSCLC However high treatment cost raise concern regarding affordability costeffectiveness across healthcare system heterogeneous pricing reimbursement mechanisms study aimed evaluate costeffectiveness benmelstobart anlotinib plus EC group compared EC alone group anlotinib plus EC group US Chinese payer perspectives finding intended inform valuebased pricing strategy evidencebased reimbursement decisionmaking partitioned survival model PSM lifetime horizon 21day cycle constructed using clinical data ETER701 trial Direct medical cost health utility input obtained national databases local hospitals published literature primary outcome incremental costeffectiveness ratio ICER calculated comparing cost qualityadjusted life year QALYs treatment strategies Scenario analyses including drug price simulation deterministic probabilistic sensitivity analyses conducted evaluate model robustness Willingnesstopay WTP threshold set 100000QALY 150000QALY US 40011QALY China US benmelstobart anlotinib plus EC group yielded ICER 12156040QALY versus EC alone group 12757909QALY versus anlotinib plus EC group 150000QALY threshold However 100000QALY threshold costeffectiveness would require reducing benmelstobarts price 131612600 mg China ICER 11766717QALY exceeded local threshold Price simulation suggested costeffectiveness could achieved price reduced 223060600 mg US 32847600 mg China Sensitivity analysis identified progressionfree survival PFS utility benmelstobart pricing major cost drivers Probabilistic analysis indicated 751 probability costeffectiveness 150000QALY US However probability costeffectiveness 0 WTP threshold 100000QALY US 40011QALY China Benmelstobart plus anlotinib EC group likely costeffective US WTP threshold 150000QALY China current prices 80 price reduction China would necessary align WTP threshold emphasizing need policy intervention drug pricing reimbursement improve patient access",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40705178/"
    },
    {
        "pmid": "40704030",
        "title": "Cost-utility and budget impact analyses of valganciclovir for cytomegalovirus retinitis in patients with human immunodeficiency virus in Thailand.",
        "abstract": "Cytomegalovirus retinitis CMVR opportunistic infection frequently seen people living HIV PLHIV cause blindness Intravenous IV ganciclovir typical CMVR treatment Thailand oral valganciclovir convenient alternative However costeffectiveness budget impact remain unclear Therefore study aimed analyse costutility budget impact oral valganciclovir compared IV ganciclovir CMVR treatment PLHIV Thailand hybrid decision treeMarkov model developed estimate costs qualityadjusted life year QALYs life year LYs Cost utility probability parameter obtained published literature national databases costutility analysis performed estimate incremental costeffectiveness ratios whereas budget impact analysis BIA performed assess financial implications Sensitivity analysis performed assess model uncertainty Oral valganciclovir dominant treatment providing higher QALYs 350 vs 323 LYs 478 vs 475 lower total cost 133630 THB vs 163024 THB IV ganciclovir Oneway sensitivity analysis revealed retinal detachment probability drug cost inpatient service cost influential parameters Probabilistic sensitivity analysis revealed 943 simulation placed oral valganciclovir dominant quadrant BIA revealed annual cost reduction 6408714 THB replacing IV ganciclovir oral valganciclovir Oral valganciclovir costeffective demonstrated budget reduction compared IV ganciclovir finding provide valuable insight enhancing CMVR management ensuring efficient healthcare resource allocation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40704030/"
    },
    {
        "pmid": "40701591",
        "title": "Assessing the quality of amoxicillin in the private market in Indonesia: a cross-sectional survey exploring product variety, market volume and price factors.",
        "abstract": "assess quality amoxicillin product Indonesias private market surveying range product available across different areas followed product sampling laboratory testing crosssectional survey employing mystery shopper purposively sample widest possible range amoxicillin product available patient across different area Indonesia Licensed unlicensed medicine outlet remote rural urban area online Amoxicillin product sold patient oral solid dry liquid formulations Quality amoxicillin products assessed using compendial testing active pharmaceutical ingredient content dissolution Samples failed quality test classified substandard outofspecification OOS raw prevalence substandard amoxicillin adjusted based national market volume product variant surveyed 476 outlets mostly pharmacy 685 website 197 drug store 109 Among 120 collected samples 59 distinct products collectively representing 95 estimated market volume oral solid product 65 dry syrups 12 110 oral solid sample tested OOS 109 3 10 dry syrup 30 sample failed originated various area type outlets found relation price quality amoxicillin oral solid amoxicillin product tested OOS represent estimated 127 national market volume found relation price quality amoxicillin Combining productvariety sampling data market volume present promising approach gain insight prevalence poorquality medical product using relatively small sample size",
        "mesh_terms": [
            "Indonesia",
            "Cross-Sectional Studies",
            "Amoxicillin",
            "Humans",
            "Anti-Bacterial Agents",
            "Private Sector",
            "Commerce",
            "Pharmacies",
            "Surveys and Questionnaires"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40701591/"
    },
    {
        "pmid": "40699577",
        "title": "Difficulty With Binary Voting Among FDA Oncology Advisory Committee Members.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40699577/"
    },
    {
        "pmid": "40693038",
        "title": "Spatiotemporal patterns and influencing factors of genotypic resistance testing utilization among people living with HIV: A 10-year retrospective analysis at a tertiary care hospital in Beijing, China (2014-2023).",
        "abstract": "Prior research indicated low genotypic resistance testing GRT human immunodeficiency virus HIV utilization China due partial cost coverage national antiretroviral therapy policies limited testing accessibility financial barriers Temporal spatial data GRT trend also scarce analyzed GRT pattern among 6895 untreated individual tertiary hospital using Joinpoint regression multivariable logistic modeling spatial analysis GeoDaSatScan GRT rate showed significant twophase upward trend increasing 536  2014 7417  2023 average annual percentage change 3130  iPi  0001 Beijing residency adjusted odds ratio aOR  2596 95  confidence interval CI 23072921 older age associated higher GRT uptake Specifically age 3544 year aOR  1207 95  CI 10261420 4554 year aOR  1335 95  CI 11041613 ≥ 55 year aOR  1424 95  CI 11261802 significantly higher odds testing Lower testing rate observed individual lower education attainment high school technical secondary aOR  0827 junior high school aOR  0835 primary school aOR  0695 unknown sexually transmitted disease STDs history aOR  0415 nonheterosexual transmission route homosexual aOR  0834 Spatial analysis identified GRT clustering across Beijing 2021 two spacetime cluster identified 20192023 20182022 study demonstrates substantial increase GRT uptake achieving balanced districtlevel distribution since 2021 Age educational attainment STDs history transmission route influence GRT utilization Improving access reducing costs implementing targeted intervention critical optimizing testing guiding antiretroviral therapy decisions",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40693038/"
    },
    {
        "pmid": "40692815",
        "title": "Off-label policy through the lens of trazodone usage and spending in the United States.",
        "abstract": "Offlabel prescribingwhen medication used indication approved Food Drug Administrationis widespread US health care system study used trazodone drug approved 1981 depression case study examine broader issue surrounding offlabel utilization spending Although approved treat depression trazodone frequently prescribed offlabel indication uncertain clinical value insomnia anxiety Using nationally representative data Medical Expenditure Panel Survey estimated approximately 24 million trazodone prescription filled 2019 health care spending 294 million least 85 prescription ∼20 million 84 spending 247 million offlabel indications primarily insomnia Health plan reimbursement per prescription nearly identical onlabel offlabel use despite significant evidence gap finding illustrate scale inefficiency offlabel prescribing highlight challenge facing clinicians patients payers propose set policy solutionsincluding public private investment evidence generation pricing drug account offlabel use valuebased reimbursementto advance efficient system offlabel use Trazodone present revealing case broader systemic problem offlabel prescribing indication uncertain clinical value",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40692815/"
    },
    {
        "pmid": "40690228",
        "title": "Managing Anticancer Drug Spending in Medicare.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40690228/"
    },
    {
        "pmid": "40689371",
        "title": "Utilization and Determinants of Anticancer Drugs Under China's National Drug Price Negotiation Policy.",
        "abstract": "Chinese government began take national drug price negotiation NDPN 2016 aiming enhance accessibility affordability anticancer drugs study aim assess utilization influence factor anticancer drug NDPN policy China Gastric cancer patient within chemotherapy included Independent variable measured age gender insurance type total medical expenditure THE length stay LOS drugtototalexpense ratio DTR primary outcome negotiated drug usage cost treatment outcome Twopart model used identify influence factor anticancer drug utilization Propensity Score Matching PSM employed evaluate impact negotiated drug utilization treatment outcome among inpatients sample included 9868 gastric cancer patient three cities Outpatient patient demonstrated limited utilization negotiated drug 133 Patients aged 6175 β0923 P  001 75 year β0946 P  005 likely use negotiated drugs Key factor influencing inpatient drug utilization included medical insurance type β0245 P001 LOS β0122 P0001 DTR 0037 P0001 use negotiated drug significant effect treatment outcomes limited utilization negotiated drug outpatient arises urgent necessity comprehensive insurance coverage significant outcome effect dedicated importance rigorously validate effectiveness drug abundant realworld evidence foreseeable future",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40689371/"
    },
    {
        "pmid": "40689243",
        "title": "Examining Pricing and Availability for Neglected Tropical Disease Therapies in the United States.",
        "abstract": "Neglected tropical disease primarily affect vulnerable population lowresource setting worldwide United States neglected tropical disease Chagas soiltransmitted helminthiases infection historically affected immigrant increasingly relevant US resident climate change examined pricing prescribing rates supply therapy used treat neglected tropical disease United States implication accessibility patient care retrospective analysis prescription rates wholesale acquisition costs shortage conducted 11 treatment product 2019 2024 aggregating data Symphony Metys First Databank NAVLIN Red Book University Utah Drug Information Service price neglected tropical disease stable albendazole price decreased 78 mebendazole price rose 60 Miltefosine remained expensive 48 000 per treatment course limited manufacturer neglected tropical disease treatment United States increasing vulnerability shortages Addressing pricing irregularity supply vulnerability requires legislative policy intervention enhance generic competition expand public manufacturing strengthen supply chains measure critical ensuring affordable accessible treatment option neglected tropical disease United States",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40689243/"
    },
    {
        "pmid": "40686673",
        "title": "Impact of COVID-19 on disease-specific mortality, healthcare resource utilization, and disease burden across a population over 1 billion in 31 countries: an interrupted time-series analysis.",
        "abstract": "COVID19 pandemic disrupted global health affected chronic disease management study quantified impact pandemic diseasespecific measure health dynamics mortality rates healthcare resource utilization HRU disease burden interrupted timeseries analysis performed examining temporal trend across disease category two periods prepandemic pandemic after January 2020 Monthly mortality data collected 31 countries monthly HRU disease burden data collected South Korea defined primary outcome diseasespecific mortality rate number patients outpatient visits day hospitalization disease burden per caput cost used generalized least square model AR 1 residual automated SARIMA model BenjaminiHochbergadjusted qvalues applied statistical significance q  005 significant increase diseasespecific mortality observed across multiple countries circulatory disease showing widespread rise HRU declined across disease categories including reduction patient numbers outpatient visits hospital stays however patient number showed sustained increase neoplasm mental disorder Although change total direct medical cost varied disease per caput cost initially increased despite decrease number patients pandemic led increased mortality disease burden limited access healthcare services Establishing resilient healthcare system appropriate public health policy key ensure continuity care national crises Ministry Food Drug Safety Korea National Research Foundation Korea Korean Government Korea Environment Industry  Technology Institute",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40686673/"
    },
    {
        "pmid": "40686094",
        "title": "A cost-effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada.",
        "abstract": "Effective weight management pharmacotherapies new alternative bariatric surgery health behaviour intervention HBI alone Comparative costeffectiveness evaluation guide decisionmaking aimed evaluate costeffectiveness sleeve gastrectomy SG RouxenY gastric bypass RYGB semaglutide tirzepatide HBI compared treatment preventing cardiometabolic complication among Canadian adult class III obesity developed cohortbased Markov model 40year time horizon examined cardiometabolic complication 40yearolds class III obesity BMI ≥40 kgmsup2sup without type 2 diabetes cardiovascular disease baseline compared SG RYGB semaglutide 24 mg tirzepatide 15 mg HBI treatment obtained data treatment effects probabilities utilities cost published literature expressed effectiveness qualityadjusted life year QALYs estimated cost Canadian public payer perspective Outcomes included incremental costeffectiveness ratio ICERs evaluated CAD 50 000QALY willingnesstopay threshold RYGB HBI costeffective strategies HBI costeffective versus treatment ICER 14 279QALY RYGB demonstrated highest QALYs 2020 costeffective strategy versus tirzepatide ICER 44 667QALY Semaglutide SG strongly dominated due higher cost lower effectiveness Tirzepatide extendedly dominated RYGB Sensitivity analysis confirmed finding showed lower drug price could improve pharmacotherapy costeffectiveness RYGB HBI costeffective managing class III obesity RYGB provided greatest health gains access remains limited Neither pharmacotherapy costeffective current prices Lower drug price could significantly improve pharmacotherapy costeffectiveness",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40686094/"
    },
    {
        "pmid": "40684026",
        "title": "Cost-Effectiveness Analysis of Toripalimab Plus Axitinib for Patients with Advanced Renal Cell Carcinoma in the United States.",
        "abstract": "RENOTORCH trial found toripalimab plus axitinib extended progressionfree overall survival patient advanced renal cell carcinoma RCC though financial burden may limit widespread use study aimed assess costeffectiveness toripalimab plus axitinib compared sunitinib monotherapy firstline therapy patient previously untreated intermediate poorrisk advanced RCC US thirdparty payer perspective threestate partitioned survival model progressionfree progression death utilized clinical outcome obtained RENOTORCH trial Progressionfree survival PFS overall survival OS modeled using various parametric function 5year horizon applying 3 annual discount rate Costs treatments administration monitoring management grade 34 adverse event ≥ 5 occurrence sourced Micromedex® Centers Medicare  Medicaid Services CMS databases Life year LY qualityadjusted life year QALY incremental cost per LY QALY estimated Oneway probabilistic sensitivity analysis conducted Subgroup analysis intermediate poorrisk patients classified International Metastatic RCC Database Consortium IMDC criteria performed using similar methods Toripalimab plus axitinib increased total cost 332359 gained 068 LY 036 QALY compared sunitinib resulting incremental cost 489747 per LY 923962 per QALY Oneway sensitivity analysis showed incremental cost per QALY sensitive change toripalimab plus axitinibs cost 150000 willingnesstopay threshold probabilistic sensitivity analysis showed nearly 0 probability toripalimab plus axitinib costeffective Similarly toripalimab plus axitinib still costeffective intermediate poorrisk patients Compared sunitinib monotherapy study suggested toripalimab plus axitinib costeffective patient advanced renal cell carcinoma US thirdparty payer perspective analysis warranted data available Despite benefit across different risk groups toripalimab plus axitinib costeffective intermediate poorrisk patients",
        "mesh_terms": [
            "Humans",
            "Axitinib",
            "Carcinoma, Renal Cell",
            "Cost-Benefit Analysis",
            "Kidney Neoplasms",
            "United States",
            "Antibodies, Monoclonal, Humanized",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Quality-Adjusted Life Years",
            "Sunitinib",
            "Cost-Effectiveness Analysis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40684026/"
    },
    {
        "pmid": "40683012",
        "title": "Exposure to cannabis marketing in the United States and differences by cannabis laws: Findings from the International Cannabis Policy Study.",
        "abstract": "growing number US state legalized adult recreational cannabis however little evidence impact cannabis policy cannabis marketing exposure date current study examined marketing exposure US including difference state cannabis illegal illegal states legal medical use medical legal recreational use recreational Data US component International Cannabis Policy Study national repeat crosssectional data survey conducted 187573 respondent aged 1665 6 annual survey wave 20182023 Adjusted mixed effect logistic regression GLIMMIX model examined difference selfreported exposure cannabis marketing noticing statelevel cannabis laws Selfreported exposure cannabis marketing differed across policy changes Noticing cannabis marketing lowest illegal state increased first 12months following medical legalization 354  vs 392  AOR116 95  CI101133 p  0034 Noticing marketing highest recreational states increase first 12months following legalization 500  vs 411  AOR141 95  CI134148 p  001 additional increase 13 year 562  AOR120 95  CI114125 p  001 4 year following legalization 639  AOR121 95  CI116127 p  001 Noticing highest among people consume cannabis younger ages Selfreported exposure cannabis marketing increase following medical recreational legalization disproportionately noticed underaged people Cannabis regulation legal market account marketing shown promote cannabis use",
        "mesh_terms": [
            "Humans",
            "United States",
            "Adult",
            "Middle Aged",
            "Adolescent",
            "Male",
            "Female",
            "Young Adult",
            "Marketing",
            "Cannabis",
            "Cross-Sectional Studies",
            "Aged",
            "Legislation, Drug",
            "Marijuana Use"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40683012/"
    },
    {
        "pmid": "40678407",
        "title": "Comparative Cost Analysis for Direct Medical Costs of Protocol Administration of Non-Small Cell Lung Cancer Treatment Regimens in Curative Intent: A Micro-Costing Study in Jordan.",
        "abstract": "Nonsmall cell lung cancer NSCLC treatment cost significantly impact healthcare systems study analyzes direct cost cost driver perioperative adjuvant systemic treatment stage III NSCLC Jordanian healthcare providers perspective using microcosting methodology employed microcosting analyze direct medical expense including drug acquisition preparation administration prepostmedications diagnostics labor wastage cost perioperative regimen used stage III NSCLC International guideline defined therapeutic regimens drug price extracted Jordan Food Drug Administrations database Published data survey quantified microcosts Among 26 assessed regimen 2 targeted therapy 10 chemotherapy 10 chemoimmunotherapy 4 immunotherapy targetedimmunotherapy agent significantly increased costs Chemotherapy regimen cost difference ranged 63368 squamous 176391 nonsquamous per cycle Antineoplastic agent primary cost drivers highest Durvalumab 9872 cycle cost Laboratory cost comprised 5073 chemotherapy 724 immunotherapy regimens Wastage contributed 1036 total cycle costs Average administration cost 35 per cycle Maximum cycle cost were targeted therapy Osimertinib 720644 immunotherapy Durvalumab 905771 immunechemotherapy DurvalumabCarboplatinPemetrexed 1135843 chemotherapy CarboplatinPemetrexed 230072 result highlight substantial economic impact cost variability among treatment regimens variability present opportunity cost reduction careful selection therapeutically equivalent regimen based pricing toxicity profiles finding emphasize need comprehensive precise cost analysis inform healthcare policy clinical practices Future research focus costeffectiveness analysis expensive agent ensure value money support evidencebased decisionmaking strengthen price negotiation suppliers",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40678407/"
    },
    {
        "pmid": "40674723",
        "title": "China's online pharmacy: its regulatory policy and a future research agenda for the emerging AI age.",
        "abstract": "recent years China witnessed remarkable digital health movement wherein online pharmacy drug ecommerce emerged disruptive business models 2019 China amended Drug Administration Law permit online sale prescription drug customers albeit certain limitations marked Chinas first national congresslevel regulatory policy online pharmacy regulation policy comprises two subpolicies one targeting thirdparty online platform involved drug sale another aimed controlled drug drug special administration prohibited sold online However regulatory policy sparked legal ethical debates first revolves around whether online platform engaged drug sale enjoy liability protection extent second center ethical dilemma concerning access controlled drug due blanket ban online sales article thoroughly examines aforementioned regulatory policy Moreover coronavirus disease2019 COVID19 pandemic surge artificial intelligence AI application within Chinas healthcare sector leading phenomenal growth AIdriven online pharmacy staffed socalled AI doctor pharmacists article outline future research agenda regulating emerging AIenabled online pharmacy postpandemic age concluding",
        "mesh_terms": [
            "China",
            "Humans",
            "COVID-19",
            "Artificial Intelligence",
            "Pharmaceutical Services, Online",
            "SARS-CoV-2",
            "Drug and Narcotic Control"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40674723/"
    },
    {
        "pmid": "40672914",
        "title": "Will centralized drug procurement policy improve enterprises' total factor productivity?",
        "abstract": "backdrop Chinas healthcare reform challenge drug pricing study investigates impact National Centralized Drug Procurement NCDP policy implemented 2018 Employing DifferenceinDifferences DID methodology quarterly data Ashare listed pharmaceutical firm 20032021 sourced WINDCSMAR databases demonstrate NCDP participation significantly reduces Total Factor Productivity  Robustness confirmed index substitution propensity score matching lag tests negative effect amplified nonstateowned enterprises nonTCM manufacturers firm high analyst coverage Mechanistically NCDP suppresses TFP through i tightened financing constraint ↑KZ index impairing capital allocation efficiency ii indirect pathway shortterm RD surge ↑RD trigger resource crowdingout effects compounded diminished investment efficiency ↑INV ultimately forming RD→investment inefficiency→TFP↓ transmission chain reconcile public welfare objective corporate sustainability propose dual optimization strategies idifferentiated financing supporti iinnovation incentive reformi establish sustainable equilibrium price control TFP enhancement providing actionable solution nationwide NCDP scaling",
        "mesh_terms": [
            "Humans",
            "China",
            "Drug Industry",
            "Efficiency, Organizational",
            "Health Policy",
            "Drug Costs"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40672914/"
    },
    {
        "pmid": "40671596",
        "title": "Affordability issues and the need for a reimbursement process of advanced therapy for inflammatory bowel diseases in India.",
        "abstract": "Inflammatory bowel disease IBD aggressive relapsing condition develop young age carry high lifetime risk medical expenses Patients moderatetosevere Crohns disease Ulcerative colitis need biologic therapy induction maintenance remission cost treating moved hospitalization surgery biologics partly reimbursed review identifies handful insurance company provide daycare coverage biologic infusion injection get reimbursed 24hour admission India varies patient patient one insurance company another biosimilars antiTNFs drive saving overall costs Patients made accept substantial cost deductibles copayments coinsurance insurance partially cover financial risk healthcare IBD remains affordable some manufacturer need comprehend payers perspective deliver best possible patient outcomes pricing strategy indicationspecificvolumebased pricing Small molecule adoption potential disrupt infusionbased reimbursement policy shifting care pharmacybased models improving access rural populations need implement universal health coverage post mortgage model used spread cost biologics time IBD payers perspective must considered determining cost product include patient healthcare policy decisionmaking",
        "mesh_terms": [
            "Humans",
            "India",
            "Inflammatory Bowel Diseases",
            "Insurance, Health, Reimbursement",
            "Reimbursement Mechanisms"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40671596/"
    },
    {
        "pmid": "40669769",
        "title": "Medicare Drug Price Negotiation Under The Inflation Reduction Act: Ensuring the Continuity of Critical Real-world Pharmaceutical Studies.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40669769/"
    },
    {
        "pmid": "40668561",
        "title": "Quantifying the Role of Specialty Medications in Medicare Part D Expenditures in Dermatology.",
        "abstract": "rising cost prescription drug major concern health care Specialty medications particularly biologics transformed dermatologic care expensive may factor disproportionate growth spending assess role specialty medication Medicare Part drug spending among physician dermatologist dermatologyfocused advanced practice clinician nurse practitioner physician assistants 2013 2022 economic analysis used Medicare Part prescriber data drug prescription 2013 2022 report prescription drug claim physician dermatologist dermatologyfocused advanced practice clinicians identified using validated administrative claimsbased definitions Data analyzed December 17 2024 May 31 2025 Prescription volumes average prices introduction new drugs primary outcome growth inflationadjusted total dermatology drug spending decomposed specialty status prescriptions prices US Food Drug Administration approval year assessed Centers Medicare Medicaid Services Part prescriber data 2013 2022 94 900 359 drug claim 24 731 dermatology care professionals inflationadjusted Medicare Part spending increased 161 annually 768 million 2013 295 billion 2022 Specialty medication contributed 984 growth increasing 308 dermatology drug spending 2013 809 2022 despite 29 prescriptions Average inflationadjusted price per 30day prescription specialty medication increased 51 per year 3738 2013 5872 2022 contrast price nonspecialty medication decreased 53 annually relative inflation 68 2013 42 2022 growth specialty medication spending due increased prescribing 805 rather higher price 195 New therapy approved 2013 Otezla Cosentyx Taltz Dupixent Tremfya Skyrizi Odomzo accounted 695 spending growth Prescription rate increased slowly older specialty drug Humira Enbrel Stelara Erivedge price increased 92 annually price newer agents Results economic evaluation suggest specialty medication become substantial factor dermatology drug spending price average dermatologic medication increased rapidly primarily reflects increased prescribing newly introduced specialty drugs therapy expand treatment options rising share cost highlight need policy balance innovation access affordability",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40668561/"
    },
    {
        "pmid": "40660747",
        "title": "Cost and clinical flow of point-of-care urine tenofovir testing for treatment monitoring among people living with HIV initiating ART in South Africa.",
        "abstract": "Pointofcare POC urine tenofovir TFV test provide timely information regarding antiretroviral therapy ART adherence support management HIV treatment clinics However limited data cost feasibility integrating POC testing HIV clinic subSaharan Africa characterized clinic flow implementation cost POC adherence testing person initiating ART HIV care clinic South Africa conducted microcosting within randomized controlled implementation trial POC TFV test government clinic Durban South Africa STREAM HIV Timeandmotion observation conducted 1st March 31st December 2022 assess staff client time needed POC TFV testing counselling estimated financial economic cost capital clinic consumables personnel using provider national government perspective estimated cost POC TFV USD 13 per client assuming clinic volume 20 individual initiating ART per month largest component cost POC TFV testing test strip consumables accounted 53 test cost median total time clinic visit POC TFV test starting client registration 4919 minutes seconds IQR 29198935 TFV testing took 922 IQR 7351411 taking 19 total clinic visit time including sample collection sample loading TFV test processing counselling provision based test results Overall 29 clinic visit time included direct clinical care assessment provider client spending median 1409 IQR 10352122 getting vitals checked receiving adherence monitoring via POC TFV testing collecting ART refill Waiting line ART took 48 clinic visit time POC TFV testing administered reasonable costs requires less 10 minute healthcare provider time and therefore may feasible implement South African clinics Findings inform policy budgetary planning ART monitoring South Africa future costeffectiveness analysis POC TFV testing NCT04341779",
        "mesh_terms": [
            "Humans",
            "HIV Infections",
            "Tenofovir",
            "South Africa",
            "Anti-HIV Agents",
            "Point-of-Care Testing",
            "Male",
            "Female",
            "Point-of-Care Systems",
            "Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40660747/"
    },
    {
        "pmid": "40659975",
        "title": "Revenue, Patents, and New Generic Competition for Prescription Drugs in the USA.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40659975/"
    },
    {
        "pmid": "40653930",
        "title": "Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top-Selling Drugs.",
        "abstract": "examine whether new Medicare inflation rebate policy associated change manufacturer pricing behavior crosssectional study 156 topselling brandname drugs used linear regression evaluate whether association drugs exposure policy ie Medicares share net US sales difference yearoveryear price change 20212022 versus 20222023 20232024 policy took effect study used Medicare spending data average sale price Centers Medicare Medicaid Services wholesale acquisition cost Eversana NAVLINs Price  Access database sale revenue estimated rebate SSR Health Vaccines biosimilars drug approved 2020 generic biosimilar competition 2023 excluded Drugs stratified whether derived sale Medicare Part B Part D median Medicare share net sale 28 IQR 1837 50 Part B drug 32 IQR 1649 106 Part drugs Median yearoveryear price change 20212022 20222023 20232024 32 29 34 Part B drug 50 59 49 Part drugs association drugs Medicare share net sale difference price change pre vs postpolicy Part B drug 2023 p  099 2024 p  009 Part drugs 10 increase drugs share Medicare sale associated 018 95 CI 001035 p  004 higher price change first year policy implementation significant association second year p  017 Medicare inflation rebate associated smaller price increase among topselling drug affected policy Additional measure needed prevent drug manufacturer raising price year extending inflation rebate commercially insured patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40653930/"
    },
    {
        "pmid": "40652608",
        "title": "Associations between local cigarette and e-cigarette prices and smoke-free legislation with prenatal smoking and birth outcomes.",
        "abstract": "state cigarette tax shown reduce disparity prenatal smoking birth outcomes less known effect local tobacco control policies examined association countylevel cigarette ecigarette price smokefree legislation racialethnic educational disparity prenatal smoking birth outcomes Using 20132018 countylevel natality data 18663683 singleton linked cigarette ecigarette price data smokefree legislation conducted conditional mixedprocess model examine association tobacco control policy prenatal smoking associated change birth outcomes included interaction raceethnicity education prices Cigarette price increase associated larger decline prenatal smoking ecigarette prices effect size decreasing across educational gradient Among woman 011 year education 10  increase cigarette price associated decrease smoking 861 percentage point White woman 292 percentage point Black woman subsequently increase infants birth weight 801 272 g respectively Increases cigarette ecigarette smokefree legislation coverage associated small decline prenatal smoking subsequent change birth outcomes Local cigarette price increase contribute flattening educational gradient prenatal smoking birth outcomes particularly among White Black women Local cigarette price may indicative fiscal policy influence smoking behavior state cigarette taxes particularly loweducated pregnant woman likely price sensitive",
        "mesh_terms": [
            "Humans",
            "Female",
            "Pregnancy",
            "Adult",
            "Tobacco Products",
            "Smoke-Free Policy",
            "Electronic Nicotine Delivery Systems",
            "Pregnancy Outcome",
            "Commerce",
            "Smoking",
            "Young Adult",
            "Birth Weight",
            "Taxes",
            "Infant, Newborn",
            "Adolescent"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40652608/"
    },
    {
        "pmid": "40646427",
        "title": "Public perceptions of high-cost cancer drugs and the implications for reimbursement decisions.",
        "abstract": "Reimbursing highcost cancer drug present challenge managing uncertainty setting appropriate prices controlling pharmaceutical expenditures examined perspective South Korean public highcost cancer drug policy option improve reimbursement treatments conducted selfrated webbased survey November December 2023 used quota sampling method based South Korean census data recruit study participants questionnaire comprised four sections sociodemographics definition highcost cancer drug reason reimbursement uncertainty associated highcost cancer drugs policy option improve reimbursement treatments 11974 invitation sent 1000 participant completed survey resulting response rate 835 Threequarters respondent agreed strongly agreed highcost cancer drug reimbursed 70 accepted need price negotiations even lead drug withdrawal delay reimbursement decisions similar proportion agreed new policy options dual pricing additional funding introduced caution South Korean public perceives reimbursement highcost cancer drug human right measure government responsibility However support reimbursement confident drug safe effective costeffective",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40646427/"
    },
    {
        "pmid": "40644379",
        "title": "Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy.",
        "abstract": "Evidence support longterm efficacy Nucleostide Analogs NAs therapy improving chronic hepatitis B CHB prognosis However determining costeffective firstline NAs remains unclear Chinas implementation New VolumeBased Procurement Policy NVBP Policy 2019 led substantial price reduction entecavir ETV tenofovir disoproxil fumarate TDF tenofovir alafenamide TAF study assesses costeffectiveness ETV TDF TAF without NVBP CHB China statetransition model parameterized using data published literature utilized compare treatment strategy encompassing nonNAs best support care BSC ETV TDF TAF without NVBP simulated lifetime cohort employed measuring outcome predicted liverrelated deaths costs qualityadjusted lifeyears QALYs incremental costeffectiveness ratio ICERs comparison NonNAs BSC TAF yielded additional 268 QALYs per person ICER 785322 USDQALY Subsequently TDF generated additional 261 QALYsperson ICER 715339 USDQALY ETV produced additional 201 QALYsperson ICER 936674 USDQALY without NVBP Incorporating NVBP ICERs TAF TDF ETV decreased 74562 USDQALY 72933 USDQALY 87111 USDQALY respectively compared nonNAs BSC willingnesstopay WTP threshold ranging 12500 USDQALY 37500 USDQALY TAF NVBP showed increased probability 51155247 optimal treatment strategy followed TDF ETV NVBP exhibiting reduced likelihood 43094245 640448 iterations analysis suggests TAF NVBP represents costeffective longterm therapy CHB TDF ETV without NVBP TAF without NVBP considered costineffective",
        "mesh_terms": [
            "Humans",
            "Hepatitis B, Chronic",
            "Tenofovir",
            "Guanine",
            "Cost-Benefit Analysis",
            "China",
            "Adenine",
            "Antiviral Agents",
            "Quality-Adjusted Life Years",
            "Alanine",
            "Male",
            "Female"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40644379/"
    },
    {
        "pmid": "40643355",
        "title": "Historical and contextual variation in daily opioid consumption rates: implications for supply control, service delivery, and research.",
        "abstract": "iBackgroundi Illegal opioids create substantial harms extent depends multiple factors including amount consumediObjectivesi examine consumption varies across time context implication treatment drug policyiMethodsi searched EBSCOhost PubMed literature individuals 1 notintreatment purchasing illegal markets 2 reporting pretreatment use treatment intake 3 opioid use disorder OUD receiving medically supplied opioids total 135 article deemed relevantiResultsi Average consumption intensity vary enormously 100 morphine milligram equivalent MME per day use outside treatment price high 600 MME typical illegal markets 11001800 MME per day supply free heroin assisted treatment injectable hydromorphone treatment MME methadone program 190460 less traditional British heroin prescribing system 6001300 Intensities tended higher recent times whereas price lower Studies fentanyl era suggest MMEs per day may much higher pastiConclusioni adaptability consumption several potential implications Expansions supply could greater effect quantity consumed prevalence Treatment protocol overdose prevention strategy may need adjust higher baseline consumption Furthermore assumption health harm longterm use may need revisiting predicated lower historical consumption intensities finding caveated limitation reporting data variation methodologies Hence greater investment monitoring consumption intensity warranted",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40643355/"
    },
    {
        "pmid": "40634893",
        "title": "Does Global Budget promote the construction of integrated healthcare delivery system? Evidence from Sanming, China.",
        "abstract": "Chinese government advancing development County Medical Community CMC establish integrated healthcare delivery network ensure health equity Recently Global Budget GB economic incentive implemented CMC Although impact GB medical expenditure demonstrated little evidence whether GB promotes collaboration among various providers article take Sanming City typical example Chinas healthcare reform case study us data 2016 2023 operation CMC Interrupted time series analysis used evaluate longterm impact GB inpatient costs cost structure service delivery analysis indicate that although direct impact GB inpatient cost significant sustains rational structure inpatient cost optimizes delivery inpatient service level institutions respect inpatient cost structure proportion drug cost secondary hospital SHs βsub3sub  0127 P  0001 tertiary hospital THs βsub3sub  0120 P  005 increased GB proportion testing inspection cost primary healthcare institution PHIs decreased βsub3sub  0215 P  005 term service delivery average length stay SHs βsub3sub  0053 P  005 THs βsub3sub  0032 P  0001 decreased admission per 100 outpatient βsub3sub  0058 P  0001 PHIs increased robustness analysis corroborated robustness results article provides empirical evidence GB mechanism enhance service coordination among different level healthcare providers provides valuable lesson promoting integrated healthcare achieving health equity China low middleincome countries",
        "mesh_terms": [
            "China",
            "Humans",
            "Budgets",
            "Delivery of Health Care, Integrated",
            "Health Care Reform",
            "Interrupted Time Series Analysis",
            "Organizational Case Studies"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40634893/"
    },
    {
        "pmid": "40633905",
        "title": "Budget impact analysis of treatment-free remission in chronic myeloid leukemia patients treated with nilotinib in Tunisia.",
        "abstract": "emergence treatmentfree remission mark significant shift clinical management chronic myeloid leukemia patients involves discontinuation tyrosine kinase inhibitor therapy maintaining sustained molecular response light this study aim evaluate budget impact associated healthcare strategy among tunisian patient treated nilotinib economic evaluation seek provide insight affordability implementing treatmentfree remission perspective Tunisian National Health Insurance Fund threeyear time horizon Markov model assessed introduction treatmentfree remission eligible population input data used transition probability identification target population obtained systematic literature review economic evaluation considered drug acquisition cost direct cost covered public payer account variability results oneway deterministic sensitivity analysis conducted varying key model parameters initial cohort 32 eligible patient within health insurance database model estimated evolution target population 230 patient three years introduction treatmentfree remission new strategy management chronic myeloid leukemia would result costsaving estimated 234 million Tunisian Dinars uncertainty analysis revealed significant impact drug price overall outcomes study provides transparent interpretable result decisionmakers economic evaluation reveals financial gain allocated address health priority within Tunisian National Health Insurance Funds budget budget impact analysis advocate implementing treatmentfree remission costsaving intervention Tunisian National Health Insurance Funds budget",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40633905/"
    },
    {
        "pmid": "40632461",
        "title": "Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.",
        "abstract": "Pembrolizumab show effectiveness treating metastatic nonsmall cell lung cancer metNSCLC subgroup patient experiencing longterm survival LTS benefits existence LTS subgroup may influence costeffectiveness pembrolizumab monotherapy compared platinumbased chemotherapy study aim assess potential implication subgroup costeffectiveness patient nonsquamous metNSCLC PDL1 ≥ 50 ineligible targeted therapies study used decision analytic model based Dutch realworld data 20082014 Two strategy simulated 1 chemotherapy strategy patient receive chemotherapy first second thirdline 2 pembrolizumab strategy patient receive firstline pembrolizumab followed chemotherapy progressing second thirdlines pembrolizumab strategy evaluated without assumption LTS subgroup LTS subgroup assumed free metNSCLCrelated progression treatment Costs 2022 € including drug costs direct medical costs family costs healthcare cost life year gained considered firstline treatment death Effects measured qualityadjusted life year QALYs incremental costeffectiveness ratio ICER assessed using €80000QALY threshold Threshold analysis performed size mortality rate LTS subgroup price pembrolizumab QALYs per patient 065 chemotherapy 124 pembrolizumab without LTS 352 pembrolizumab LTS Average cost per patient €58800 chemotherapy €154600 pembrolizumab without LTS €178600 pembrolizumab LTS Pembrolizumab without LTS costeffective compared chemotherapy ICER €167600QALY pembrolizumab LTS 30 simulated population cost effective ICER €43100QALY Threshold analysis showed LTS subgroup size least 10 halving price pembrolizumab needed pembrolizumab costeffective Pembrolizumab costeffective firstline treatment patient metNSCLC PDL1 ≥ 50 Netherlands least 10 patient longterm survivors Without longterm survivors treatment costeffective Therefore crucial consider longterm survivor assessing costeffectiveness immunotherapy metNSCLC",
        "mesh_terms": [
            "Humans",
            "Antibodies, Monoclonal, Humanized",
            "Cost-Benefit Analysis",
            "Carcinoma, Non-Small-Cell Lung",
            "Lung Neoplasms",
            "B7-H1 Antigen",
            "Antineoplastic Agents, Immunological",
            "Quality-Adjusted Life Years",
            "Male",
            "Netherlands",
            "Female"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40632461/"
    },
    {
        "pmid": "40624840",
        "title": "Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.",
        "abstract": "Therapeutic monoclonal antibody mAbs often designed bind target via antigenbinding domain Fabs also engage cell surface receptors FcγRs FcRn Fc regions may result variety functional outcomes including antibody dependent cellular cytotoxicity ADCC antibodydependent cellular phagocytosis ADCP complementdependent cytotoxicity CDC alteration circulating halflives Engineering Fc region achieve desirable pharmacology pharmacokinetics widely adopted strategy drug development Fc region modified amino acid substitution glycoengineering resulting enhanced reduced effector functions preferential binding FcR subtypes pHdependent binding FcRns alteration binding effector activity mAbs may potentially also accompanied undesirable effect safety concerns Critical assessment pharmacology safety nonclinical setting essential exposing human engineered mAb Fcmodified mAbs choice vitro vivo nonclinical pharmacology safety model need account specie difference FcR expression function potentially divergent effect Fc modification human versus nonclinical species impact target cognate ligand expression patterns potential impact emergent antidrug antibody directed mAb Using variety industry case studies highlight key aspect nonclinical pharmacology toxicology testing strategies factor influence choice nonclinical models translatability findings input health authority suggest best practice approach nonclinical testing Fc modified mAbs",
        "mesh_terms": [
            "Humans",
            "Protein Engineering",
            "Antibodies, Monoclonal",
            "Animals",
            "Immunoglobulin Fc Fragments",
            "Receptors, Fc",
            "Antibody-Dependent Cell Cytotoxicity",
            "Translational Research, Biomedical",
            "Drug Development",
            "Drug Industry"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40624840/"
    },
    {
        "pmid": "40623875",
        "title": "Interventions to mitigate drug shortages in public health systems in sub-Saharan Africa: a scoping review protocol.",
        "abstract": "Globally drug shortage affect low middle highincome country different degrees challenge associated drug shortage health systems particularly public health facilities consequent multiple adverse effect patient health system led country continue explore implement different strategy combat challenge Various factor implicated drug shortage range manufacturing concerns demand issues supply chain disruption regulatory issues effect drug shortage health system range poor patient compliance therapeutic failure antimicrobial resistance low morale among healthcare worker public distrust government services Furthermore effect drug shortage public health facility include unavailability drug patients hospitalisation readmissions associated cost could avoided high outofpocket expenditure suffered patient patient resort buying drug private pharmacy price usually exorbitant prohibitive putting patient risk treatment default due lack affordability Successful mitigation strategy deployed prevent manage drug shortage subSaharan Africa SSA remain unshared despite potential strategy serve valuable lesson evidence scientifically synthesised reported scoping review synthesise evidence provide policy guidance better planning health service resources resulting improved quality life citizens underscoring importance functional responsive health systems Using Joanna Briggs Institute JBI scoping review methodology fivestage review outlined 1 determining research question 2 search strategy 3 inclusion criteria 4 data extraction 5 analysis presentation results literature search use PubMed SCOPUS Elsevier Science Direct search interfaces reflecting empirical grey literature focus literature published 2000 2025 study start end date 1 September30 November 2025 twostage screening process used determine eligibility articles article individually assessed eligibility two reviewers third reviewer resolve disagreements data eligible article extracted charted using standardised form Extracted data analysed using narrative descriptive analyses Ethical approval required scoping review use previously published data require human participation result search disseminated academic presentation conference peerreviewed publications",
        "mesh_terms": [
            "Humans",
            "Africa South of the Sahara",
            "Scoping Review as Topic",
            "Pharmaceutical Preparations",
            "Public Health",
            "Delivery of Health Care"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40623875/"
    },
    {
        "pmid": "40621761",
        "title": "The Pharmacoeconomics and its Evaluation in Enhancing the Indian Healthcare System.",
        "abstract": "Escalating healthcare cost increasing demand healthcare system increased need efficient resource allocation Pharmacoeconomics vital field quantifies compare value therapeutic drug treatments provides systematic framework decisionmakers pharmaceutical industry government private sector optimize healthcare delivery spending review aimed explore role pharmacoeconomic model assessing economic clinical value therapies emphasizes importance costeffectiveness costutility costbenefit costminimization analysis balancing cost outcome guiding healthcare resource allocation Pharmacoeconomic methodology involve evaluating costs processes outcome associated therapeutic interventions Key method include costminimization costeffectiveness costutility costbenefit analyses approach critical regulatory compliance reimbursement decisions cost assessments sustaining pharmaceutical models review reveals pharmacoeconomic tool CostEffectiveness Analysis CEA CostUtility Analysis CUA CostBenefit Analysis CBA widely used guide healthcare policy decisions particularly resourceconstrained settings CEA commonly applied method due simplicity CUA gaining traction advanced policy framework like Health Technology Assessment HTA India pharmacoeconomic research emerging face barrier limited access realworld data absence national reimbursement systems high outofpocket costs Innovative method like machine learning pharmacogenomics explored improve relevance precision evaluations pharmacoeconomic model offer valuable insight healthcare decisionmaking realworld impact limited inconsistency data quality variation implementation standards India fragmented governance low public health spending lack coordination among stakeholder hinder effective application Addressing systemic challengessuch establishing interoperable data systems standard treatment guidelines equitable healthcare accessis crucial Tailored approaches including localized utility value digital health initiatives essential make pharmacoeconomics practical influential tool policy formulation resource allocation India similar settings Pharmacoeconomic study evaluate clinical efficacy adverse effects production cost incorporating perspective patients providers payers communities India unique challenge limited rural healthcare access infrastructure disparities high outofpocket expense necessitate tailored adaptations Strategies integrating accessibility metrics localized data equity considerations preventive care tiered pricing publicprivate partnership enhance healthcare delivery Pharmacoeconomic model essential improving health outcomes ensuring equitable resource allocation addressing diverse need India",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40621761/"
    },
    {
        "pmid": "40618906",
        "title": "Relationship between an adult-use Cannabis law and Cannabis use by type in a cohort of New Jersey young adults.",
        "abstract": "Limited research evaluated impact cannabis policy young adult cannabis use full implementation retail outlet opened cannabis product type study examined relationship adultuse cannabis retail sale New Jersey United States young adult cannabis use type Data New Jersey young adult 1823 years Policy Communication Evaluation PACE New Jersey Study Generalized estimating equation model estimated difference prevalence ever past 30day use cannabis subtypes Waves 13 MarchNovember 2021 n  1439 Wave 4 JuneJuly 2022 n  1127 adultuse retail sale began Ever cannabis use among New Jersey young adult higher postretail sale period presales 581  vs 489  p  001 odds ever cannabis use 42  higher 95  CI  32 54  postretail period Ever use dried herb post vs pre 444  vs 385  p  001 drink 70  vs 48  p  001 edible 459  vs 356  p  001 topicals 64  vs 46  p  005 past 30day edible use 118  vs 90  p  001 higher postretail use product type differ Cannabis use overall among certain subtypes eg edibles increased among New Jersey young adult three month adultuse cannabis retail sale began demonstrating increased access legal cannabis sale may encourage use Continued monitoring needed longer followup period New Jersey state legalizing cannabis",
        "mesh_terms": [
            "Humans",
            "New Jersey",
            "Young Adult",
            "Male",
            "Female",
            "Cannabis",
            "Adolescent",
            "Commerce",
            "Marijuana Use",
            "Marijuana Smoking",
            "Prevalence",
            "Cohort Studies",
            "Legislation, Drug"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40618906/"
    },
    {
        "pmid": "40616298",
        "title": "Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries.",
        "abstract": "increasing effort streamlining market access innovative drugs current acceptance health technology assessment HTA body nontraditional trial design still unclear aim study assess perspective drug developer acceptance nontraditional trial design HTA body Europe Eleven semistructured interview conducted expert gain insight perception nontraditional trial design acceptance HTA body Netherlands Germany United Kingdom Sweden France Future perspective recommendation facilitating acceptance nontraditional trial provided expert highlighted HTA bodies preference randomized controlled trial nontraditional trial designs degree acceptance varied countries Experts recommended multistakeholder discussion drug developer HTA body early scientific advice reevaluation evidence requirements EUHTA regulation viewed potential opportunity harmonization limiting innovative approach result study highlighted significant variation acceptance nontraditional trial design HTA body across Europe Actions needed facilitate progressive view nontraditional clinical trial design ensure fast patient access highly innovative treatments",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40616298/"
    },
    {
        "pmid": "40611094",
        "title": "Healthcare resource use and costs among patients with COVID-19 in the United States.",
        "abstract": "COVID19 remains common US uptodate data health care resource utilization cost remain limited particularly Omicron predominance study conducted using administrative claim data HealthVerity database available record medical claims pharmacy claims laboratory tests charge data master related enrollment including COVID19 events December 24 2021 April 30 2022 extracted Outpatient inpatient health care resource utilization HCRU cost 28day followup period COVID19 index date calculated total 1203769 patient COVID19 included HCRU analysis these 377945 nonmissing cost data included costing analysis median age 43 years 903  65 year age total 704 least one comorbidity 405 filled least one medication prescription potential major drugdrug interaction DDI ritonavir preceding 12 months Among COVID19 patients 444 outpatient 53 emergency room 12 urgent care visits 19 hospitalized Among hospitalized patients median length stay 3 days 189 admitted intensive care unit 34 required invasive mechanical ventilation Total mean treatment cost followup period 4965 outpatient 2686 pharmacy 2278 among patient never hospitalized 33329 among hospitalized patient with 22919 inpatient care HCRU treatment cost higher patient aged 65 older comorbidities medication prescription ritonavir DDIs regardless whether required hospitalization first four month Omicron wave economic burden COVID19 remained substantial Older age comorbidities associated higher HCRU treatment costs study provides data future research evaluating full economic impact COVID19 US",
        "mesh_terms": [
            "Humans",
            "COVID-19",
            "United States",
            "Female",
            "Male",
            "Middle Aged",
            "Adult",
            "Aged",
            "Health Resources",
            "Patient Acceptance of Health Care",
            "Health Care Costs",
            "Hospitalization",
            "SARS-CoV-2",
            "Comorbidity",
            "Young Adult",
            "Adolescent"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40611094/"
    },
    {
        "pmid": "40610972",
        "title": "A survey of availability, price, and affordability of innovative negotiated anticancer medicines: a retrospective study in Jiangsu Province, eastern China.",
        "abstract": "emergence innovative anticancer medicine revitalized cancer treatment prospects improving accessibility innovative anticancer medicine key goal national pharmaceutical policies Despite significant effort National Medical Security Administration reform National Reimbursement Drug List NRDL concern regarding utilization newly included anticancer drug persist study aim assess accessibility 23 Innovative Negotiated Anticancer Medicines INAMs Jiangsu Province developed region eastern China retrospective survey conducted across 319 healthcare institution Jiangsu Province 285 included analysis Data obtained procurement record 23 INAMs evaluated use medicine based three aspects availability price measured defined daily dose cost DDDc affordability 435 23 INAMs encountered difficulty obtaining them 304 23 INAMs difficult obtain notable disparity availability 23 INAMs secondary tertiary healthcare institutions median DDDc Group Group C showed progressive annual reduction DDDc 19 INAMs decreased study period three drug remained unchanged one drugs DDDc actually increased Family poverty caused medicine pronounced among rural residents affordability rural patient significantly lower urban patient p  005 2021 2022 accessibility INAMs improved 2020 2022 However accessibility INAMs influenced various factors disparity still exist access across different healthcare institution urban rural areas Effective sustainable policy need developed ensure equitable access medicine patients",
        "mesh_terms": [
            "Retrospective Studies",
            "China",
            "Humans",
            "Antineoplastic Agents",
            "Health Services Accessibility",
            "Drug Costs",
            "Negotiating"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40610972/"
    },
    {
        "pmid": "40609636",
        "title": "Referencing Drug Prices of Other Countries May Not Sustainably Lower Prices in the United States: Lessons From Europe.",
        "abstract": "Trump Administration issued Executive Order May 12 2025 intent equalize pricing across developed countries MostFavored Nation approach international reference pricing IRP IRP used extensively Europe resulted shortterm budget savings However list price quickly converged major highincome markets Germany France without evidence reduced prices Despite frequent use confidential price agreement differentiate net price country cannot afford price levels access innovative medicine delayed reduced suggests introduction IRP United States could limit access designated reference countries without sustainable reduction US price levels Instead referencing price countries United States establish system value assessment medicines whether time launch drug market several years",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40609636/"
    },
    {
        "pmid": "40608336",
        "title": "Prescription Use and Spending After the Introduction of a Real-Time Prescription Benefit Tool.",
        "abstract": "Realtime prescription benefit RTPB tool provide pointofcare information clinician time prescribing may reduce prescription cost patient payers assess trend prescription use spending among Medicare Advantage beneficiary national health insurer first year clinician access RTPB tool cohort study used 2018 2020 administrative data national insurer compare prescription fill beneficiary receiving prescription clinician practice RTPB tool fill prescribed clinician without access tool Trends prescription spending fill year practice adopted RTPB tool in March 2019 measured using differenceindifferences design Data analyzed November 2022 June 2024 Access RTPB tool within national electronic health record software vendor main outcome total prescription spending beneficiary outofpocket spending number prescription fills Secondary outcome included percentage fill insurerowned mailorder pharmacy percentage fill 90day supply subgroup analysis drug class appearing frequently RTPB tool highcost prescription drug classes sample included 2 805 060 beneficiary mean SD age 709 92 years 567 female 147 Black individuals 805 White individuals mean SD monthly outofpocket cost 291 904 total prescription cost 2132 10663 26 21 prescription fill per month introduction RTPB tool change prescription spending estimated outofpocket spending change 12 95 CI 07 30 estimated total prescription spending change 05 95 CI 02 12 number prescription fill estimated change 001 95 CI 001 002 among beneficiary prescribed medication clinician practice RTPB tool cohort study 28 million patients simply providing clinician access RTPB tool associated anticipated benefit patient payer first year tool released research design deploy RTPB tool maximize potential benefit needed",
        "mesh_terms": [
            "Humans",
            "United States",
            "Female",
            "Male",
            "Aged",
            "Health Expenditures",
            "Medicare Part C",
            "Cohort Studies",
            "Drug Prescriptions",
            "Aged, 80 and over"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40608336/"
    },
    {
        "pmid": "40608305",
        "title": "Health and Economic Impact of Periodic Hepatitis C Virus Testing Among People Who Inject Drugs.",
        "abstract": "Periodic hepatitis C virus HCV testing recommended people inject drug PWID optimal testing frequency remains unknown evaluate health benefits costs costeffectiveness alternative HCV testing frequency PWID costeffectiveness analysis extended previously published agentbased network simulation model HCV transmission sharing injection equipment among PWID Networkbased HCV transmission calibrated longitudinal data Social Networks Among Appalachian People study published literature PWID network US evaluate HCV testing strategy sparse PWID network setting lower HCV transmission dense network setting higher HCV transmission Data collected November 2008 August 2010 data analyzed September 2017 December 2019 Periodic HCV testing treatment alternative average testing frequency among PWID access use HCV care Changes cumulative qualityadjusted lifeyears QALYs health care cost 60 year in 2021 US dollars incremental costeffectiveness ratio ICERs discounted 3 annually mean initial age 1552 simulated PWID 32 years Compared testing HCV testing treatment among PWID 10year intervention period increased QALYs 25 46 cost 05 23 across average testing frequency ranging every 2 year monthly lower transmission setting testing every 2 year weakly dominated frequent testing strategies testing every year every 6 months every 3 months every month ICERs 6000 per QALY 9300 per QALY 24 200 per QALY 138 400 per QALY respectively higher transmission setting testing every 2 year every year weakly dominated testing every 6 months every 3 months every month ICERs 14 000 per QALY 30 100 per QALY 93 300 per QALY respectively Results sensitive risk primary infection reinfection well access utilization HCV testing service among PWID economic evaluation study based common benchmark costeffectiveness frequent HCV testing among PWID costeffective lower higher transmission settings",
        "mesh_terms": [
            "Humans",
            "Cost-Benefit Analysis",
            "Substance Abuse, Intravenous",
            "Hepatitis C",
            "Quality-Adjusted Life Years",
            "Male",
            "Mass Screening",
            "Female",
            "Adult",
            "Hepacivirus"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40608305/"
    },
    {
        "pmid": "40607077",
        "title": "Biosimilars in dermatology: New opportunities and obstacles.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40607077/"
    },
    {
        "pmid": "40606773",
        "title": "Program Report-Transplant Manitoba Adult Kidney Program Cutting Costs, Not Corners: Value of Quality Improvement Initiatives.",
        "abstract": "Provision highquality evidencebased patient care sustainable universal health system core Canadian Medical Education Directions Specialists CanMEDs expectation Transplant Manitoba Adult Kidney Program TMAKP embraced responsibility addressing inefficiency practice multipronged quality improvement QI strategies including reducing unnecessary interventions implementing innovative strategies aligning clinical practice emerging evidence Using seamlessly embedded continuous QI clinical research learning health system program achieved substantial cost saving increased opportunity deceased donor kidney transplantation purpose analysis measure cost saving associated QI initiatives Transplant Manitoba Adult Kidney Program database quality metrics Manitoba Health Physicians Manual April 1 2024 PubMed quantify potential cost savings employed 3pronged approach reduced testing costcounting exercise conducted using historical transplant activity 831 prevalent 83 incident patients project number test avoided direct cost per test Second cost saving generic mycophenolic acid presented ratio generic brand name drug costs projected cost saving prevalent patient receiving average dosing Third increased kidney utilization cost saving per kidney transplant derived published study extrapolated using predicted additional transplants Net health care system saving across payer assessed 1year time horizon TMAKP reduced unnecessary testing adopted generic medications implemented innovative strategies achieving 2530026 projected annual 1year cost savings QI initiative saving augment overall costeffectiveness kidney transplantation compared dialysis Implementing evidencebased protocol using personalized riskstratified approach viral monitoring novel donorspecific antibody surveillance strategy aligned testing clinical risk minimizing patient burden highlighting benefit seamlessly integrating research learning health systems Programs hepatitis Cviremic donor kidney agetargeted allocation increased transplant opportunity optimized deceased donor organ use Manitobas initiative demonstrate importance validation stakeholder engagement iterative adaptation driving sustainable improvement transplantation care Critically requires foresight health care administrative system invest effective ongoing QI embed research clinical practice improve patient health system outcomes analysis limited reliance projected cost savings require validation realworld audit confirm impact addition valuable QI efforts improving patient outcomes may increase costs highlighting need balanced perspective assessing stewardship initiatives Finally analysis limited projected cost saving evaluate clinical outcomes process adherence implementation effectiveness experience highlight potential QI initiative optimize care resource utilization within Canadas publicly funded health system effort reduced unnecessary testing minimized patient burden expanded transplant opportunities illustrating stewardship balance fiscal responsibility highquality stateoftheart patient care implementing evidencebased protocols TMAKP achieved additional 2530026 projected cost saving 1 year Future annual cost saving continue rising growing prevalent kidney transplant population Manitoba saving reallocated critical health care services expanding access improving outcome patient beyond transplantation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40606773/"
    },
    {
        "pmid": "40606225",
        "title": "Prescription for made in America? Tariffs and U.S. drug manufacturing.",
        "abstract": "Tariffs US pharmaceutical import recently proposed article examines potential effect tariff US domestic drug manufacturing focusing differential impact branded generic drugs contend generic manufacturing laborintensive operates thin profit margins strong competition usually constrains price increases However supply dominated tariffaffected country capacity limit may lead spotmarket price increases Unless tariffdriven global price increase outweigh amortized cost relocation higher domestic production costs US reliance foreign supplier generic likely continue contrast branded manufacturer greater incentive reshore production Branded manufacturers patentprotected monopoly provide sufficient pricing power absorb cost relocation Branded manufacturer also incentive relocate production active pharmaceutical ingredient APIs US Domesticallyproduced branded APIs could exported final processing lower cost imported back US finished drug without incurring tariffs Tariff policy uncertainty may influence manufacturers relocation decisions Among possible unintended consequence added pressure tariff global pharmaceutical manufacturers compromised product quality drug shortages higher prices retaliatory action like export quota bans reciprocal tariff stand out",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40606225/"
    },
    {
        "pmid": "40604442",
        "title": "Global and regional burden of four drug use disorders in the elderly, 1990 to 2021: an analysis of the global burden of disease study.",
        "abstract": "global population ages burden drug use disorder DUDs among elderly rising imperative conduct quantitative analysis disease burden affecting vulnerable population Utilize Global Burden Disease Study 2021 database obtain incidence rate disabilityadjusted life year DALYs opioids cocaine amphetamines cannabis among elderly aged 6089 across 204 country 5 SDI region 1990 2021 Employ Joinpoint regression analysis calculate average annual percentage change AAPC agestandardized incidence rate ASIR agestandardized DALYs rate ASDR Use Das Gupta method decompose analyze impact change age structure population growth epidemiology DALYs period Finally apply Nordpred model predict DALYs global highburden region 2022 2035 four DUDs opioids highest disease burden Joinpoint analysis indicates 1990 2021 ASIR ASDR remained stable Cocaine use disorder ASIR remained stable ASDR increased AAPC 094 95 CI 077111 burden amphetamine cannabis use disorder generally stabilized Geographic heterogeneity evident regional national levels ASDR four DUDs increasing highSDI area remaining stable declining SDI areas Highincome North America represented United States show higher burden disease Decomposition analysis show population growth main factor affecting change burden DUDs regions highincome North America mainly affected epidemiological changes According Predictive models DALYs DUDs global elderly population still rise especially man group North America burden DUDs among elderly varies across countries regions SDI levels genders underscoring need targeted public health policy adjustment strategic allocation medical resource mitigate burden",
        "mesh_terms": [
            "Humans",
            "Aged",
            "Global Burden of Disease",
            "Aged, 80 and over",
            "Male",
            "Middle Aged",
            "Female",
            "Global Health",
            "Substance-Related Disorders",
            "Disability-Adjusted Life Years",
            "Incidence",
            "Cost of Illness",
            "Cocaine-Related Disorders"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40604442/"
    },
    {
        "pmid": "40598486",
        "title": "Risk thresholds for soft versus hard cardiovascular disease outcome models for initiating statin therapy among Chinese adults: a cost-utility analysis.",
        "abstract": "Current guideline atherosclerotic cardiovascular disease ASCVD primary prevention mostly recommend risk score predict risk nonfatal myocardial infarction fatal ischemic heart disease IHD fatal nonfatal ischemic stroke hard outcomes ignoring burden nonfatal IHD outcomes explored optimal risk threshold statin initiation using nonlaboratorybased soft hard ASCVD outcome model compared costutility model Chinese population constructed Markov cohort model estimate incidence ASCVD events costs qualityadjusted life year QALYs lifetime social perspective simulation cohort constructed using data China Kadoorie Biobank CKB Input data included cost utility statin efficacy parameter derived published literature used CKBASCVD model predict 10year risk different risk threshold guide statin initiation incremental costeffectiveness ratio ICER estimated cost per QALY gained Sensitivity analysis performed explore uncertainty models optimal risk threshold 18 soft ASCVD model 10 hard ASCVD model ICERs 701348QALY 654071QALY respectively optimal threshold robust stratified analysis region sex oneway sensitivity analysis wide range input parameters Probabilistic sensitivity analysis showed optimal threshold around 70 chance costeffective analyzed age group optimal threshold costeffective adult aged 3059 year aged 6075 years threshold strategy based soft ASCVD model mostly costsaving compared based hard model treat proportion population risk threshold 18 soft ASCVD model 10 hard ASCVD model acceptable costutility profile Chinese population soft ASCVD model costeffective hard model used screening tool ASCVD primary prevention",
        "mesh_terms": [
            "Humans",
            "Cost-Benefit Analysis",
            "Hydroxymethylglutaryl-CoA Reductase Inhibitors",
            "Middle Aged",
            "Male",
            "Female",
            "China",
            "Quality-Adjusted Life Years",
            "Aged",
            "Markov Chains",
            "Cardiovascular Diseases",
            "Risk Assessment",
            "Adult",
            "Atherosclerosis",
            "East Asian People"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40598486/"
    },
    {
        "pmid": "40598337",
        "title": "Analysis of the efficiency and effectiveness of technology transformation through the introduction of ADC in the Emergency Department: a Taiwanese case study.",
        "abstract": "study evaluates impact Automated Dispensing Cabinets ADCs workflow efficiency cost savings medication therapy management Emergency Department Taiwanese regional hospital ADCs key technology healthcare aimed improving efficiency effectiveness medication management processes Data collected hospital’s information system comparing one year one year ADC implementation study focused Emergency Department Dajia Hospital included comparison Shalu Hospital Additionally semistructured interview conducted nurse pharmacist gather qualitative insights implementation ADCs significantly improved workflow efficiency reducing time required drug preparation administration leading average time saving 2568 min per patient Cost saving realized 1099 reduction nursing activity costs amounting 8332625 annually ADCs also enhanced medication therapy management improving drug tracking availability However challenge manual error medication dispensing system limitation identified ADCs improve operational efficiency costeffectiveness Emergency Departments reducing healthcare professionals’ workload enhancing medication management Despite benefits ongoing training system optimization necessary address remaining challenge enhance overall performance online version contains supplementary material available 101186s12913025129816",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40598337/"
    },
    {
        "pmid": "40594450",
        "title": "National and sub-national HIV/AIDS epidemiology, socioeconomic influences, and risk factors in Iran from 1990 to 2021, global burden of disease 2021 study.",
        "abstract": "Human immunodeficiency virus HIV remains global health challenge Iran face significant HIV issue rising incidence mortality rates antiretroviral therapy improved life expectancy projection indicate aboveaverage increase next years aimed report national subnational burden HIVAIDS risk factor Iran 1990 2021 sex age sociodemographic index SDI analysis used Global Burden Disease 2021 data agestandardized incidence rates prevalence death disabilityadjusted life year DALYs Cause Death Ensemble Model used estimate HIV mortality DisModMR 21 nonfatal outcomes Comparative risk assessment conducted evaluate burden HIVAIDS attributable risk factor condomless sex drug use intimate partner violence smoothing spline model used determine relationship SDI agestandardized DALY rate HIVAIDS count rate reported 95 uncertainty intervals 1990 agestandardized incidence rate HIVAIDS Iran among sex 02 01 07 prevalence rate 15 10 25 death rate 01 01 01 DALY rate 42 41 44 per 100000 2021 agestandardized proportion per 100000 follows incidence 23 18 30 prevalence 216 176 264 death 06 06 06 DALY 317 308 329 Males higher agestandardized rate female 2021 However female showed higher relative increase agestandardized rate 1990 2021 2021 3539 age group observed highest DALY rates Drug use leading risk factor 199 187 211 followed condomless sex 51 45 58 agestandardized DALY rate increased SDI SDI 065 decreased affected province Kermanshah Hormozgan Fars burden HIV Iran risen significantly male young adult affected Drug use leading risk factor infection following years interdisciplinary education policy healthcare effort necessary reduce burden incidence",
        "mesh_terms": [
            "Humans",
            "Iran",
            "Male",
            "Female",
            "Risk Factors",
            "Adult",
            "Global Burden of Disease",
            "HIV Infections",
            "Middle Aged",
            "Adolescent",
            "Incidence",
            "Young Adult",
            "Prevalence",
            "Socioeconomic Factors",
            "Acquired Immunodeficiency Syndrome",
            "Disability-Adjusted Life Years",
            "Child",
            "Aged"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40594450/"
    },
    {
        "pmid": "40593655",
        "title": "Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa.",
        "abstract": "Although viral suppression attained adult living diagnosed HIV East Central Southern West Africa ECSWA challenge remain sustained adherence daily oral pill taking population Here evaluate potential effectiveness costeffectiveness introduction new combination longacting injectable drug lenacapavir  cabotegravir increase level sustained viral suppression find potential significant impact HIV death disability adjusted life years including due decrease mother child transmission lenacapavir  cabotegravir sourced cost around  80 per year less analysis suggests potential policy introduce costeffective setting ECSWA Recognising limitation modelling study suggest implementation study conducted confirm viability approaches",
        "mesh_terms": [
            "Humans",
            "Africa",
            "Anti-HIV Agents",
            "Cost-Benefit Analysis",
            "HIV Infections",
            "HIV-1",
            "Infectious Disease Transmission, Vertical",
            "Pyridones",
            "Acetamides",
            "Indazoles",
            "Diketopiperazines"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40593655/"
    },
    {
        "pmid": "40588718",
        "title": "Beyond the jab: Modeling HIV vaccine acceptance in sexual and gender minorities with behavioral economic demand.",
        "abstract": "study investigation utility behavioral economic demand curve quantitative model showing consumption change price assessing acceptance hypothetical HIV vaccine among sexual gender minority SGMs Two experiment used simulated purchase task hypothetical scenario measuring purchasing decisions SGMs recruited Reddit LGBTQ community organization across United States Experiment 1 participant randomly assigned nine instructional set combining varying vaccine administration mode oral mucosal subcutaneous different dosage schedule one dose two doses one dose annually Experiment 2 examined bundling HIV vaccine one nine health commodity affected demand Participants also responded question assessing demographics HIV risk behaviors experience racial discrimination trust institutions result demonstrated exponentiated demand equation effectively modeled vaccine acceptance across condition median Rsup2sup  092 Contrary expectations vaccine characteristic minimal influence demand Q₀ Rsup2sup  0007 log α Rsup2sup  0001 Instead individual factor significantly influenced demand intensity consumption price  0 Q₀ price sensitivity sensitivity consumption increasing price α Significant predictor Q₀ included injection drug use history experience racial discrimination trust science Low household income strongest predictor log α Bundling HIV vaccine health commodity showed subtle effect acceptance condom dental examination significantly differing reference category finding suggest behavioral economic approach inform policy decision pricing bundling strategy targeted intervention maximize HIV vaccine uptake among SGMs face disproportionate HIV risk without requiring exposure nonmarketready vaccines",
        "mesh_terms": [
            "Humans",
            "AIDS Vaccines",
            "Male",
            "Female",
            "Adult",
            "Economics, Behavioral",
            "Sexual and Gender Minorities",
            "HIV Infections",
            "Young Adult",
            "Patient Acceptance of Health Care",
            "Adolescent",
            "Middle Aged"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40588718/"
    },
    {
        "pmid": "40586741",
        "title": "Online Availability of Diamond Shruumz Before and After FDA Recall Initiation: Qualitative Assessment and Simulated Test Purchasing.",
        "abstract": "Reports hospitalization associated Diamond Shruumzbranded mushroomcontaining product October 2024 led manufacturers recall restricted sale distribution accessibility new emerging psychoactive product study seek assess continuing online availability mushroomcontaining edible product diverse ecommerce landscape specifically aiming identify characterize online availability recall initiation retrospective online market surveillance Diamond Shruumz product using structured automated search query employed identify online product marketing availability Online surveillance included monitoring multiple social medium platforms cannabis ecommerce websites search engine query June 22 June 27 2024 immediately preceding manufacturerinitiated recall Postrecall simulated purchase conducted July 12 2024 platforms website domain identified continuing actively market sell product online product listings Prior product recall total 4117 product listing across 1600 3886 social medium post usergenerated comments 11 027 cannabis ecommerce websites 2509 6094 hyperlink internet search query generated content analysis Review online source revealed 49 social medium posts 8 ecommerce shops 67 domain identified actively marketing selling product prior recall Postrecall identified 45 6716 remaining domain continued market product different online sources Simulated purchase revealed 15 3333 domain successfully transacted test purchase 30 6666 transaction failed account verification payment failure Diamond Shruumz recall exemplifies ongoing challenge unknown consumer harm associated new emerging substance marketed sold internet especially concerning product appeal younger audience variety edible flavored products recall initiated product became unavailable study found postrecall online vendor continued market sell products indicates ongoing challenge effectuate recall online enforcement diverse ecommerce landscape rapidly bring new novel psychoactive substance market",
        "mesh_terms": [
            "Retrospective Studies",
            "United States",
            "Internet",
            "United States Food and Drug Administration",
            "Humans",
            "Social Media"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40586741/"
    },
    {
        "pmid": "40586645",
        "title": "Delay in receiving lab test results increases the costs of treating an episode of care for treating urinary tract infections.",
        "abstract": "provide first national study examining impact health care cost treating episode urinary tract infection function time delay receiving antimicrobial susceptibility test results used nationally representative data set privately insured adult dependents retrospective analysis included receiving urine bacteria test susceptibility testing ultimately diagnosed urinary tract infection Using regression analysis estimate episode carebased treatment cost associated day delay receiving susceptibility test result controlling patient age gender number comorbid conditions Delays receiving test result allow filling prescription diagnosis increase health plan treatment costs analysis looked patient susceptibility test ultimate diagnosis urinary tract infection examined day test two outcomes diagnosis prescription filled Even 1 day delay added 1600 2022 US dollars health plan spending treat condition additional cost traced increased hospitalization condition day delay Delays prescription filled added treatment costs Receiving test result day test could reduce treatment cost 40 whole range bacterial tests analysis focused one  urine bacterial susceptibility culture test  limited patient ultimately diagnosed urinary tract infection analysis provides first national estimate increased cost treating urinary tract infection due delay receiving test results Slow turnaround time receiving test result bacterial infection increase hospitalization health plan employer spending treating infections need new technology allow rapid result tests",
        "mesh_terms": [
            "Humans",
            "Urinary Tract Infections",
            "Male",
            "Female",
            "Retrospective Studies",
            "Middle Aged",
            "Adult",
            "Aged",
            "Anti-Bacterial Agents",
            "Episode of Care",
            "Microbial Sensitivity Tests",
            "Time Factors",
            "Young Adult",
            "Health Expenditures",
            "Adolescent",
            "United States"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40586645/"
    },
    {
        "pmid": "40580411",
        "title": "A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya.",
        "abstract": "Access direct oral anticoagulant DOACs subSaharan Africa limited due prohibitive upfront costs making warfarin standard care many patients especially relying publicsector healthcare study evaluated costeffectiveness using DOAC rivaroxaban compared warfarin treating venous thromboembolism VTE cardiovascular disorder caused blood clot veins western Kenya developed discretetime individual statetransition Markov model simulate VTE patients qualityadjusted lifeyears QALYs annual treatment cost rivaroxaban warfarin therapy strategy Transition state probability derived realworld eventrate data observed patient treated rivaroxaban n  160 warfarin n  116 VTE Moi Teaching Referral Hospital western Kenya Basecase parameter value obtained cohort event rates local costs literaturederived utility values Costeffectiveness assessed 1year time horizon using incremental costeffectiveness ratio ICER threshold US602040 per QALY gained equivalent three time Kenyas 2021 per caput GDP Deterministic probabilistic sensitivity analysis conducted assess parameter model uncertainty 12 months total mean treatment cost per patient 21600 17300 using warfarin rivaroxaban respectively basecase analysis rivaroxaban therapy resulted additional 0023 QALYs per patient compared warfarin ICER  186200 per QALY gained Based probabilistic sensitivity analysis Monte Carlo simulation costs utility values event rate varied rivaroxaban costeffective compared warfarin 841 simulation willingnesstopay threshold 602040 per QALY Oneway sensitivity analysis scenario analysis stable rivaroxaban therapy resulting fewer cost higher QALYs study rivaroxaban clinically economically superior alternative warfarin research may catalyze discussion policymakers industry partner scale appropriate use rivaroxaban resourceconstrained settings",
        "mesh_terms": [
            "Rivaroxaban",
            "Humans",
            "Warfarin",
            "Cost-Benefit Analysis",
            "Kenya",
            "Venous Thromboembolism",
            "Anticoagulants",
            "Quality-Adjusted Life Years",
            "Markov Chains",
            "Female",
            "Male",
            "Factor Xa Inhibitors",
            "Middle Aged",
            "Cost-Effectiveness Analysis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40580411/"
    },
    {
        "pmid": "40578894",
        "title": "Process evaluation of a randomised trial of a triple low-dose combination pill strategy to improve hypertension control: a qualitative study.",
        "abstract": "High blood pressure BP significant global health issue many treated patient failing achieve BP control Triple Pill v Usual Care Management Patients MildtoModerate Hypertension TRIUMPH trial evaluated effectiveness costeffectiveness acceptability early use lowdose triple fixeddose combination BPlowering drug triple pill compared usual care management hypertension TRIUMPH trial showed superior BP control triple pill strategy compared usual care process evaluation TRIUMPH trial aimed explore contextual factor influenced trial outcomes implementation triple pill strategy mechanism effect potential barrier facilitator implementing triple pill strategy routine practice Guided UK Medical Research Councils framework semistructured interview conducted 23 patient 13 healthcare provider involved TRIUMPH trial Data analysed using framework analysis method NVivo Hypertension care Sri Lanka hindered absence systematic screening overcrowded public clinics Despite free medication provision public clinics long waiting time occasional stockouts posed challenges TRIUMPH trial intervention usual care delivered context better usual care including teambased management reduced waiting times monetary assistance travel routine adherence monitoring intensive followup triple pill strategy provided simplified regimen better access BPlowering medication better BPlowering efficacy Key barrier implementation routine practice included triple pills large size therapeutic inertia restrictive regulatory policy regarding fixeddose combinations Implementation triple pill strategy routine practice requires health system strengthening provider training supportive policy measure replicate effectiveness seen trial ACTRN12612001120864 SLCTR2015020",
        "mesh_terms": [
            "Humans",
            "Hypertension",
            "Antihypertensive Agents",
            "Female",
            "Male",
            "Qualitative Research",
            "Middle Aged",
            "Drug Combinations",
            "Sri Lanka",
            "Aged",
            "Cost-Benefit Analysis",
            "Drug Therapy, Combination",
            "Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40578894/"
    }
]